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CHAPTER 1 
General introduction 

TAXONOMY, GENOMIC ORGANIZATION AND STRUCTURE OF HIV-1 
Human immunodeficiency virus type 1 (HIV-1) was identified in 1983 as the causative agent 
of the acquired immunodeficiency syndrome (AIDS)'·'. HIV-1 has been included in the genus 
Lenliviruses of the Retroviridae family (subfamily Lentivirinae). Several related lentiviruses have 
been identified,which in some cases induce a pathogenesis in their natural host, similar to that 
induced by HIV-1('). These include: 
, HIV-2 in humans' 
, simian immunodeficiency virus (SIV) in non-human primates5." 
, feline immunodeficiency virus (FIV) in cats, and closely related lentiviruses in other 
Felidae"·" 
bovine immunodeficiency virus (SIV) in cows 15 
caprine arthritis-encephalitis (CAEV) in goats 16 
equine infectious anaemia virus (EIAV) in horses" 
Maedi-Visna virus in sheep" 
The genomic organisation of these lentiviruses shows many similarities although differences exist 
(Figure 1) ". On basis of these similarities and their phylogenetic relationship (Figure 2) it has been 
postulated that the immunodeficiency viruses (HIV, SIV and FIV) have diverged from a common 
ancestor"'''. Phylogenetically HIV-1 may be divide into different subtypes'O Results of analysis 
of a large panel ofV3 domain sequences of HIV-1 strains from each phylogenetic subtype seems 
to indicate that these subtypes represent introductions of cladal founder viruses into different 
human subpopulations21. Similarities in structure, genomic organization and pathogenesis have 
prompted investigators to use infection of animals with lentiviruses related to HIV-1, as model 
systems for HIV-1 infection in humans. However, differences in the pathogeneses of lentivirus 
infections and in the mechanisms of envelope glycoprotein mediated entry, indicate that caution 
should be taken in extrapolating findings in these systems to HIV-1 infection of humans. 
The mature HIV-1 particle is sphericle with a diameter of approximately 100nm". The two 
positive stranded RNA molecules encoding the virus proteins bind several small structural proteins 
and the reverse transcriptase, thereby forming the ribonucleoprotein. During the budding process 
several other regulatory proteins are also encapsulated within the virion. The cone shaped core 
consisting of the p24 protein holds the ribonucleoprotein. This ribonucleoprotein is surrounded by 
the myristilated p17 which is attached to the virion lipid bilayer via an interaction with the 
transmembrane glycoprotein gp41. The highly glycosylated surface protein gp120 is non 
covalently attached to the gp41 molecule. Electron microscopical studies have shown that 72 
spikes, which each consist oftri- or tetrameric complexed gp41-gp120 molecules, protrude from 
the HIV-1 particle"'''. Also proteins olthe cell are incorporated in the virion membrane, during the 
budding process". 
HIV-1 INFECTION IN HUMANS: TRANSMISSION AND PATHOGENESIS 
Infectious HIV-1 can be recovered from several human organs and tissues including peripheral 
blood and semen'. As a consequence HIV-1 may be transmitted during hetero- and homosexual 
contacts, by needle sharing, by needle stick accidents, by blood transfusions and vertically from 
mother to infant'6-". HIV-1 infection at the cellular level is initiated by the high affinity interaction 
of the gp120 molecule with it's primary cellular receptor CD4"·31. The main targets of HIV-1 
infection are therefore CD4 expressing cells. These include T lymphocytes of the helper 
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Fig. 1. Genomic organization of the five major groups of primate lentiviruses. The HIV-1 group includes HIV-1 and 
SIVcpz; the HIV-2 group includes HIV-2, SIVsmm, SIVmne and SIVmac. Adapted with permission from Hayami, M" 
Ido, E. and Miura, T. Survey of SIV among nonhuman primate populations. in CUrrent Topics in Microbiology and 
Immunology, vol. 188, pages 1-20. 
phenotype', cells of the monocyte/macrophage lineage in lymphoid organs", brain", alveolar 
fluid" and bone marrow". Furthermore, follicular dendritic cells (FoC's), Langerhans cells and 
peripheral blood dendritic cells may become infected'6-". Only recently it was shown that dendritic 
cells in secondary lymphoid organs are a primary reservoir of HIV-1 producing cells in vivo during 
the asymptomatic phase of the infection". Both HIV-1 and HIV-2 may also infect C04- cells in 
vitro, but the significance of this finding for the in vivo situation has not been demonstrated"'''. 
Three different stages of HIV-1 induced pathogenesis in humans may be distinguished: 
The acute phase: 
The acute phase of the HIV-1 infection runs a subclinical course in 30-50% of the cases42. Mild 
and transient symptoms may occur similar to an influenza- or mononucleosis like illness. More 
sever clinical symptoms during the acute stage of the HIV-1 infection are associated with a rapid 
progression towards AIDS". Initially high levels of HIV-1 p24 core antigen can be detected in the 
peripheral blood, a concurrent sharp decline in C04' T cells suggests a high replication rate and 
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Fig. 2. Phylogenetic tree of AIDS-related viruses. The tree was constructed after allignment of the nucleotide sequence 
of a part of the pol gene (integrase). The number of estimated nucleotide substitutions per site is given at the top of 
the figure; horizontal branch length indicates the genetic distance. Adapted with permission from Hayami, M., Ida, E. 
and Miura, T. Survey of SIV among nonhuman primate populations. in CUrrent Topics in Microbiology and Immunology, 
vol. 188, pages 1·20. 
a direct cytopathic effect of the virus in these cells". An immune mediated cell killing of HIV-1 
infected CD4+ cells can't be excluded however despite the fact that the first HIV-1 specific CD8+ 
cytotoxic T lymphocytes (CTL) in the circulation are generally detected after initiation of the CD4+ 
cell decline45.". Furthermore redistribution of CD4' cells may contribute to the decline in CD4' cells 
in the peripheral blood. The subsequent decrease in free HIV-1 p24 core antigen levels and the 
concurrent rise of CD4+ cells to nearly normal levels has been attributed to the development of 
an HIV-1 specific immune response and a self limiting nature of the primary HIV-1 infection47 • 
HIV-1 specific CD8+ CTL and HIV-1 specific antibodies are detected around the time that the 
HIV-1 p24 core antigen levels in circulation start to decline"'''. Despite the fact that in vitro virus 
neutralizing (VN) antibodies are detected much later, in vivo locally produced VN antibodies, 
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antibody dependent cellular cytotoxicity and formation of antigen-antibody complexes by HIV-1 
specific antibodies may contribute to the decline in the free HIV-1 p24 core antigen levels found 
soon after infection. 
The asymptomatic phase: 
The period between initial infection and the time of AIDS diagnosis may vary from one to more 
than fifteen years49. A recent study has shown that the viral load in an infected individual is highly 
predictive for the length of the asymptomatic period50• Studies on asymptomatic individuals, who 
differ significantly in their disease progression rates, suggested that the length of the 
asymptomatic period may depend on the biological phenotype of the initial virus inoculum and/or 
on the quantity and quality of the HIV-1 specific immune response"-54. Only recently host genetic 
factors have been shown to contribute to the susceptibility of the host to HIV infection and the rate 
of disease progression". During the asymptomatic phase CD4 cell numbers and the ratio 
between CD4' and CDS' cells usually decline gradually". Only low to undetectable levels of free 
HIV-1 p24 core antigen levels are found in the peripheral blood50,56. Antibodies against all major 
HIV-1 proteins are found in HIV-1 seropositive individuals during this phase whereas the CDS' 
CTl response seems to be more restricted"'''. Most of the latter data were however generated 
with antigens from heterologues virus strains. During this phase only low numbers of HIV-1 
infected cells are detected in the peripheral blood. In the primary lymphoid organs (lymph nodes 
and spleen) high numbers of HIV-1 particles are sequestered on the cell surface of dendritic cells 
and a high percentage of CD4' T cells are non productively infected"'''. The FDC network and 
the lymph node architecture are both relatively intact although follicular hyperplasia is observed 
in most cases''. As mentioned above HIV-1 in situ hybridization stUdies of adenoids have shown 
that cells expressing DC markers are productively infected and may form syncytia in the absence 
of in vitro syncytium inducing (SI) virus variants in the peripheral blood lymphocytes". 
The symptomatic phase: 
The symptomatic phase of HIV-1 infection is preceded by a sharp decline in CD4' cell 
numbers56 . The diagnosis AIDS is made on basis of AIDS defining illness and/or CD4' cell 
numbers below 200/ml of blood". During the later stages of the HIV-1 infection, the FDC network 
and it's HIV-1 trapping ability are destroyed and germinal centres start to involute". Furthermore 
the percentage of productively infected CD4' T cells increases". Several different manifestations 
of the immunological disorder resulting from HIV-1 infection have been described". Many of the 
opportunistic infections observed are caused by intracellular pathogens, which indicates a loss 
of cellular immunity in the final stages of the disease. , 
GENETIC AND PHENOTYPIC VARIATION OF HIV-1 
One of the hallmarks of HIV-1 infection in the human host is the existence of genotypic and 
phenotypic variation within one individual". The variation observed is caused by the incorporation 
of other nucleic acid residues than the originally encoded, during reverse transcription of viral RNA 
strands into DNA. Due to the lack of a proof reading system, up to 10 nucleic acid changes are 
introduced in the HIV-1 genome during each replication cycle in vitro"'''. The in vivo nucleotide 
substitution rate has been estimated to be between 0.4x10-3 and 15.Sx1 0.3 /site/year depending 
on the gene stUdied". The in vivo population diversity is limited by at least two mechanisms, First 
not each nucleic acid change results in a "viable" mutant or in a mutant that differs in amino acid 
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composition (silent mutations), and second both humoral and cellular immune responses may limit 
the replication of certain mutants. The variation introduced in the envelope glycoprotein clusters 
in five discrete regions called hypervariable regions one to five (Vi to V5)"'. Naturally occurring 
changes introduced in several of these regions have been shown to change the sensitivity of the 
virus to neutralizing antibodies and the in vitro biological phenotype of the virus~n These findings 
suggest that both properties are involved in adaptation to, and subsequent persistence of the virus 
in the host. Alternatively these properties may be linked, resulting in simultaneous changes of 
which only one is important for persistence of the virus in the host. 
In vitro biological properties, used to classify viruses include: the ability of the virus to induce 
formation of multinucleated cells (the so called SI capacity)73,74, the replication rate of the virus",76, 
the ability to persistently infect either monocyte derived macrophages (MOM's) or immortalized 
T celilines73,74,77 and the ability to induce single celllysis78.80. These biological properties proved 
to be highly interrelated"''': non syncytium inducing (NSI) HIV-i strains are little cytopathic, have 
a low replication rate and usually have the ability to infect MOM's. SI HIV-i strains on the other 
hand are usually highly cytopathic, replicate to high titers and are able to infect immortalized T cell 
lines. It should be realized however, that a whole range of intermediate phenotypes may exist 
simultaneously in the host",". It has furthermore been shown that the in vitro biological 
characteristics of HIV-i strains, like SI capacity and overall pathogenicity do not always correlate 
with their in vivo behaviour"'·aa. The most commonly used system to classify HIV-i strains 
according to their in vitro biological phenotype was described by Cheng-Mayer et al.73 and 
Tersmetle et al.74 ,89. This system uses the difference in SI capacity and cellular host range to 
classify viruses into SI and NSI strains. While introducing the system it was recognized that the 
presence of viruses of the respective phenotypes correlates with the stage of the disease and the 
rate of disease progression in the host. Many stUdies described thereafter have confirmed that 
SI variants are isolated from about 50% of the individuals that progress towards AIDS with a 
severe clinical disease manifestation",". Furthermore, several studies have shown that SI 
variants may be isolated around seroconversion from patients with more severe clinical 
manifestation of primary infection",52,,.. These individuals usually progress more rapidly towards 
AIDS. After primary infection in most cases NSI variants persist in the host despite the fact that 
SI variants may be isolated in vitto from the initial inoculum"),". Whether this is a reflection of a 
low prevalence of SI variants in the inoculum that have a selective advantage in vi/to, of a 
preferential outgrowth in vivo of NSI variants, or of a reflection of the route of infection still remains 
elusive. 
Several of the other biological characteristics may also be used to classify HIV-i strains",79.6'. 
It has been suggested that these features are more relevant for the in vivo pathogenicity of the 
virus9().e6. The virus strains used in the studies presented in this thesis are predominantly classified 
according to their SI capacity. 
HIV-i ENTRY 
In vitto studies have shown that HIV-i entry is a result of pH-independent fusion of viral and 
cell membrane'~95. It can however not be excluded that in vivo opsonization of virus particles may 
lead to endocytosis by cells of the monocytic cell lineage and subsequent fusion in the early 
endosome at low pH as observed with e.g. influenza virus'6,,,. It has recently been shown that 
opsonized virus particles may be rendered infectious by binding to FOC's". The mechanism by 
which these cells specialized in antigen presentation, render seemingly inactivated virus particles 
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infectious and the resulting mechanism of entry is unclear. It has been postulated that FOC's 
present antigen in the presence of antigen specific antibodies by disrupting the antigen-antibody 
complexes. In the case of HIV-1 this would allow the initial interaction of gp120 with C04 on the 
target cell to take place. 
Three subsequent phases may be postulated in the process of HIV-1 glycoprotein mediated 
cell entry: 
1) Binding of the virion to the cell membrane, 
2) Induction of conformational changes within the C04-gp120 complex resulting in a fusogenic 
state of the complex in close proximity to the cell membrane, 
3) Induction of conformational changes within the gp41 molecule resulting in insertion of the gp41 
N-terminal stretch of hydrophobic amino acids into the opposing cell membrane thereby 
destabilizing the cell membrane and allowing fusion of the virion and cell membranes. 
Binding of the virion to the cell membrane 
The V3100p on HIV-1 gp120 of T cell line adapted (TCLA) HIV-1 strains and supposedly also 
other positively charged loops protruding from the gp120 molecule, has been shown to bind to 
negatively charged cellular counterparts, like sugar residues and the COR3 domain on C04"·lO'. 
It has been postulated that this initial low affinity binding enables the virus to scan the cell 
membrane for C04, after which the entry process is initiated by the high affinity interaction of 
gp120 with C04. The V3 loop on primary HIV-1 strains does not seem to be readily accessible 
on the glycoprotein complex however for such an interaction'oo.lO'. Furthermore V3 loop specific 
antibodies block HIV-1 entry at a stage following HIV-1 binding'o"lO'. It therefore seems likely that 
HIV-1 binding is initiated by the high affinity interaction between gp120 and C04 or by the 
interaction between cell encoded proteins incorporated in the HIV-1 particle and a cellular 
counterpart'o,. 
Induction of conformational changes within the CD4-gp120 complex 
A whole array of conformational changes have been described in both gp120 and C04 after 
binding of gp120 to sC04 and cell membrane associated C04"·106-lO'. The exact role of these 
changes in the process of HIV-1 envelope glycoprotein mediated entry is not clear yet. After initial 
binding of the virion to the cell a considerable distance must be bridged by the N-terminal part of 
the gp41 molecule in order to insert itself into the cell membrane. Furthermore both the virion and 
cell membrane are negatively charged entities which results in a electrostatic repulsion of virion 
and cell membranes. Conformational changes in the HIV-1 glycoprotein-C04 complex therefore 
seem to be necessary to bring the virion membrane in closer proximity to the cell membrane. At 
least two changes are believed to contribute to this phenomenon. First C04 has been postulated 
to bend at a hinge region between 02 and 0310" and second, shedding of gp120 after binding to 
C04 may also contribute to this phenomenon"o. Since primary HIV-1 strains do not readily shed 
gp120 after C04 binding'o,.,".,,,, alternative changes within the glycoprotein complex may lead 
to bending gp120 outside the gap needed for the insertion of the gp41 fusion domain into the cell 
membrane. Only little is known about the changes in the envelope glycoprotein complex of 
primary HIV-1 strains after it's binding to C04. It seems likely however that the changes parallel 
those described for HIV-2 and SIVagm during receptor induced activation of membrane fusion 
since these viruses also do not readily shed their SU after binding to C04,oa.'13.'14. 
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Induction of conformational changes within the gp41 molecule 
Virus receptor mediated membrane fusion has been most thoroughly studied in influenza HA 
mediated fusion. Analysis of the crystal structure of HA2 in the fusogenic state indicates that the 
association of HA2 leucine zipper regions into a coiled coil structure is essential for the formation 
of the fusion attack complex. The bending of the HA2 molecule results in a stretch of alpha helices 
forming the central coiled coil core of the HA2 fusion attack complex""". This triple stranded 
central core seems to be required to bridge the distance between virion and cell membrane. 
Studies on the conformational changes within the HIV-1 glycoprotein complex induced by CD4 
binding, are seriously hampered by the fact that crystal structures of the envelope glycoprotein 
in it's native conformation and in the fusion attack complex, have safar not been produced. The 
present knowledge about the conformation of the glycoprotein complex is largely limited to the TM 
part of the glycoprotein complex. Based on peptide inhibition experiments, and in line with the 
model proposed for the HA2 part of the influenza virus heamagglutinin in it's native form and as 
a fusion attack complex, Matthews et a/. proposed a model for the formation of a HIV-1 TM fusion 
attack complex"'. In this model the formation of a central coiled coil core structure by the leucine 
zipper regions of the TM glycoprotein, is an essential step in the fusion process 117. Formation of 
this central core in the native state is inhibited by the putative distal alpha helix'18. In parallel with 
the HA2 model, this alpha helix may be part of the central core in the fusion attack complex by 
placing itself on top of the central core, thereby bridging the space between viral and cellular 
membranes". Insertion of the fusion related sequence into the adjacent membrane is thought to 
destabilize the cell membrane, which eventually allows fusion of the membranes to take place 119. 
The interaction of the HIV-1 glycoprotein complex with membrane associated CD4 is required 
but not sufficient for HIV-1 entry"'. Recently it was shown that expression of proteins belonging 
to the C-X-C and C-C chemokine receptor subfamilies of the G-protein binding receptor 
superfamily, is required for HIV-1 entry'21."'. HIV-1 strains proved to have different requirements 
for these second receptors. Infection of TCLA HIV-1 strains proved to depend on expression of 
the 13 chemokine receptor LESTR also called fusin, whereas primary macrophage-tropic HIV-1 
strains required expression of the CC CKR5 chemokine receptor. It was furthermore shown that 
genetic variation in the CC CKR5 chemokine receptor may have a pronounced influence on the 
susceptibility to HIV-1 infection and on the rate of disease progression after HIV-1 infection". 
RELATIONSHIP BETWEEN ANTIGENIC STRUCTURE OF THE HIV-1 ENVELOPE 
GLYCOPROTEIN COMPLEX AND BIOLOGICAL ACTIVITY OF ANTIBODIES 
Presently the database of antibodies directed against linear epitopes on the gp41 and gp120 
molecules, constructed by the Los Alamos Laboratories at the world wide web site http://hiv-
web.lanl.gov/immuno/ab, contains antibodies which recognize virtually the complete amino acid 
sequence of the gp160 molecule. On the folded monomeric gp120/gp160 a limited set of these 
antibodies bind to their epitope". Besides these antibodies, a range of antibodies have been 
described of which the binding is dependent on either the tertiary or quaternary structure of the 
envelope glycoproteins"·'23. The linear and tertiary epitopes on gp120 all cluster within discrete 
and sometimes overlapping antigenic sites on monomeric gp120". The antigenic sites that are 
able to induce VN antibodies all cluster on one face of the gp120 molecule suggesting that this 
face is pointed towards the surface of the multimeric glycoprotein complex, whereas non VN 
9 
antibody inducing antigenic sites seem occluded within the complex (Figure 3). 
Fig. 3. Antibody cross-competition map of the surface of the HIV-1 gp120 glycoprotein. The top three drawings 
lIIustrate the core of the competition map of gp120 from three different perspectives, with the surface seen in the upper 
left-hand illustration presumably exposed on the assembled envelope glycoprotein oligomer. The binding sites for CD4 
and groups of monoclonal antibodies are depicted. Overlap of epUepes indicates reciprocal inhibition of monoclonal 
antibody binding in ELISA, whereas adjacent epitopes are used to model unidirectional inhibitory or enhancing effects. 
The lower two drawings include epitopes that were displayed as surface projections. In the lower right-hand figure, 
the V2 epitopes were removed for clarity. Adapted with permission from J.P. Moore and J. Sodroski, J. Vlral. 70,1863-
1872. 
Of the linear and tertiary epitopes able to induce VN antibodies the V2, V3 and CD4 binding 
domain (CD4 bd) on HIV-1 gp120 and amino acid 679-685 on gp41 (ELDKWAS) are described 
in most detail (for review see Poignard et al.'24). TCLA HIV-1 strains, may be readily neutralized 
by antibodies directed against these antigenic sites. The VN capacity of these antibodies is both 
dependent on the relative affinity of the antibody for the HIV-1 strain tested and on the exact 
location of the epitope within the antigenic site"·'07·'25.,,'. Several mechanisms by which HIV-1 
glycoprotein specific antibodies neutralize TCLA HIV-1 strains may be considered, including: 
1) inhibition of CD4 binding 
2) induction or inhibition of conformational changes leaving the envelope glycoprotein complex 
unable to exert further function 
3) interference with HIV-1 glycoprotein/second receptor binding 
4) interference with post entry events 
Inhibition of CD4 binding 
A vast amount of MAb's directed against the C4 domain and the CD4bs that interfere with 
monomeric gp120/sCD4 binding has been described. It does not seem likely however, that the 
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mechanism of neutralization of these MAb's is the direct result of inhibition of virion binding to it's 
cellular receptor"'. 
Induction or inhibition of conformational changes 
It has recently been shown that V3 specific MAb's may induce shedding of gp120, which results 
in the irreversible inactivation of the virion'''. TClA HIV-1 strains may also be neutralized under 
. conditions where shedding of gp120 does not take place'''. This observation indicates that 
additional mechanisms of neutralization may contribute to the neutralizing capacity of these 
MAb's. VN antibodies directed against other antigenic sites like V1N2 , CD4i, C4 and the CD4bs, 
which do not induce shedding of gp120128 , have been shown to induce conformational changes 
in monomeric gp120 which increase or decrease the affinity of sCD4 and MAb's directed against 
other antigenic sites". Whether these changes are also induced in the multi me ric envelope 
glycoprotein complex and whether these changes reduce the fusogenic or CD4 binding capacity 
of the HIV-1 glycoprotein complex remains elusive. The binding of the human monoclonal 
antibody (HuMAb) IAM-2F5 to it's epitope is reduced in the presence of sCD4'30. This implies that 
the epitope of IAM-2F5 is obscured within the fusogenic state of the HIV-1 envelope glycoprotein 
complex. It may be postulated that IAM-2F5 blocks the induction of conformational changes 
required to get the HIV-1 envelope glycoprotein complex into it's fusogenic state. Alternatively lAM 
2F5 may either directly or sterically hinder the binding of gp41 to a cell membrane protein. 
Interference with HIV-J glycoprotein/second receptor binding 
Secondary to the high affinity interaction of gp120 with CD4, a low affinity interaction is required 
to induce the fusion attack complex'20. Parts of the V1N2, V3 and C4 domains seem likely 
candidates for taking part in such an interaction, since these domains have been shown to interact 
as a complex in receptor mediated membrane fusion'31.'''. Antibodies directed against these 
antigenic sites may neutralize HIV-1 by inhibiting this secondary interaction. The Ca" binding site 
within gp41 has been postulated to bind to a cellular second receptor'''. VN antibodies binding 
to epitopes in the vicinity of this second receptor contact site, like IAM-2F5 may sterically hinder 
this interaction. 
Interference with post entry events 
It has been speculated that Fab fragments of HuMAb IgG1-b12 may exert their function after 
entry of HIV-1 into the cell by inhibiting the un coating of the ribonucleoprotein (N. Dimmock, 
personal communication). 
ANTIBODY MEDIATED ENHANCEMENT OF HIV-1 
Besides mediating virus neutralization, antibodies directed against the envelope glycoprotein 
complex may also mediate enhancement of infectivity in vitro. Until recently two mechanisms by 
which HIV-1 specific antibodies may facilitate HIV-1 entry have been described"4 These include: 
Fc receptor and complement receptor mediated antibody dependent enhancement of HIV-1 
infection (Fc-ADE an C'-ADE). Several cell types express receptors for the Fc portion of antibodies 
and for factors of the complement system that bind to antibody-antigen complexes '35.'36. These 
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receptors mediate endocytosis of foreign antigens, thereby facilitating inactivation of the pathogen, 
break down of the antigen in the lysosomal compartment and subsequent antigen processing and 
presentation. In vitro studies indicate that HIV-1 may have found ways to take advantage of this 
system'37.'40. The mechanism by which HIV-1 specific antibodies facilitate entry of HIV-1 into these 
cell types is not fully understood. Fc-ADE and C'-ADE are however thought to facilitate initial 
binding of the virion to the cell after which the gp120-CD4 interaction may initiate fusion'''''''. 
Whether the resulting mechanism of HIV-1 glycoprotein mediated entry is indeed similar to HIV-1 
envelope glycoprotein mediated entry into T cell lines still remains to be shown. Alternatively 
opsonisation of virus particles has been shown to enable HIV-1 to enter these cells independent 
of membrane associated CD4'39. How CD4 independent entry in the presence of antibodies and 
complement is facilitated remains unclear. It may be hypothesized that opsonization of the HIV-1 
particle may facilitate endocytosis of the virion and subsequent pH induced viral fusion within the 
early endosome, by a mechanism that would parallel entry of influenza virus.,·115. Alternatively, 
binding of the virion to the cell via Fc- or C' receptors may allow the HIV-1 transmembrane 
molecule to bind to a cellular receptor, eventually allowing pH independent fusion of virion and cell 
membrane to take place. 
The soluble form of the CD4 receptor may also enhance entry of specific HIV-2 strains and 
SIVagm into CD4' and CD4' cell lines respectively by a mechanism called receptor activated 
membrane fusion""". We and others have recently shown that in HIV-1 infection such a 
mechanism is also operational'45.,". Furthermore HIV-1 specific antibodies also enhanced entry 
of HIV-1 strains susceptible to sCD4 mediated enhancement. 
The role of antibody mediated enhancement in in vivo HIV-1 infection has been subject of 
debate. Differences in properties of HIV-1 strains isolated in vitro in the absence of HIV-1 specific 
antibodies and cell free HIV-1 strains found in vivo however suggest that antibody mediated 
enhancement of HIV-1 does playa role in in vivo HIV-1 infection"·'''. Furthermore, enhancement 
of EIAV and FIV infection has been observed in vivo after vaccination and subsequent challenge 
of ponies and cats respectively'48."'. These observations indicate that indeed enhancement of 
lentivirus infection may become a serious threat for lentivirus vaccine development. 
AIM OF THIS STUDY 
The induction of HIV-1 specific antibodies that prevent HIV-1 infection or limit the spread of the 
virus during the initial stages of the infection is thought to be an essential feature of a successful 
future vaccine. HIV-1, SIV and FIV candidate vaccines that elicit whole envelope glycoprotein 
specific antibody responses have sofar had limited success in preventing infection '48.'50. These 
observations indicate that increasing our knowledge of mechanisms that underlay primary HIV-1 
glycoprotein mediated entry and of the way in which HIV-1 glycoprotein specific antibodies 
modulate this entry, may be crucial for successful HIV-1 vaccine development. The studies 
presented in this thesis were initiated to increase our understanding of the way in which HIV-1 
envelope specific antibodies may interfere with, or modulate the sequence of events that lead to 
viral entry. 
The generation and characterization of materials and in vitro and in vivo systems, used to study 
these phenomena are described in chapter 2, 3, 4 (HIV-1 envelope specific HuMAb's), 5 
(envelope trans-complementation assay) and 7 (xeno-GvHD mouse model). In chapters 5 and 6 
in vitro studies into the mechanism of primary HIV-1 entry and the modulation of primary HIV-1 
glycoprotein mediated entry by human antibodies and sCD4 are described. In vitro studies on the 
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protective capacity of HIV-1 specific antibodies have several obvious shortcomings like the 
absence of HIV-1 susceptible monocytes and macrophages and the absence of tissue distribution 
of HIV-1 infected and susceptible cells. These aspects may all contribute to the outcome of HIV-1 
infection in humans. In chapter 7 the protective capacity of in vitro virus neutralizing human 
antibodies is studied in a human to mouse chimeric model, in which these aspects are taken into 
account. In the general discussion (chapter 8), the data presented, are discussed in the light of 
the current knowledge in this field and oftheir relevance for HIV-1 vaccine development. 
References 
1. 8arre-Sinoussi, F, Chermann, JC, Rey, F, et al. (1983) Isolation of a T-Iymphotropic retrovirus from a patient 
at risk for acquired immune deficiency syndrome (AIDS). Science 220:868-871. 
2. Gailo, Re, Sarin, PS, Gelmann, EP, et al. (1983) Isolation of human T-cell leukemia virus in acquired immune 
deficiency syndrome (AIDS). Science 220:865-867. 
3. Cavacini, LA, Emes, Cl, Power, J, Duval, M, & Posner, MR. (1994) Effect of antibody valency on interaction 
with cell-surface expressed HIV-1 and viral neutralization. J. Immuno!. 152:2538-2545. 
4. Clavel, F, Guyader, M, Guelard, D, Salle, M, Monlagnier, L, & Alizon, M. (1986) Molecular cloning and 
polymorphism of the human immune deficiency virus type 2. Nature 324:691-695. 
5. Kanki, PJ, McLane, MF, King, NW, Jr., et a!. (1985) Serologic identification and characterization of a macaque 
T-Iymphotropic relrovirus closely relaled 10 HTLV-III. Science 228:1199-1201. 
6. Tsujimoto, H, Cooper, RW, Kodama, T, et al. (1988) Isolation and characterization of simian immunodeficiency 
virus from mandrills in Africa and its relationship to other human and simian immunodeficiency viruses. J. Viro!. 
62:4044-4050. 
7. Emau, P, McClure, HM, Isahakia, M, Else, JG, & Fultz, PN. (1991) Isolation from African Sykes' monkeys 
(Cercopithecus mitis) of a lentivirus related to human and simian immunodeficiency viruses. J. Viro!. 
65:2135-2140. 
8. Daniel, MD, Li, Y, Naidu, YM, et a!. (1988) Simian immunodeficiency virus from African green monkeys. J. Viro!. 
62:4123-4128. 
9. Hue!, T, Cheynier, R, Meyerhans, A, Roelants, G, & Wain~Hobson, S. (1990) Genetic organization of a 
chimpanzee lentivirus related to HIV~1. Nature 345:356~359. 
10. Peeters, M, Honore, C, Huet, T, et a!. (1989) Isolation and partial characterization of an HIV~related virus 
occurring naturally in chimpanzees in Gabon. AIDS 3:625~630. 
11. Hirsch, VM, Olmsted, RA, Murphey~Corb, M, Purcell, RH, & Johnson, PRo (1989) An African primate lentivirus 
(SIVsm) closely relaled to HIV-2. Nalure 339:389-392. 
12. Pedersen, NC, Ho, EW, Brown, ML, & Yamamoto, JK. (1987) Isolation of a T~lymphotropic virus from domestic 
cats with an immunodeficiency~like syndrome. Science 235:790~793. 
13. Brown, EW, Yuhki, N, Packer, C, & O'Brien, SJ. (1994) A lion lentivirus related to feline immunodeficiency virus: 
epidemiologic and phylogenetic aspects. J. Viral. 68:5953~5968. 
14. Langley, RJ, Hirsch, VM, O'Brien, SJ, Adger-Johnson, D, Goeken, RM, & Olmsled, RA. (1994) Nueleolide 
sequence analysis of puma lentivirus (PLV~14): genomic organization and relationship to other lentiviruses. 
Virology 202:853-864. 
15. Gonda, MA, Braun, MJ, Carter, SG, eta1. (1987) Characterization and molecular cloning ofa bovine lentivirus 
related to human immunodeficiency virus. Nature 330:388~391. 
16. Saltarelli, M, Ouerat, G, Konings, DA, Vigne, R, & Clements, JE. (1990) Nucleotide sequence and transcriptional 
analysis of molecular clones of CAEV which generate infectious virus. Virology 179:347-364. 
17. Narayan, 0 & Cork, LC. (1985) Lentiviral diseases of sheep and goats: chronic pneumonia 
leukoencephalomyelitis and arthritis .. Rev. Infect. Dis. 7:89·98. 
18. Varmus, H. (1988) Relroviruses.(Review]. Science 240:1427-1435. 
19. Tsujimoto, H, Hasegawa, A, Maki, N, et al. (1989) Sequence of a novel simian immunodeficiency virus from a 
wild·caught African mandrill. Nalure 341:539-541. 
20. Meyers, G., J. A. Berzofsky, B. Korber, R. F. Smiths, and G. N. Pavlakis. 1992. Human retroviruses and AIDS. 
Los Alomos National Laboratories, Los Alomos New Mexico. 
21. Korber, BT, MacInnes, K, Smith, RF, & Myers, G. (1994) Mutational trends in V3 loop protein sequences 
observed in different genetic lineages of human immunodeficiency virus type 1. J. Viro!. 68:6730~6744. 
13 
22. Gelderblom, HR, Ozel, M, & Pauli, G. (1989) Morphogenesis and morphology of HIV, Structure-function 
relations. Arch. Viral. 106:1-13. 
23. Dams, RW, Lamb, RAJ Rose, JK, & Helenius, A (1993) Folding and assembly of viral membrane proteins. 
Virology 193:545-562. 
24. Earl, PL, Dams, RW, & Moss, 8. (1992) Multimeric CD4 binding exhibited by human and simian 
immunodeficiency virus envelope protein dimers. J. Viro!. 66:5610-5614. 
25. Arthur, LO, Bess, JW, Jr., Sowder, Re, 2d, et al. (1992) Cellular proteins bound to immunodeficiency viruses: 
implications for pathogenesis and vaccines. Science 258:1935-1938. 
26. Hirsch, MS, Wormser, GP, Schooley, RT, et a!. (1985) Risk of nosocomial infection with human T-cell 
Iymphotropicvirus III (HTLV-III). N. Engl. J. Med. 312:1-4. 
27. Robert-Guroff, M, Weiss, SH, Giron, JA, et al. (1986) Prevalence of antibodies to HTLV-I, -II, and -III in 
intravenous drug abusers from an AIDS endemic region. JAMA 255:3133-3137. 
28. Peckham, CS, Tedder, RS, Briggs, M, et al. (1990) Prevalence of maternal HIV infection based on unlinked 
anonymous testing of newborn babies. Lancet 335:516-519. 
29. Klatzmann, 0, Champagne, E, Chamaret, S, et al. (1984) T-Iymphocyte T4 molecule behaves as the receptor 
for human retrovirus LAV. Nature 312:767-768. 
30. Dalgleish, AG, Beverley, PC, Clapham, PR, et al. (1984) The CD4 (T4) antigen is an essential component of 
the receptor for the AIDS retrovirus. Nature 312:763-767. 
31. Lasky, LA, Nakamura, G, Smith, OH, et aL (1987) Delineation of a region of the human immunodeficiency virus 
type 1 gp120 glycoprotein critical for interaction with the CD4 receptor. Cell 50:975-985. 
32. Embretson, J, Zupancic, M, Ribas, JL, et al. (1993) Massive covert infection of helper T lymphocytes and 
macrophages by HIV during the incubation period of AIDS. Nature 362:359-362. 
33. Gartner, S, Markovits, P, Markovitz, OM, Betts, RF, & Popovic, M. (1986) VIrus isolation from and identification 
of HTLV-IlIILAV-producing cells in brain tissue from a patient wilh AIDS. JAMA 256:2365-2371. 
34. Salahuddin, SZ, Rose, RM, Groopman, JE, Markham, PO, & Gallo, RC. (1986) Human T Iymphotropic virus type 
III infection of human alveolar macrophages. Blood 68:281-284. 
35. Gendelman, HE, Narayan, 0, Molineaux, S, Clements, JE, & Ghotbi, Z. (1985) Slow, persistent replication of 
[entiviruses: role of tissue macrophages and macrophage precursors in bone marrow. Proc. Natl. Acad. Sci. U. 
S. A. 82:7086-7090. 
36. Frankel, SS, Wenig, BM, Burke, AP, et al. (1996) Replication of HIV-1 in dendritic cell-derived syncytia at the 
mucosal surface of the adenoid. Science 272:115-117. 
37. Armstrong, JA & Horne, R (1984) Follicular dendritic cells and virus-like particles in AIDS-related 
lymphadenopathy. Lancet 2:370-372. 
38. Patterson, S & Knight, SC. (1987) Susceptibility of human peripheral blood dendritic cells to infection by human 
immunodeficiency virus. J. Gen. Viro!. 68:1177-1181. 
39. Conaldi, PG, Serra, C, Oolei, A, et a!. (1995) Productive HIV-1 infection of human vascular endothelial cells 
requires cel! proliferation and is stimulated by combined treatment with interleukin-1 beta plus tumor necrosis 
factor-alpha. J. Med. Virol. 47:355-363. 
40. Trujillo, JR, Wang, WK, Lee, TH, & Essex, M. (1996) Identification of the envelope V3100p as a determinant of 
a CD4-negative neuronal cell tropism for HIV-1. Virology 217:613-617. 
41. Clapham, PR, McKnight, A, & Weiss, RA (1992) Human immunodeficiency virus type 2 infection and fusion of 
CD4-negative human cell lines: induction and enhancement by soluble CD4. J. Virol. 66:3531-3537. 
42. Cooper, DA, Gold, J, Maclean, P, et al. (1985) Acute AIDS retrovirus infection. Definition of a clinical illness 
associated with seroconversion. Lancet 1:537-540. 
43. Henrard, DR, Daar, E, Farzadegan, H, et a!. (1995) Virologic and immunologic characterization of symptomatic 
and asymptomatic primary HIV-1 infection. J Acquir.lmmune. Defic. Syndr. Hum. Retrovirol. 9:305-310. 
44. Daar, ES, Moudgil, T, Meyer, RD, & Ho, DO. (1991) Transient high levels of viremia in patients with primary 
human immunodeficiency virus type 1 infection. N. Eng1. J. Med. 324:961-964. 
45. Borrow, P, Lewicki, H, Hahn, BH, Shaw, GM, & Oldstone, MB. (1994) Virus-specific CD8+ cytotoxic 
T-Iymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 
infection, J. Virol. 68:6103-6110. 
46. Koup, RA, Safrit, JT, Cao, Y, et a1. (1994) Temporal association of cellular immune responses with the initial 
control of viremia in primary human immunodeficiency virus type 1 syndrome. J. Virol. 68:4650-4655. 
47. Phillips, AN. (1996) Reduction of HIV concentration during acute infection: independence from a specific 
immune response. Science 271:497-499. 
14 
48. Moore, JP, Cao, Y, Ho, DO, & Koup, RA. (1994) Development of the anti-gp120 antibody response during 
seroconversion to human immunodeficiency virus type 1. J. Viral. 68:5142-5155. 
49. Deacon, NJ, Tsykin, A, Solomon, A, et a!. (1995) Genomic structure of an attenuated quasi species of HIV-1 
from a blood transfusion donor and recipients. Science 270:988-991. 
50. Mellors, JW, Rinaldo, CR, Jr., Gupta, P, White, RM, Todd, JA, & Kingsley, LA. (1996) Prognosis in HIV-1 
infection predicted by the quantity of virus in plasma. Science 272:1167-1170. 
51. Fiore, JR, Bjorndal, A, Peipke, KA, et al. (1994) The biological phenotype of HIV-1 is usually retained during and 
after sexual transmission. Virology 204:297-303. 
52. Oka, 8, Ida, S, Shioda, T, et al. (1994) Genetic analysis of HIV-1 during rapid progression to AIDS in an 
apparently healthy man. AIDS Res. Hum. Retroviruses 10:271-277. 
53. Blanche, S, Mayaux, MJ, Rouzioux, C, et al. (1994) Relation of the course of HIV infection in chl1dren to the 
severity of the disease in their mothers at delivery. N. Engl. J. Med. 330:308-312. 
54. Klein, MR & Miedema, F. (1995) Long-term survivors of HIV-1 infection. Trends. Microbial. 3:386-391. 
55. Samson, S, Libert, F, Doranz, BJ, et al. (1996) Resistance to HIV-1 infection in caucasian individuals bearing 
alleles of the CCR-5 chemokine receptor gene. Nature 382:722-725. 
56. Miedema, F, Tersmette, M, & van Lier, RA. (1990) AIDS pathogenesis: a dynamic interaction between HIV and 
the immune system. Immunol. Today 11:293-297. 
57. Johnson, RP & Walker, BD. (1994) Cytotoxic T lymphocytes in human immunodeficiency virus infection: 
responses to structural proteins. Curf. Top. Microbial. Immuno!. 189:35-63. 
58. Riviere, Y, Robertson, MN, & Buseyne, F. (1994) Cytotoxic T lymphocytes in human immunodeficiency virus 
infection: regulator genes. Curro Top. Microbia!. Immuno!. 189:65-74. 
59. Pantaleo, G, Graziosi, C, Demarest, JF, et a!. (1993) HIV infection is active and progressive in lymphoid tissue 
during the clinically latent stage of disease. Nature 362:355-358. 
60. Mathur-Wagh, V, Enlow, RW, Spigland, I, et al. (1984) longitudinal study of persistent generalised 
lymphadenopathy in homosexual men: relation to acquired immunodeficiency syndrome. Lancet 1: 1 033-1 038. 
61. Anonymous. (1992) 1993 revised classification system for HIV infection and expanded surveillance case 
definition for AIDS among adolescents and adults. MMWR. Morb. Mortal. Wkly. Rep. 41:1-19. 
62. Hahn, BH, Shaw, GM, Taylor, ME, et al. (1986) Genetic variation in HTLV-Ill/LAVovertime in patients with AIDS 
or at risk for AIDS. Science 232:1548-1553. 
63. Roberts, JD, Bebenek, K, & Kunkel, TA. (1988) The accuracy of reverse transcriptase from HIV-1. Science 
242:1171-1173. 
64. Preston, BD, Poiesz, BJ, & Loeb, LA. (1988) Fidelity of HIV-1 reverse transcriptase. Science 242:1168-1171. 
65. Willey, RL, Rutledge, RA, Dias, S, et a!. (1986) Identification of conserved and divergent domains within the 
envelope gene of the acquired immunodeficiency syndrome retrovirus. Proc. Nat!. Acad. Sci. U. S. A. 
83:5038-5042. 
66. Broliden, PA, von Gegerfelt, A, Clapham, P, et al. (1992) Identification of human neutralization-inducing regions 
of the human immunodeficiency virus type 1 envelope glycoproteins. Proc. Natl. Acad. Sd. U. S. A. 89:461-465. 
67. Moore, JP, Satientau, OJ, Wyatt, R, & Sodroski, J. (1994) Probing the structure of the human immunodeficiency 
virus surface glycoprotein gp120 with a panel of monoclonal antibodies. J. Viral. 68:469-484. 
68. Moore, JP & Sodroski, J. (1996) Antibody cross-competition analysis of the human immunodeficiency virus type 
1 gp120 exterior envelope glycoprotein. J. Viral. 70:1863-1872. 
69. Groenink, M, Andeweg, AC, Fouchier, RA, et al. (1992) Phenotype-associated env gene variation among eight 
related human immunodeficiency virus type 1 clones: evidence for in vivo recombination and determinants of 
cytotropism outside the V3 domain. J. Viral. 66:6175-6180. 
70. Andeweg, AC, Groenink, M, Leeflang, P, et al. (1992) Genetic and functional analysis of a set of HIV-1 envelope 
genes obtained from biological clones with varying syncytium-inducing capacities. AIDS Res. Hum. Retroviruses 
8:1803-1813. 
71. Groenink, M, Fouchier, RA, Broersen, S, et al. (1993) Relation of phenotype evolution of HIV-1 to envelope \/2 
configuration. Science 260:1513-1516. 
72. Fouchier, RA, Groenink, M, Kootstra, NA, et at (1992) Phenotype-associated sequence variation in the third 
variable domain of the human immunodeficiency virus type 1 gp120 molecule. J. Viral. 66:3183-3187. 
73. Cheng-Mayer, C, Seta, D, Tateno, M, & Levy, JA. (1988) Biologic features of HIV-1 that correlate with virulence 
in the host. Science 240:80-82. 
74. Tersmette, M, de Goede, RE, AI, BJ, et a1. (1988) Differential syncytium-inducing capacity of human 
immunodeficiency virus isolates: frequent detection of syncytium-inducing isolates in patients with acquired 
15 
immunodeficiency syndrome (AIDS) and AIDS-related complex. J. Virol. 62:2026-2032. 
75. Fenyo, EM, Morfeldt-Manson, L, Chiodi, F, et al. (1988) Distinct replicative and cytopathic characteristics of 
human immunodeficiency virus isolates. J. Viro!. 62:4414-4419. 
76. Tersmette, M, de Goede, RE, AI, BJ, et a!. (1988) Differential syncytium-inducing capacity of human 
immunodeficiency virus isolates: frequent detection of syncytium-inducing isolates in patients with acquired 
immunodeficiency syndrome (AIDS) and AIDS-related complex. J ViroI62:2026-2032. 
77. Schuitemaker, H, Kootstra, NA, Groenink, M, de Goede, RE, Miedema, F, & Tersmette, M. (1992) Differential 
tropism of clinical HIV-1 isolates for primary monocytes and promonocytic cell lines. AIDS Res. Hum. 
Retroviruses 8:1679-1682. 
78. Cao, J, Park, IW, Cooper, A, & Sodroski, J. (1996) Molecular determinants of acute single-cell lysis by human 
immunodeficiency virus type 1. J. Virol. 70:1340-1354. 
79. Bergeron, L & Sodroski, J. (1992) Dissociation of unrntegrated viral DNA accumulation from single-cell lysis 
induced by human immunodeficiency virus type 1. J. Virol. 66:5777-5787. 
80. Dedera, D & Ratner, l. (1991) Demonstration of two distinct cytopathic effects with syncytium 
formation-defective human immunodeficiency virus type 1 mutants. J. Virol. 65:6129-6136. 
81. Schuitemaker, H, Koot, M, Kootstra, NA, et at (1992) Biological phenotype of human immunodeficiency virus 
type 1 clones at different stages of infection: progression of disease is associated with a shift from 
monocytotropic to T-cell-tropic virus population. J. Virol. 66:1354-1360. 
82. Schuitemaker, H, Koolstra, NA, de Goede, RE, de Wolf, F, Miedema, F, & Tersmette, M. (1991) Monocytotropic 
human immunodeficiency virus type 1 (HIV-1) variants detectable In all stages of HIV-1 infection lack T-cell line 
tropism and syncytium-inducing ability in primary T-cell culture. J. Virol. 65:356-363. 
83. Groenink, M, Fouchier, RA, de Goede, RE, et al. (1991) Phenotypic heterogeneity in a panel of infectious 
molecular hUman immunodeficiency virus type 1 clones derived from a single individual. J. Viral. 65:1968-1975. 
84. Donaldson, YK, Bell, JE, Holmes, EC, Hughes, ES, Brown, HK, & Simmonds, P. (1994) In vivo distribution and 
cytopathology of variants of human immunodeficiency virus type 1 showing restricted sequence variability in 
the V3100p. J. Virol. 68:5991-6005. 
85. Innocenti-FranciUard, P, Brenget K, Guillon, C, et al. (1994) Blood monocytes infected in vivo by HIV-1 variants 
with a syncytium-inducing phenotype. AIDS Res. Hum. Retroviruses 10:683-690. 
86. Mosier, D & Sieburg, H. (1994) Macrophage-tropic HIV: critical for AIDS pathogenesis? Immunol. Today 
15:332-339. 
87. Gulizia, RJ, Levy, JA, & Mosier, DE. (1996) The envelope gp120 gene of human immunodeficiency virus type 
1 determines the rate of CD4-positive T-cell depletion in SCID mice engrafted with human peripheral blood 
leukocytes. J. Virol. 70:4184-4187. 
88. Mosier, DE, Gulizia, RJ, Macisaac, PO, Torbett, BE, & Levy, JA. (1993) Rapid loss of CD4+ T cells in 
human-PBL'SCID mice by noncytopathic HIV isolates. Science 260:689-692. 
89. Koot, M, Vos, AH, Keet, RP, et al. (1992) HIV-1 biological phenotype in long-term infected individuals evaluated 
with an MT-2 cocultivation assay. AIDS 6:49-54. 
90. Cornelissen, M, Mulder~Kampinga, G, Veenstra, J, et at (1995) Syncytium-inducing (81) phenotype suppression 
at seroconversion after intramuscular inoculation of a non-syncytium-inducing/SI phenotypically mixed human 
immunodeficiency virus population. J. Virol. 69:1810-1818. 
91. Zhu, T, Mo, H, Wang, N, et al. (1993) Genotypic and phenotypic characterization of HIV-1 patients with primary 
infection. SCience 261 :1179-1181. 
92. Zhang, LO, MacKenzie, P, Cleland, A, Holmes, EC, Brown, AJ, & Simmonds, P. (1993) Selection for specific 
sequences in the external envelope protein of human immunodeficiency virus type 1 upon primary infection. J 
ViroI67:3345-3356. 
93. McClure, MO, Marsh, M, & Weiss, RA. (1988) Human immunodeficiency virus infection of CD4-bearing cells 
occurs by a pH-independent mechanism. EMBO J. 7:513*518. 
94. Maddon, PJ, McDougal, JS, Clapham, PR, et a!. (1988) HIV infection does not require endocytosis of its 
receptor, CD4. Cell 54:865-874. 
95. Orloff, GM, Orloff, SL, Kennedy, MS, Maddon, PJ, & McDougal, JS. (1991) Penetration of CD4 T cells by HIV-1. 
The CD4 receptor does not internalize with HIV, and CD4-related signal transduction events are not required 
for entry. J. Immunol. 146:2578-2587. 
96. Pauza, CD. (1991) The endocyUc pathway for human immunodeficiency virus infection. Adv. Exp. Med. BioI. 
300:111-38; discussion 139-4. 
97. Bullough, PA, Hughson, FM, Skeilel, JJ, & Wiley, DC. (1994) Structure of inHuenza haemagglutinin at the pH 
16 
of membrane fusion. Nature 371 :37~43. 
98. Heath, SL, Tew, JG, Szakal, AK, & Burton, GF. (1995) Follicular dendrilic cells and hUman immunodeficiency 
virus infectivity. Nature 377:740·744, 
99. Moore, JP. (1993) A monoclonal antibody to the CDR·3 region of CD4 inhibits soluble CD4 binding to virions 
of human immunodeficiency virus type 1. J, Virol. 67:3656-3659, 
100, Yahi, N, Sabatier, JM, Baghdiguian, S, Gonzalez-Scarano, F, & Fantini, J. (1995) Synthetic multimeric peptides 
derived from the principal neutralization domain (V3 loop) of human immunodeficiency virus type 1 (HIV-1) 
gp120 bind to galactosylceramide and block HIV-1 infection in a human CD4-negative mucosal epithelial cell 
line. J. Virol. 69:320-325. 
101, Harouse, JM, Coliman, RG, & Gonzalez-Scarano, F, (1995) Human immunodeficiency virus type 1 infection of 
SK-N-MC cells: domains of gp120 involved in entry into a CD4-negative, galaclosyl ceramide/3' sulfo-galactosyl 
ceramide-posilive cell line, J, Viral. 69:7383-7390. 
102. Bou-Habib, DC, Roderiquez, G, Oravecz, T, et at (1994) Cryptic nature of envelope V3 region epitopes protects 
primary monocytotropic human immunodeficiency virus type 1 from antibody neutralization. J. Virol. 
68:6006-6013. 
103. Moore, JP & Nara, PL (1991) The role of the V3100p of gp120 in HIV infeclion. AtDS 5 SuppI2:S21-33. 
104. Nara, PL, Garrity, RR, & Goudsmit, J. (1991) Neutralization of HIV-1: a paradox of humoral proportions. FASEB 
J 5:2437-2455. 
105. Berman, PW & Nakamura, GR. (1994) Adhesion mediated by intercellular adhesion molecule 1 attenuates the 
potency of antibodies that block HIV-1 gp160-dependent syncytium formation. AIDS Res. Hum. Retroviruses 
10:585-593. 
106. Sattentau, OJ, Moore, JP, Vignaux, F, Traincard, F, & Poignard, P. (1993) Conformational changes induced in 
the envelope gtycoproteins of the human and simian immunodeficiency viruses by soluble receptor binding. J 
ViroI67:7383-7393. 
107. Sattentau, OJ & Moore, JP. (1995) Human immunodeficiency virus type 1 neutralization is determined by 
epitope exposure on the gp120 oligomer. J. Exp. Med. 182:185-196. 
108. Stamatatos, L & Cheng-Mayer, C. (1995) Structural modulations of the envelope gp120 glycoprotein of human 
immunodeficiency virus type 1 upon oligomerization and differential V3 loop epitope exposure of isolates 
displaying distinct tropism upon virion·soluble receptor binding. J. Virol. 69:6191-6198. 
109. Kwong, PD, Ryu, SE, Hendrickson, WA, et al. (1990) Molecular characteristics of recombinant human CD4 as 
deduced from polymorphic crystals. Proc. Nat!. Acad. Sci. U. S. A 87:6423-6427. 
110. Moore, JP, McKeating, JA, Weiss, RA, & Saltentau, QJ. (1990) Dissociation ofgp120 from HIV-1 virions induced 
by soluble CD4. Science 250:1139-1142. 
111. Groenink, M, Moore, JP, Broersen, S, & Schulte maker, H. (1995) Equal levels of gp120 retention and 
neutralization resistance of phenotypically distinct primary hUman immunodeficiency virus type 1 variants upon 
soluble CD4 treatment. J. Virol. 69:523-527. 
112. McKeating, JA, McKnight, A, & Moore, JP. (1991) Differential loss of envelope glycoprotein gp120 from virions 
of human immunodeficiency virus type 1 isolates: effects on infectivity and neutralization. J ViroI65:852-860. 
113. Allan, JS. (1991) Receptor-mediated activation of immunodeficiency viruses in viral fusion. Science 
252:1322-1323. 
114. Moore, JP, McKeating, JA, Weiss, RA, Clapham, PR, & Sattentau, OJ. (1991) Receptor mediated activation of 
immunodeficiency viruses in viral fusion. Science 252:1322-1323. 
115. Carr, CM & Kim, PS. (1993) A spring-loaded mechanism for the conformational change of influenza 
hemagglulinin. Cell 73:823-832. 
116. Matthews, T J, Wild, C, Chen, CH, Bolognesi, DP, & Greenberg, Ml. (1994) Structural rearrangements in the 
transmembrane glycoprotein after receptor binding. Immunological Rev. 140:93-104. 
117. Wild, C, Dubay, JW, Greenwell, T, et aL (1994) Propensity for a leucine zipper-like domain of human 
immunodeficiency virus type 1 gp41 to form oligomers correlates with a role in virus-induced fusion rather than 
assembly of the glycoprotein complex. Proc. Nat!. Acad. Sci. U. S. A. 91:12676-12680. 
118. Chen, CH, Matthews, TJ, McDanal, CB, Bolognesi, DP, & Greenberg, ML (1995) A molecular clasp in the 
human immunodeficiency virus (HIV) type 1 TM protein determines the anti-HIV activity of gp41 derivatives: 
implication for viral fusion. J. Virol. 69:3771-3777. 
119. Bosch, ML, Earl, PL, Fargnoli, K, et al. (1989) Identification of the fusion peptide of primate immunodeficiency 
viruses. Science 244:694-697. 
120. Maddon, PJ, Dalgleish, AG, McDougal, JS, Clapham, PR, Weiss, RA, & Axel, R. (1986) The T4 gene encodes 
17 
the AIDS virus receptor and is expressed in the immune system and the brain. Cell 47:333-348. 
121. Alkhalib, G, Combadiere, C, Broder, CC, et al. (1996) CC CKR5: A RANTES, MIP-1 alpha, MIP-1 beta Receptor 
as a fusion cofactor for macrophage-tropic HIV-1. Science 272:1955-1958. 
122. Feng, Y, Broder, CC, Kennedy, PE, & Berger, EA. (1996) HIV-1 entry cofactor: Functional cDNA cloning of a 
seven-transmembrane, G-protein-coupled receptor. Science 272:872-877. 
123. Earl, PL, Broder, ce, Long, D, et at (1994) Native oligomeric human immunodeficiency virus type 1 envelope 
glycoprotein elicits diverse monoclonal antibody reactivities. J. Viral. 68:3015-3026. 
124. Poignard, P, Kiasse, PJ, & Sattentau, OJ. (1996) Antibody neutralization of HIV-1. Immunol. Today 17:239-246. 
125. Laman, JD, Scheliekens, MM, Lewis, GK, et al. (1993) A hidden region in the third variable domain of HIV-1 IIIB 
gp120 identified by a monoclonal antibody. AIDS Res. Hum. Retroviruses 9:605-612. 
126. Langedijk, JP, Back, NK, Durda, PJ, Goudsmit, J, & Meioen, RH. (1991) Neutralizing activity of anti-peptide 
antibodies against the principal neutralization domain of human immunodeficiency virus type 1. J. Gen. Virol. 
72:2519-2526. 
127. Dimmock, NJ. (1996) Rev. Med. Virol. 5:165-179. 
128. Poignard, P, Fouts, T, Naniche, D, Moore, JP, & Sattentau, OJ. (1996) Neutralizing antibodies to human 
immunodeficiency virus type-1 gp120 induce envelope glycoprotein subunit dissociation. J. Exp. Med. 
183:473-484. 
129. Thali, M, Furman, C, Helseth, E, Repke, H, & Sodroski, J. (1992) Lack of correlation between soluble 
CD4-induced shedding of the human immunodeficiency virus type 1 exterior envelope glycoprotein and 
subsequent membrane fusion events. J. Vlrol. 66:5516-5524. 
130. Sattentau, OJ, Zolla-Pazner, S, & Poignard, P. (1995) Epitope exposure on functional, oligomeric HIV-1 gp41 
molecules. Virology 206:713-717. 
131. Koito, A, Harrowe, G, Levy, JA, & Cheng-Mayer, C. (1994) Functional role of the V1N2 region of human 
immunodeficiency virus type 1 envelope glycoprotein gp120 in infection of primary macrophages and soluble 
CD4 neutralization. J. Virol. 68:2253-2259. 
132. Stamatatos, L & Cheng-Mayer, C. (1993) Evidence that the structural conformation of envelope gp120 affects 
human immunodeficiency virus type 1 infectivity, host range, and syncytium-forming ability. J. Virol. 
67:5635-5639. 
133. Ebenbichler, CF, Stoiber, H, Schneider, R, Patsch, JR, & Oierich, MP. (1996) The human immunodeficiency 
virus type 1 transmembrane gp41 protein is a calcium-binding protein and interacts with the putative 
second-receptor molecules in a calcium-dependent manner. J. Virol. 70:1723-1728. 
134. Morens, DM. (1994) Antibody-dependent enhancement of infection and the pathogenesis of vi raJ disease. Clin. 
Infecl. Dis. 19:500-512. 
135. Fanger, MW, Shen, L, Graziano, RF, & Guyre, PM. (1989) Cytotoxicity mediated by human Fc receptors for IgG. 
Immunol. Today 10:92-99. 
136. Wilson, JG, Andriopoulos, NA, & Fearon,DT. (1987) CR1 and the ceil membrane proteins that bind C3 and C4. 
A basic and clinical review. Immuno!. Res. 6:192-209. 
137. Trischmann, H, Davis, 0, & Lachmann, PJ. (1995) Lymphocytotropic strains of HIVtype 1 when complexed with 
enhancing antibodies can infect macrophages via Fc gamma RIll, independently of CD4. AIDS Res. Hum. 
Retroviruses 11 :343-352. 
138. Takeda, A, Tuazon, CU, & Ennis, FA. (1988) Antibody-enhanced infection by HIV-1 via Fc receptor-mediated 
entry. Science 242:580-583. 
139. Homsy, J, Meyer, M, Tateno, M, Clarkson, S, & Levy, JA. (1989) The Fc and not CD4 receptor mediates 
antibody enhancement of HIV infection in human cells. Science 244:1357-1360. 
140. Jouault, T, Chapuis, F, Olivier, R, et at (1989) HIV infection of monocytic cells: role of antibody-mediated virus 
binding to Fc-gamma receptors. AIDS 3:125-133. 
141. Lund, 0, Hansen, J, Soorensen, AM, Mosekilde, E, Nielsen, JO, & Hansen, JE. (1995) Increased adhesion as 
a mechanism of antibody-dependent and antibody-independent complement-mediated enhancement of human 
immunodeficiency virus infection. J. Viral. 69:2393-2400. 
142. Bakker, LJ, Nottet, HS, de Vas, NM, et al. (1992) Antibodies and complement enhance binding and uptake of 
HIV-1 by human monocytes. AIDS 6:35-41. 
143. June, RA, Schade, SZ, Bankowski, MJ, et al. (1991) Complement and antibody mediate enhancement of HIV 
infection by increasing virus binding and provirus formation. AIDS 5:269-274. 
144. Allan, JS, Strauss, J, & Buck, OW. (1990) Enhancement of SIV infection with soluble receptor molecules. 
Science 247:1084-1088. 
18 
145. Schutten, M, Andeweg, AC, Bosch, ML, & Osterhaus, AD. (1995) Enhancement of infectivity of a non-syncytium 
inducing HIV-1 by sCD4 and by human antibodies that neutralize syncytium inducing HIV-1. Scand. J.lmmunoJ. 
41:18·22. 
146. Sullivan, N, Sun, Y, Li, J, Hofmann, W, & Sodroski, J. (1995) Replicative function and neutralization sensitivity 
of envelope glycoproteins from primary and T -cell line-passaged human immunodeficiency virus type 1 isolates. 
J. Viral. 69:4413·4422. 
147. Schreiber, M, Petersen, H, Wachsmuth, C, Muller, H, Hufert, FT, & Schmitz, H. (1994) Antibodies of 
symptomatic human immunodeficiency virus type 1-infected individuals are directed to the V3 domain of 
noninfectious and not of infectious virions present in autologous serum. J. Virol. 68:3908-3916. 
148. Siebelink, KH, Tijhaar, E, Huisman, Re, et al. (1995) Enhancement of feline immunodeficiency virus infeclion 
after immunization with envelope glycoprotein subunit vaccines. J. Virol. 69:3704-3711. 
149. Wang, SZ, Rushlow, KE, IsseI, CJ, et al. (1994) Enhancement of EIAV replication and disease by immunization 
with a baculovirus-expressed recombinant envelope surface glycoprotein. Virology 199:247-251. 
150. Hulskotte, EG, GereUi, AM, Siebelink, KH, et a!. (1995) Vaccine-induced virus-neutralizing antibodies and 
cytotoxic T cells do not protect macaques from experimental infection with simian immunodeficiency virus 
SIVmac32H (J5). J. Viral. 69:6289-6296. 
19 
j 
j 
j 
j 
j 
j 
j 
j 
j 
j 
j 
j 
j 
j 
j 
j 
j 
j 
j 
j 
j 
j 
j 
j 
j 
j 
j 
j 
j 
j 
j 
j 
j 
j 
j 
j 
j 
j 
CHAPTER 2 
Further characterization of an antigenic site of HIV-1 
gp120 recognized by virus neutralizing human 
monoclonal antibodies. 
AIDS 7:919-923. (1993) 

Further characterization of an antigenic site of HIY-1 gp120 
recognized by virus neutralizing human monoclonal 
antibodies 
Martin Schutten, Aine McKnight·, Robin C. Huisman, Marcus Thalit, 
Jane A. McKeating·, Joseph Sodroskit, Jaap Goudsmitt 
and Albert D. Osterhaus 
Objective: The aim of this study is to characterize antigenic sites on HIV-1 gp120 which 
may be important for the development of active and passive immunization strategies 
against HIV-1 infection. 
Design: Two HIV-1-seropositive individuals were selected from the Amsterdam cohort 
and Epstein-6arr virus (EBV)-transformed B cells were generated from their peripheral 
blood mononuclear celis, which produce t-flV-1-specific human monoclonal antibodies 
(HuMAb). 
Melhods: HuMAb were generated and selected based on their reactiyities with native 
gp120. Reactivity with HtV-1 strains from phylogenetically different subfamilies was 
determined by immunostaining and virus neutralization assays. Specificity for the 
CD4-binding site was tested by an inhibition enzyme-linked immunosorbent assay and 
amino acids (aa) involved in the binding of the HuMAb were identified with a set of 
gp120 molecules with single aa substitutions. 
Results: Three HuMAb (CP13, CP44, GP68) were generated, all recognizing a conserved 
conformation dependent epitope within, or topographically near, the CD4-binding site 
of gp120. HuMAb GP13 and GP68 neutralized a broad range of HIV-l strains from 
phylogenetically different subfamilies, whereas HuMAb GP44 exhibited a more restricted 
pattern of neutralizing activity. The patterns of gp120 aa involved in their binding were 
unique for each of these HuMAb. 
Conclusions: The pattern of reactivities of these three HIV-1-neutralizing HuMAb 
developed in these studies is similar to, but distinct from other human and rodent 
MAb that recognize this antigenic site of H1V-1 gp120. 
AIDS 1993, 7:919--923 
Keywords: HIV-1, neulralizing anlibodies, human monoclonal antibody, gp120, 
CD4-binding site, virus neutralization, passive immunization. 
Introduclion 
Several studies in which vims-neutralizing (VN) anti· 
bodies were passivel}' transferred, indicated that anti· 
viral antibodies pia}' a major role in the protection 
from lentivirus infections [1-4J. Sera from HIV-l-
infected individuals have been shown to neutralize a 
.... ide ['"JIlge of HIV-l strains originating from Europe, 
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the United States of America and Africa [51. Antibod-
ies recognizing a conformation dependent antigenic 
site, overlapping with the CD4-binding site on gp120 
are responsible for a major part of the VN cross-
reacti\ity in human sera (6,7J. To investigate the na-
ture of this antigenic site in more detail, monoclonal 
antibcx:1ies (MAb) of this specificity are of great value. 
To date, a limited number of human J\1Ab/(HuMAb) 
specific for this site have been derived from North 
American HIV-l-seropositive individuals. Furthermore, 
rodent MAb, which inhibit binding of gp120 to CD4, 
have been generated against HIV-l Hill gp120 (8-12J. 
Here, we describe the generation of VN Hul\1Ab pro-
duced by Epstein-Barr virus (EBV) transformation of 
peripheral blood mononuclear cells (PBMC) from two 
Dutch HIV-l-seropositive indr.iduaJs. The characteriza~ 
tion of these antilxxlies and the corresponding epi-
topes are presented. 
Materials and methods 
Cell lines and virus strains 
Human IIeL1 CD4 + celis and the human lymphoid 
cell lines C8166 and H9 were maintained in Dulbecco's 
mcxlified Egale's medium (DMEM) or RPMI·I640 su-
plemented v.ith fetal calf serum (FCS) [131. The fol-
lowing \irus strains, with the sUbtype indicated accord-
ing to Meyers et (11. [141. were used for immunostain· 
ing and virus neutralization: UlB (tAl isolate, subt)Ve 
B), Itl' and MN (suh~'Pc B) [15,16], 5F2 (sub~'Pe 
B)[17], NY~5/IAV~1 (sub~e B), Z34, Z84 (sub~'Pe D) 
and Z129 [5], GL~ I and GI.·3 [9], U455 (sl1b~'Pe A)[ 51 
and CBLA [51. The HIV~2 strain CBU2 [181 and ROD 
[191 were also used. 
Generation of human B cell clones and HuMAb 
PBMC were isolated from 40 ml blood of four 
HIV-l-seropositive asymptomatic adult males of the 
Amsterdam cohort, and generation of EBV-trans-
fomleci B·ceU lines with these PBMC WJS perfomled 
as described pre\iously {20j. For the identification ~md 
characteri7..ation of antibodies in culture supernat;.lI1t'\, 
an enzyme-linked immllnosorbent assay (EIJSA) sys-
tem deSCribed by Robinson [111 was used with re-
combinant HN-1 IIlB gpI20, recombinant HIV·I lIlB 
gpI60 and recombinant HIV-2 gpIOS produced in 
a baculovims expression system (American Biotech· 
nologies Inc., Cambridge, Massachusett'\, USA), feline 
immunodeficiency virus (PIV) glycoprotein [21J and 
simian immunodeficiency \irus (S1\' m3.C2SI) cell Irsate 
[22] as antigens. 
Immunostaining assay 
The degree of conservation of the epitopes recognized 
by the HuMAb generated in these sLUdies was tested 
24 
in a preViously described immunostaining assay with 
the above mentioned \ims strains {23J. 
ELISA systems 
TIle HliMAb GP13 and GP6B generated in the course 
of this study were biotinylated with NIIS·d·succin-
imidobiotin as recommended by the manufacturer 
(Sigma Chemie, Axel, The Netherlands). Recombinant 
gp120 (sec above, 75 ng/ml) was coated to the EUSA 
plate with affinity-pUrified polrclonal antibody raised 
in sheep against the HIV-l gpI20 carboxy temlinus 
{24,2S}. gp120·coated plates were incubated for 1 h 
at 37°C with serial dilutions of biotinylated HuMAb 
and after wa'\hing incubated for 1 h at 37°C with 1: 20 
diluted StreptABComplex HRP (OAKO lVS, Glostmp, 
Denmark). The dilution resulting in the half maximum 
optical density (OD) 450run (mid·point titre) of the 
biotin}1ated HuMAb was detemlined. To detennine 
the inhibition of the biotin}1ated HuMAb b}' the dif-
ferent HuMAb and soluble CD-i (sCD4), the gp120 
coated plates were preincubated for I h with 80 ~d se-
rially diluted I IuMAb or sCD4. A5 a negative control, 
a broadly reactive HuMAb (K14, immunoglobulin G 1 
(IgGl) specific for IIIV-l gp41 was used [201, and 
20~t1 of the biotinylated HuMAb (mid-point titre) W..L'i 
added. The EUSA was further developed as described 
above. These assays were perfomled in triplicate; the 
me-J.n of the results of dle three independent assays is 
gh'en. 
The EUSA used for the determination of the specificity 
of the HuMAb for a described set of mutant gpl20 gly· 
coproteins [261 was performed v.ith a previousl)' de-
scribed assa}' deyeloped by Dr J. McKeating (Chester 
ileatly Laboratories, London, UK) [2S,27J. The reduc· 
tion in binding is giwn as the mean percentage of the 
binding by the wild· tyPe glycoproteins, and calculated 
from the results of two independent assays according 
to the fOffimla: 
(
OD45Omutant - oD450baCkground) 
% '" 100 x OD450WT _ OD450background 
VN assay 
The microtiter VN assa}' used in these studies h;l'\ been 
described previousl>, [13]. Briefly, 1000 median tissue 
culture infective doses (TClDSO ) of \inlS s[Qck in ..to ~ll 
was incubated v.ith lO ~t1 of serial dilutions of protein 
A purified HuMAb for 1 h at 37·C, then incubated \\ith 
100 ~d of 2 x lOS/ml C8166 or 119 cells for 1 h at 37·C. 
After 5 days of culture, the wells were microscopically 
scored for the presence of syncytia. Data presented are 
taken from representath'e experiments. Sevep',1 con· 
trol experiments Were performed, including multiple 
testing of diJt"erent virus stocks with different HuMAh 
preparations. Similar result,> were obt;.lined in all of 
these cases. 
Results 
General properties of newly generaled gp120-specific 
HuMAb 
Screening of cloned EBY·transfoffiled PBMC from two 
out of four donors (numbers 1171 and 658) yielded 
one B·celiline from the first donor (EBV GPU) and 
two from the second (EBY GP44, EBY GP68), all 
three produced Hut-.tAb of the IgGl subclass reactive 
in an EUSA with recombinant HIV·l lllB gp120 and 
gpl60. These cell lines were subcloned until> 99.9% 
chance of clonality was obtained (20). These I1uMAb 
failed to recognize envelope glycoproteins of I1IV-
2, SI\'mac, and FI\' in EUSA (d'lta not shown), indi-
t.<lting that these three Hul\.lAb react specifically with 
HIY·} gp120. To delineate the antigenic sites recog· 
nized by these three HuMAb, we tested their capacity 
and that of sCD4 to inhibit the binding of biotincon· 
jugaled HuMAb GP13 (Fig. la) and Gp6g (Fig. lb) al 
their midpoint titer (18.8 and % ng/ml, respectiveUr) 
to HIV-l Hill gp120 in the inhibition EUSA. The bind· 
ing of GP13 and GP68 to gp120 was not inhibited b}' 
the gp41 specific Hu{\1Ab. GP13 ,md GP68 lllutuaHy 
inhibited each other to approximately lhe same extent 
wherC'dS nearly 100 times more GP44 wa,> needed for 
the same inhibition of the binding of bOlh antibod· 
ies. The binding of GP13 ;md GP68 to gp120 could 
also be inhibited by pre-incubation of the wells with 
approximately 10 or 100 ng sCD4 perml respectively. 
These dat~l indicate that the HuMAb GPI3, GP44 ,md 
GP68 recognize an antigenic site located within or to· 
pographicall}' near the CD4·binding site of gp120. 
~ " I 
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Fig. 1. Mean reduction percentages of 00450 nm values {lb· 
t,linro by preincubation of gp120 coated enzyme-l(ked im· 
munosorbent assay plates with non-labelJed human monoclonal 
antibodies tHul-.'tAb) or solublc<sl C04. and subsequent addition 
of biotin labelJed HuMAb GP13 (a) ,1nd CP681b) at midpoint titres 
n8.8 and 98 nglml respectivellyJ. Concentrations of non·labelled 
HllMAb are given in ngflTlllhorizontal axisl. All assays WN(, e,)f' 
ned out lJl triplicate and S.d. wele less then 2% in all cases. CPU 
!-+-);GP44(-·+-·~GP68(-x-);K14(·-+- -);sC04( x ). 
Specificity of HuNtAb GP13, GP44 and GP68 
To determine the degree of conservation of the epi· 
lope recognized by these three HUMAb, they were 
tested for their abHil}' to stn.in ceUs infected with 
HIY isolates from three out of five ph}10genetic sub· 
families of HIY-l [14J in the immunostaining assay. 
All HlV-l strains tested (n = 12) were recognized b}' 
these HuMAb, whereas the two IIIV·2 strains tested 
were not recognized in this assay (data not shown). 
Table 1. HJV-' neutralizing activity of human monoclonal antibodies. 
Virus Strain cpn CPH or" 
HIV-l Sf1 0.1' 
'" 
07 
HIV-' MN 30 > 240 11 
HIV·' !lIB 4S > 240 30 
HIV·1 Rf 90 > 240 > 250 
HIV-1 CBl< 12 > 240 11 
HIV-1 Z34 8 > 240 11 
HIV·2 ROD > 250 > 240 > 250 
HIV-2 CBL·22 > 250 > 240 >2'" 
'In I'ilro virus neurtalizing activity presented as the lowest concentration 
of human monoclonal actr.ity in ~lg/ml. gi\ing 90-95".1> reduction of the 
numbers of syncytia in a syncytium inhibition assay using 1000 median 
tissue culture infective doses ITODso-l. 
The broadest HIV·}·neutralizing activity was observed 
for HuMAb GP13 which neutralized all the HIV·l 
.strains tested. The concentrations of antibody needed 
to neutralize 1000 TCIDso of the different virus strains, 
ranged from 0.1 to 90 J-Ig/ml for HIV-lsf2 and for 
HIV.I RF, respectivel}'. Also, HuMAb GP68 exhibited a 
relativelr broad VN activity. It only failed to neutralize 
I [IV· 1 RF nt the antibody concentrations tested ( < 250 
l-'g/ml). IluMAb GP44 only neutralized HTV·I SF2 un· 
der these conditions at levels ~ 60 Jlg/Illl (Table I). 
Recognition of mulant HlV·1 gp120 molecules by 
HuNtAb GP13, GP44 and GP68 
The reactivities in EUSA of these three IluMAb with a 
p,mel of mutant HIY·l gp120, containing single amino· 
acid (aa) substitutions [26], arc presented as percent· 
ages of their reactivities 'with the wild· type (I lXBc2) 
gpl20 in Fig. 2. For comparison, the reactivities of 
these mutant gl}'coproteins With sCD4 and HuMAb 
F105, a previously described HuMAb of similar sped· 
ficit)" are also shown [1O,28J. Changes in threonine 
257, aspartic acid 368 or glutamic acid 370 abrogated 
recognition by the GPI3, GP44 and GP68 antibodies. 
Changes in recognition by these antibodies were also 
seen for the 256 Sly ,md 262 N/r mUl<Ults, v-.11ich 
exhibit a certain degree of confonnational alteration 
relatiw to the v-.'ild·t}tpe envelop gircoproteins {26J. 
Recognition of the gp120 glycoprotein by the GP6B 
MAb was uniquely affected by changes in lysine 117 
and tyrosine 435. 
Discussion 
In this study we ha\'e described the generation of 
three EBY·transformed B·ce!I lines from the PBMC of 
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immunodeficiency virus type 1 strains. 
J. Gen. Viral. 76:1665-1673. (1995) 
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A type-specific human immullodeficiency virus type 1 
(HIV-I)-ncutralizing human monoclonal antibody 
(HuMAb MN215) is described that reacts with Ihe V3 
domain of a number of subtype n viOls strains. Pepscan 
analysis indicated that amino acids at both sides of the 
tip of the V3 loop were invohred in the binding of 
Hul'vlAb fo,'lN215. The minimum epitope in a V3 
sequence, obtained from the donor from whom the cell 
line originated, was 9 amino acids long and proved to be 
located at the C-terminal side of the tip of the loop. In 
a replacement Pepscan analysis, individual amino acids 
of the V3100Jl important for binding ofHur\'lAb MN215 
Introduction 
Virus neutralizing (VN) antibodies are belieYCd to playa 
major role in the pathogenesis of human inmmno-
deficiency virus type 1 (HIV-l) infection. Suppression of 
virus replication during the relatively long asymptomatic 
period is believed to be mediated at least in part by the 
humoral immune response (Page el al., 1992; Watkins el 
af., 1993). The identification and characterization of 
antigenic sites on the glycoproteins of HIV-I that elicit 
VN antibodies therefore seems to be a prerequisite for 
the rational development of passive and active immuni-
zation strategies. The third variable domain (V3 domain) 
of the outer membrane glycoprotein (gpI20) of HIV-I 
has been shown to elicit VN antibodies (Goudsmit el af., 
1988; Palker et al., 1988). Despite the variability within 
this antigenic site, certain antibodies directed against this 
domain may neutralize a wide range of virus strains 
• Author for correspondence. Fa:;; +31 \0 4365145. e·maH 
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were identified, Amino acids at positions 15 (H), 16 (I), 
17 (G) and 18 (P) were found to be essential for binding 
of the antibody, whereas changes at positions 19 ofG to 
N, 20 ofR to K and 23 ofF to L, as well as the addition 
of a negative charge at the C terminus, improved 
binding, Thus, amino acids inyolYed in the binding of 
HuMAb MN215 arc primarily located within highly 
variable regions of the V3loop. HuMAb :MN215 showed 
a higher affinity for the V3 domain sequences and 
recombinant eJlyelope giycoproteins derived from nOIl-
syncytium-inducing strains than for those deriyed from 
syncytium-inducing strains. 
(Langedijk el al., 1991; Ohno et al., 1991; Gorny ef ai" 
1992), Certain human monoclonal antibodies (HuMAbs) 
directed against the V3 domain arc therefore likely 
candidates for passive immunization therapies. A mouse 
monoclonal antibody directed against the V3 domain of 
the HIV-l lIlB strain has been shown to protect a 
chimpanzee against a challenge with the homologous 
virus strain when the antibody was administered prior to 
challenge (Emini et ai" 1992), 
The V3 domain has been shown to be an important 
denominator for the phenotype of the virus: it directly 
influences the syncytium-inducing (SI) capacity and cell 
tropism of the virus, Mutations in the V3 domain of 
HIV-l strains or the exchange of this region between 
highly related but phenotypically distinct glycoproteins 
may change their biological phenotypes (Freed & Risser, 
1991; de long el al., 1992; Andeweg el al., 1993), It has 
also been shown that the V3 domain consensus sequence 
of non-syncytium-inducing (NSI) HIV-l strains difrers in 
several aspects from the V3 consensus sequence of Sf 
HIV-I strains (Fouchier et aI" 1992). A similar phenom-
enon has been observed when the V3 domain consensus 
sequence of macrophage-tropic and T cell-tropic HIV-l 
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strains were compared (Chesebro elaf., 1992). Therefore, 
it may be expected that certain antibodies directed 
against this site display different reactivities with HIV-l 
strains of diHerent phenotypes. HIV-I strains isolated 
during the asymptomatic period of 111V-I infection are 
predominantly of the NSI phenotype and are therefore 
considered important targets for early passive immuni-
zation therapies (Roos el al., 1992; Zhang el al., 1992; 
Zhu el al., 1993). Studies with V3 domain-specific 
HuMAbs have primarily focused on their reactivities 
with HIV-l strains of the SI phenotype, since these HIV-
1 strains are most commonly used in assay systems. Here 
we describe the generation and characterization of a 
HIV-I V3 domain-specific HuMAb that reacts pre-
dominantly with HIV-l strains of the NSI phenotype. 
Methods 
Gel/erat/oll of a human B (I'll clolle producing 1'3 dOlllain>specific 
flllMAb. Peripheral blood mononuclear cells (PBMC) were isolated 
from 40 ml heparinized blood of an mY-I·seropositiw asrmptomatic 
adult male of the Amsterdam cohort (donor 4658) four years after 
seroconversion; generation of Epstein-Barr virus (EBYHransformed 
B cell lines was perfonned essentially as pre\iously described (Te.!uwsen 
et al., 1990; Schutten t't af., 1993). The B cell line described in the 
present paper was fused with the mouse--human hcterohybridoma 
F3n6 (Foung c( al., 1984) and subcloned several times, after which it 
was expanded into flasks. 
For the idcntification of antibodies in culture su~matant, ELISA 
plates (Costar) were coatcd with a 23 amino acid ~ptide, purchased 
from American DioTe.:hnologies, spanning the tip of the V3 loop of 
HIY-I MN gpI20. This ~ptide was coated overnight at 4 °C in PBS 
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pll 7·5at 750 ng/ml. The ELISA was developed as previouslyde,cribed 
(Schutten N III., 1993). Twelve peptide, representing the V3 region of 
HIV-I subtype B (Uniwrsal (subtype B consensus; Meyers ('lar., 1992), 
MN, Sc. SF1. CDC4. HXB2, WM52, RF and NY /5 strains] and 
subtype D (ELI, Z2 and Z6 strains) (Meyers e( al., 1992) were 
purchased from American BioTechnologies and coated unda the same 
conditions for determination of the cross·re,activity. IgG subclass 
determination was carried out in ELISA with subclass-specific mouse 
monoclonal antibodies (Seralab). The HIV-I gpl20 V3 loop sequence 
from \irus in the serum of donor #658 \\as determined as described 
previously (Wolfs f( Ilr., 1991). 
Pcptideillhibilio/l ELISA. HuMAb MN215 was incubated with seri,,1 
dilutions of the HIV-I Un;\·mal, }.IN, SF2 and SC V3 peptidcs at a 
concentration at which half of the maximum binding \\a5 achie\·ed in 
a solid phase V3100p peptide ELISA using the HIY-I MN V3 peptide. 
Furthermore. peptides generated by Dr C. Sia (Connaught Labora-
tories, Canada) were used in this assay. These ~ptides were generated 
on the basis of consensus SI and NSI sequences obtained from a 
previously described set of eight recombinant em·dop proteins derived 
from two donors (#16 and #320) from the Amsterdam cohort (Fig. I: 
Andeweg f( Ill., 1992). This sel consisted of fOllf recombinant 
glycoproteins per donor, of which two were deriwd from viruses with 
the SI phenotype and two from \·iruses \\ith the NSI phenotype. ELISA 
plates coated with the HIV-J MN V3 peptide were incubated for 1 hat 
37°C with these HuMAb MN215-peptide mb .. tures, which were 
preincubated O\wnight at 4 0c. The ELISA waseompleted as de,cribed 
above. 
PCPSCUII analysis. r~ps.;'an analysis was ~rformcd as originally 
described by Geysen ef al. (1984) and modified by Langedijk ef al. 
(1991). In short, peptides were synthesized on poly~th)·!ene rods and 
tested with HuMAb MN215 in an ELISA according to established 
procedUres (Langedijk cl af., 1991). A set ofpcptidc5 ofbetwe.!n 8 and 
16 amino acids in length, \\ith all but 1 amino acid overlapping, were 
synthesized l\ith sequence. derived from the HIV-I MN gp120 V3100p 
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Fig. I. Comparison of HI V-I V3 domain amino acid sequences. The asterisk indicates Y3 sequences from different HIV-I strains from 
which peptides were used in solid phase peptide and peptide inhibition ELISA. The Dutch consensus, 1658-3 and 11658-27 Y3 
sequences were used in Pepscan. 
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(Fig. I; Meyers t'l af., 1992) and one sequence more rdated to the 
Dutch consensus V3 sequence (Fig. I; Holley et al., 1991). To 
determine the individual amino add which was important for binding 
of HuMAb MN215 to its epitope, peptide analogues were made from 
the Dutch V3 wnsensus sequence (from position 12 to 27) by 
substituting single amino adds. The amino acids \\ithin this sequence 
were substituted for amino acids which have been prown to Ix-
prevalent at each position in Dutch HTV-I isolates (Holley t'l al., 1991) 
or by amino acids \\ith different biochemical properties. Numbering of 
the amino acids in the HIV-I gpl20 V3100p was according to LaRosa 
et af. (1990). 
Rdmire IIJJillilY of lI1ol1ocfunal alllihodtes for 1111'-1 gp160. Recom-
binant Hl\q en\'do~ glycoproteins, which we haw described recently 
(Ande\\'eg el a/., 1992), were e~pre~sed in HeLa cells by a recombinant 
vaccinia virus (rVV) expression system. The rVVs nsed were 320-2a.5 
and 320 .. 2a.7 (donor ,u20; phenotype 51), 320 .. 2a.3 and 320-2a.6 
(donor ,u20; phenotype NSf). [6.1 and 16.2 (donor #16; phenotype 
SI). and 16.3 and 16A (donor 16; phenotype NSI) (Andeweg cl a/ .. 
1992). At 24 h after rVV infection. HeLa cells \\ne lysed with 1% 
empigen in PBS, in the presence of proteinase inhibitors (10 ,Ig/m[ 
aprotinin, I nm-P;\ISF; H~hringa M;mnheim). For HIV-J MN 
glycoproteins, persistently infected SupTI cells were cocnltured \\1Ih 
uninfected SnpTI cells at a ratio of 1 :4. After 3 days cells were 
centrifug<"d and lysed as described above. Cell I) sates Wefe divided into 
aliquots and the amount ofgpJ20/160 was determined in a catching 
antibody ELISA as previomlyde;cribed (Moor.:, 1990). Equal amounts 
of gp120/160 \\en~ coated to ELISA plates and the concentration 
\\here 50% of the ma.\imum A Hn was reached \\ith the HuMAbs was 
taken as a rdative measure for affinity. The HuMAbs directed against 
more conser .... ed sites on gpl6Q used in this ELISA have been prel'ious[y 
described {Teeu\\sen cl aL 1990; Gorny ('/ al .. 1993; Schulten <'I al .• 
1993). 
Vifl/I flllry il/hibilioll assa)'. The' cm' gcne encoding the Ho,-,ombinant 
16.2 SI glycoprotein II-as cloned into an c.\pre,sion vector as previonsly 
described (Andeweg l'f al .. 1993) and subsequently used to generate 
chimeric infectious ,-irlls using a IrtlllJ complementation assay. In short, 
;m <'Ill'·defective HIV-I provirus, encoding the bacterial CAT reporter 
gene, wa, complemented by the 16.251 fIJI' gene for a single round of 
replication by ,-,o·transfection into the CD-l- COS cel! line. This 
resulted in the production of virions carr)'ing heterologous envelope 
glycoproteins which could infect CD-l+ ~'Clls like the SupTI cells used 
in this study (Helseth t'I al .. 1990). After 3days cell-free supernatant 
\\a5 collect.:d by centrifugation and (rozm at _135°C. ror inf<"ction 
the amount ofp24 antigen, as determined \\ilh a p24 ELISA kit (V5; 
Organon Teknika). \\a5 ci.llibrated and the lewl of envelope expression 
I\as checked \\ith the capture antibody ELISA (see above). Infection 
\\<lS p<"rfonned overnight at 37 0(' in I ml medium. After 24 h the cells 
were washed and cultur<"d for 72 h. CAT aeti\-ity in these cells was 
measured in a preliously described CAT assay using a two·phas.: 
.:xtractioll s)stem (Seed & Sheen, 1988). CAT activities of the cells were 
considered a direct measure of virus infectivity in the,e assays. 
Results 
Generation ofHII/\/Ah MN215 
Screening of the supernatants of more than 2000 B cell 
lines obtained by EBV transformation of PBMC col-
lected from donor #658 and subcloning of positive cell 
cultures yielded one B cell line V ... IN215) producing an 
IgG I antibody that recognized a peptide with the V3 
domain sequence of the HIV-I rvlN strain. This B cell 
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Fig. 2. Reacti,ities ofHuMAb MN215 and sefllm from donor 658 \\1th 
different HIV-l V3 peptides. Midpoint titres ofHnMAb MN215 (filled 
bars) and serum taken from donor 658 4 years after saoconvcrs;on 
(hatched b3f$), at which 50% of ma:o.imum A llo was reached in an 
ELISA \\ith V3 domain peptides from dilleren\ subtype B (Universal, 
;\IN, SF1, Sc. NY /5, CDC4, RF, WM52, HXB2)and subtype D(ELl, 
Zl, Z6) HIV-l strains (see Fig. I). 
line continued to produce these V3 domain-specific 
antibodies at levels of 4 ~Ig/ml after fusion with the 
mouse-human heterohybridoma F3B6 and further sub-
cloning. The cell line was considered clonal on the basis 
of the limiting dilution procedure used (Schutten et al., 
1993), 
Cross reaelMly of /luMAb MN215 lI'itll d(Oerelll 
HJV-I 1"3 domain pep/ides 
V3 loop sequences of HIV-I derived from donor #658 
at 3 and 60 months after seroconversion (#658-3 and 
#658-27, respectively) proved to be closely related to the 
SUbtype B HIV-l V3 loop consensus sequence (Fig. 1). 
When tested in a solid phase peptide ELISA with V3 
domain peptides representing subtype Band D HIV-l 
strains, the serum from donor #658 taken 4 years after 
seroconversion showed specificity for peptides derived 
from SUbtype B HIV-I strains (Fig, 2), We subsequently 
tested HuMAb IvlN215 for its reactivity in a solid phase 
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Pig. 3. Peptide inhibition ELISA of HuMAb MN215 with VJ loop 
peptide-so An~ YaluC"s obtained in a solid phase HIV-I MN \'3 peptide 
ELISA with a standard concentration HuMAb MN2[S, incubated 
with serial thr~fold dilutions of the T<'spectiw peptid .... , [HI"-J 
Unirmai (.), MN (+), SC (+), SF2 (T); see Fig. 1J using a starling 
peptide concentration of 3 x to-II mol. 
peptide ELISA with pcp tides derived from oiflcrent 
subtype B HIV-l strains and with peptides derived from 
subtype D HIV-l strains (Fig. 2). The highest reactivity 
of Hul ... fAb MN215 was found with the HIV-l Universal 
consenslis and the HIV-J r..,[N sequences. It also reacted 
with V3 domain peptides derived from the HIV-I SC and 
SF2 strains. Since solid phase peptide ELISA values may 
not be considered to represent an adequate measurement 
of the relative affinity of an antibody for a given peptide, 
we also performed a peptide inhibition ELISA with the 
peptides showing reactivity with Hul."fAb MN215 (Fig. 
3). HuMAb MN215 showed a relatively high afllnity for 
the HIV-I MN peptide and for the HIV-I Universal V3 
and l-lIV-l SC peptides, but it bound with a much lower 
affinity to the HIV-I SF2 peptide. 
Millimum epitope recognized by HIlMAb MN215 
The minimum epitope recognized by l-luMAb MN215 
was determined by Pepscan analysis using 8 to 16 amino 
acid peptides, overlapping by all but one amino acid, 
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spanning the HIV-I lvlN V3 loop. The minimum epitope 
was defined as the shortest common sequence found in 
peptides reactive with HuTVIAb I'vIN215. No reactivity 
could be found in this Pepscan analysis with overlapping 
peptidcs of 8 to 14 amino acids. The shortest peptide 
showing reactivity with Hul\'IAb MN215 was a 15 amino 
acid peptide spanning the tip of the loop (GPGR) and 
amino acids at the C- and N-terminal side of this 
structure (Fig. 4a). A similar analysis was carried out 
with 7 to 13 amino acid peptides with the Dutch 
consensus sequence. The minimum epitope recognized 
by HuMAb MN215 with this V3 loop sequence proved 
to be 9 amino acids long and consisted of amino acids at 
the N-terminal side of the tip of the V3 loop only (Fig. 
4b). 
!lIdMdllal amiI/o acids iI/mired ill IfIlMAb MN215 
bindillg 
Differences between dOllor #658 and the Dutch 
consensus V3 domain sequences were introduced in a set 
of peptides based on the Dutch consensus sequence for 
Pepscan analysis. Substitutions S to G at position 13, T 
to A at position 28 and E to D at position 30, which were 
observed in donor #658 as compared to the Dutch 
consensus, did not influence the binding capacity of 
HuMAb MN215 (data not shown). The role of individual 
amino acids at both sides of the tip of the loop was 
determined by using peptide analogues which differed in 
only I amino acid from the peptide with the Dutch 
consensus sequence peptides in a separate Pepscan 
analysis (KSlHIGPGRAFYT) (Fig. 5). 
Five single amino acid substitutions caused improved 
binding capacity of HuMAb MN215: 
I) Substitution G to N at position 19 and R to K at 
position 20, which are both well tolerated at that position 
in a type II p turn (Wilmot & Thornton, 1988; Ghiam et 
al., 1994). 
2) F to L at position 23, which results in a smaller 
surface area and more rotational freedom. 
3) Y to E and T to E at position 24, both resulting in 
a more negative charge on the C-terminal side of the tip 
of the loop. 
Substitution of amino acids ut the tip of the loop for 
amino acids with low frequency in known type II p turns 
were not well tolerated in the Pepscan with r ... fN2 I 5 
(20 P --t L, 21 G --t P, 21 G --t A and 22 R --t P; Wilmot 
& Thornton, 1988; langedijk et al., 1991). Reactivity of 
Hul\'IAb l\'IN215 with the V3100p therefore seems to be 
dependent on the type 11 p turn at the tip of the loop 
(LaRosa et (11.,1990; Ghiara el 01., 1994). 
A peptide was subsequently constructed in which all 
these mutations from the Dutch eonsenslIs sequence 
(KSIHIGPNKALEE) had been applied. HuMAb 
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Fig. 5. Reacti\itic5 of HuMAb MN215 in a Pepscan analysis with 
peptidcs modified from the Dutch consensus sequence, by replacing one 
amino acid compared to the native se-quence (KSIHIGPGRAFYT). 
The SD was kss than 00 [ A 1\0 units. 
poorly in this assay. The other HuMAbs directed against 
more conserved epitopes on gpl60 did not clearly 
distinguish between the giycoproteins derived from 
viruses with the two phenotypes. 
VN activity ofHIt,\/Ab MN215 towards Sf strains 
It has been shown by others that HIV-J NSI strains 
arc highly resistant to VN activity by human antibodies 
(BOll-Habib et (II., 1994). In accordance with these 
observations we failed to demonstrate inhibition of entry 
by chimeric IIlV-! carrying the recombinant 16.4 NSI 
glycoprotein in the virus entry inhibition assay ( > 90 % 
of c.p.m. without Huh'IAb at 200 pg/ml of HuMAb 
MN21S). Howcycr, despite the low relali\'e affinity of 
HuMAb MN215 for the SI HIV-J glycoprotein from 
donor # 16, it did inhibit entry of chimeric virus carrying 
the \6.2 SI glycoprotein, albeit at high concentrations 
(about 60 ~(g/ml for 50% inhibition and < 200 ~(g/ml 
needed for 90% inhibition). As expected HuMAb Kl4 
failed to inhibit entry of these chimeric viruses (Table 2). 
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Fig. 6. Peptide inhibition ELISA orHu~tAb :-'IN215 VJ loop p.:ptides 
derived from NSI and SI viruses from two individual, (donors 16 and 
J20). A1)O values were obtuined in a solid phuse HIV-l MN VJ peptide 
ELISA \\ith a standard concentration of HuMAb MN2l5 incubated 
\\ith serial threefold dilutions of the resp..-..:ti\"e p.:ptlde5. The5e were 
derived from sequences ofdont'd SI and NSI viruses from donors 16 
and 320 from the Amsterdam cohort {116 SI (+). 116 NSI (.). #.120 
SI (*). #.120 NSI (B); sce fig. 1]. A sturting peptide concentration of 
.1 X IO-JI lIlol was us.:d. 
Table I. Relative affinity of HuM Abs for glycoproteills 
of Sf and NSf HfV-/ strains 
HuMAb Epitop.: ilJ20 SI 1320 NSI -1'16 Sl #16 NSI >IN 
MN2l5 V3 domain <4·t 48 <4' 84 <4' 
257-D VJ domain 250 250 125 125 128 
GPIJ CD4 bd 84 100 84 3.1 84 
KI4 gp.jl 42 10 84 55 42 
• Dilution could not be determined because reactivity did not reach 
plateau value at the conc.:ntrations tested. 
t Dilutions ofthc r,:sJX-..:tivc Jlul\fAbs, starting at 1 ~lg/ml. at which 
50% of the muximum binding wus reached in the antibody cuptur.: 
ELISA with the cdllysates of rVV-infected HELA c~l!s. 
Discussion 
We ha\'c described an HIV-I-neutralizing HuMAb 
(HuMAb MN21S; JgGl) that proved to react with the 
V3 domain of a selection of subgroup B virus strains. 
This HuMAb displayed a higher aflinity for NSI than for 
SI glycoproteins within the same host. 
Variation in the V3 domain within the host-delimited 
Table 2. Inhibition of entry of chimeric HIV-J, carrying 
the #16.2 SI glycoprotein, by HuMAb MN215 as 
meaS/fred in the \'irus entry inhibition assay 
Percentage of Percentage of 
HuMAb ma);imum ma);imum 
concentration c.p.m. using c.p.m. using 
(l1g/ml) HuMAb K14 lIuMAb MN215 
0 100' 100 
25 105 82-9 
50 98 55·7 
100 98 39·2 
200 91 2\·9 
• Percentage from c.p.m. using 16.2 51 elll" gene without addition of 
HuMAb [(c. p.m. with HuMAb/c.p.ll1. without antibody) x 1001. 
quasi species distribution has been shown to be concen-
trated at the N- and C-terminal sides of the tip of the 
loop (Epstein et al., 1991; Kuiken et al., 1992). Both the 
lip and the base of the loop are relatively conserved 
(LaRosa et al., 1990). Variation within the V3 domain is 
believed to be largely driven by the VN antibody 
response. Consequently, an important part of this 
response seems to be directed against both sides of the 
loop. The relatively long minimum epitope determined 
by Pcpscan analysis with the HIV-l !\·IN sequence 
(15 amino acids) and the mutational analysis of the 
l'vIN215 epitope indicated that amino acids involved in 
binding of HuMAb MN215 are also primarily concen-
trated in these areas with high variation. HuMAb 
MN215 is therefore directed against those parts of the V3 
domain against which most of tile VN antibody response 
in seropositive individuals is directed. 
Recently, two other HuMAbs have been described 
with a minimum epitope on the HIV-I MN V3 loop 
sequence of 15 amino acids in length (Gorny et aI., 1993). 
We were able to narrow the core epitope down to 
9 amino acids at the C-terminal side of the type II p turn 
by using a sequence more related to the V3 sequence 
derived from the virus of donor #658.11 should, howevcr, 
be stressed that the type II {1 turn and the N-terminal 
parts of the V3 loop also contribute to the optimum 
binding of thc HuMAb. 
Combining all amino acids giving improved binding of 
HuMAb MN215 in one peptide did not result in a 
peptide recognized by HuMAb r.,·IN215, indicating the 
importance of intramolecular interactions for optimum 
epitope presentation. Combining all the criteria for the 
'best fitting' MN215-binding peptides with actually 
described V3 sequences of HIV-] (LaRosa et al., 1990) 
resulted in the following V3 sequence: KSj 
GfHIGPGKAFYTTGEjDI. This sequence exhibits a 
striking similarity with the conserved consensus V3 loop 
sequence of macrophage-tropic HIV -I strains (Chesebro 
el al., 1992). Prcvious reports have shown that all NSI 
strains isolated so far have the combination of no chargc 
at position 13 and negative or no charge at positio1l30 of 
the V3100p, whereas SI HIV-] strains havc a positively 
charged residue at either onc ofthesc positions (Fouchier 
el 01., 1992). Others havc shown that negative charge at 
the C-tcnninal side of the V3 loop is associated with less 
SI capacity (de Jong ef af., 1992). Negative or uncharged 
residues at these positions are also important for binding 
of HuMAb MN215 to V3 peptides. On the basis of the 
Pepscan data it can be concluded that changes ,vi thin the 
V3 loop resulting in morc SI capacity for the virus will 
decrease the affinity of HuMAb MN215. Indeed, when 
tested in a peptide inhibition ELISA and in a catching 
antibody ELISA, with wholc solid phase gp160, HuMAb 
MN215 showed a significantly higher amnity for the V3 
domains of NSI than for the V3 domains of SI viruses 
within the two donors tested. The other HuMAbs tested, 
directed against more conserved epitopes of gp160, did 
not discriminate between the peptides and glycoproteins 
representing difrerent phenotypes from the two donors. 
The V3 loop of the SI recombinant envelop proteins 
from donor #16 have been shown to transfer the 
phenotype when exchangcd with the V3 loop of an NSI 
recombinant envelop protein from donor # 16 (Andeweg 
et al., 1993). The amino acid differcnces between the SI 
and NSI V3 domains are therefore believed to be 
important for the SI capacity of HIV -I strains. On the 
basis of the data presented it is vcry likely that HuMAb 
MN215 has a higher amnity for the NSI and 
macrophage-tropic HTV-I strain within a host-delimited 
quasispecies distribution than for the SI and T cell line-
tropic strains. Despite the fact that HuMAb MN215 was 
selected for reactivity with a HIV-l MN V3100p peptide 
and despite its high amnity for the HIV-I MN V3 loop 
peptide in both solid phase peptide ELISA and peptide 
inhibition ELISA, HuMAb MN215 only bound with low 
affinity to the HIV-I MN V3100p whcn it was presented 
in the context of the whole HIV-I MN glycoprotein. 
These findings indicate that antigenicity data generated 
with isolated pcptides in solid phase assays (Moore, 
1993) and also with isolated peptides in solution may not 
be representative of the antigenicity of these structures in 
their natural configuration. It has been shown that 
macrophage-tropic HIV-I strains need a certain con-
formation of their V3 loop (lnnocenti-Fral1dllard et al., 
1994), which is apparently recognized by HuMAb 
MN215. This may explain why the 'suboptimum' V3 
sequence of donor #320 NSI, which is not recognized by 
HuMAb MN215 in Pepscan analysis (data not shown), 
stiiJ results in a glycoprotein that is more emdently 
recognized than the # 16 SI or the #320 SI glycoprotcins. 
The Jow relative amnityof HuMAb MN215 for the HIV-
I MN glycoprotcin is in accordance with the Jow 
reactivity in FACScan analysis of this antibody observed 
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with HIV-I f\'IN-infected SupTl cells (unpublished 
results) and the relatively low VN capacity of this 
antibody towards HIV-I ·MN and SF2 (A. ~-1cKIl.ight, 
personal comlllunication). We also showcd that HuMAb 
MN215 inhibited entry of a chimeric HJV-I strain 
carrying the recombinant 16.2 SI HIV-I glycoprotein, 
albeit very inefilciclltly. The CD4-binding domain (CD4 
bd)-specific I-IuMAb GPI3, which neutralizes T cell line-
adapted HIV-I strains (Schutten t't al., 1993), did not 
neutralize the 16.2 SI chimeric virus at the concen-
trations tested (data not shown) although this antibody 
has a significantly higher relative amnity for the 16.2 SI 
glycoprotein than HuMAb MN215. This stresses the 
relatively high VN capacity of antibodies directed against 
the V3 domain. It was unexpected that HuMAb MN2l5 
did not inhibit entry of a chimeric virus carrying the 16.4 
NSI glycoprotein, which it preferentially recognizes. 
However, an aOlnity-purified immunoglobulin pre-
paration from seropositive individuals (HIVIG; Prince 
et al., 1991) also failed to do so (data not shown). The 
inability of HuMAb MN215 to neutralize an NSl virus 
under conditions at which it does neutralize an SI virus, 
which it recognizes with lower amnily, should therefore 
be considered in the light of general difficulties en-
countered with the neutralization of non-T ccll line-
adapted NSI HIV-l strains (Bou-Habib et al., 1994). 
The authors \\ish to thllnk Ms C Kruyssen for help in prepllrlng the 
manuscript. This work WlIS supported by a grant from the Dutch 
Organization for Scientific Research (NWO grant number 900-506--
131). 
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CHAPTER 4 
Molecular characterization of variable heavy and 
light chain regions of five HIV type 1-specific human 
monoclonal antibodies. 
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ABSTRACT 
We have reported the generation and charaderization of four HJV-l neutralizing human monoclonal antibod-
ies. Three antibodies recognize a conformational epitope within the CD4-binding site of RIV-I gp120 and onc 
recognizes a linear epitopc located within the hypen'ariablc V3 domain of gp120. In the present study we re-
port the nucleotide sequences of the cDNAs encoding the \'ariahle regions of the heavy and light chains of these 
antibodies. Molecular characteristics, closest germline genes, and the pulatlve extent of somatic mutation are 
presented. Two of the four heavy chain yariable (VII) regions are derh'cd from the Vnl gene family, one from 
Ihe Vu3 gene family, and one from the VH5 gene family. In addition, the VII chain ofa previously described hu-
man monoclonal antibody, directed against HIV-l gp41, is dcrh'ed from the Vn3 gene family. The degree of 
nucleotide variation between these fh'e antibodies and their closest germline counterparts ranges from 4 to 
12%, mainly located in the complementarity· determining regions. Significant nucleotide sequence homology 
with preyiously described germllne diversity (D) genes could be found for only two oftive antibody D segments. 
Joining (JIl) gene segments utilized are JII4 or J1I6. Two light chain variable (VL) regions are deriyed from a 
V.) gene segment, one from a V,,4. one from a V).2, and one from a V).6 gene segment. 
INTRODUCTION 
ACQUIRED IMMUNODEFlCIENCY SYNDRO~tE (AIDS) is the late-stage disease of infection with human immunodeficiency 
virus (HI V). Counter-AIDS strategies include the development 
of active immunization protocols (0 prevent HIV infection, and 
passive immunization protocols for postexposure therapy. 
Passive immunization in particular may be important in pre-
\'Cnting transmission of HIV from infected mothers 10 their off-
spring! and in preventing infection after accidental exposure. 
These goals may be achie\'ed by the administration of a cocktail 
of human monoclonal antibodies (MAbs), capable of neutraliz-
ing a variety of HIV strains. 
HIV-I infection elicits at least two major types of neutraliz-
ing antibodies directed against gp120. One is directed against 
the hypervariable V3 domain, the other against the conserved 
CD4-binding site (b.s.). Antibodies directed against the V3 do-
main are found already in the early phase of infection. Initially 
it was proposed that V3 domain-specific antibodies would pre-
dominantly neutralize the eliciting HN-I strain.2-5 However, it 
has been demonstrated that several V3 domain-spedfic anti-
bodies have much broader reactivities than previously sug-
gested.6 -9 Emini el 01. showed that chimpanzees, passiyely im-
munized with an HIV-l HIB neutralizing V3 domain-specific 
antibody, were protected against infection with the homologous 
mv srrain. IO.!! Antibodies directed against this side are there-
fore likely candidates for passive immunization. Antibodies di-
rected against the CD4 b.s. are detected later in infection and 
ha\'e a wide range of neutralizing activity against HIV -1 strains. 
owing to the conserved nature of the CD4 b.S. 12 The neutraliz-
ing capacity of these antibodies seems to be generally lower. as 
compared to the V3 domain-specific antibodiesY Equimolar 
mixtures of human MAbs, directed against either of these two 
sites, may have a synergistic mY-neutralizing effect.14-16 We 
described Ihe generation and characterization of four HIV-I-
neutralizing human MAbs: one V3 domain~specific antibody 
(MN215) and three antibodies directed against the CD4 b.s. 
(OPiJ, GrM. and GP68).9.17 OPI3. ON4, and OP68 display 
D.:rartment of Virology, Erasmus Uni\'cr~ity. RoUerdam, Dr. Molewa!erplein 50. P.O. 110\ I7J8. J()(X) DR Rouerdam. the Netherland~. 
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broadly HIV-I-neutralizing activity, whereas l\'fN215 reacts prc-
dominantly with macrophagc-tropic and non-syncytium-
inducing (NSI) mv -I strains_9 During thc asymptomatic stage of 
the HIV-I infection predominantly HIV-I strains of the NSI phc-
notype are found.]8 A low efficiency of the primary immune re-
sponse in eliminating NSUmacrophage-tropic HIV-l strains or a 
preferential transmission of these mV-1 strains has been sug-
gested.]9 This makes MN215 a likely candidate to be used in 
preparations for early passive immunization therapies. Here .... 'C 
report the molecular characterization of the variable heavy and 
light chain regions of these four human MAbs, and of a previ-
ously described broadly reactivc human MAb CK14) direeted 
against an epitope on illY-I gp4L20 Although this is a nonneu-
tralizing MAb, it was included in these studies because of a pos-
sible synergistic therapeutic effect in a cocktail of human MAbs. 
Molecular characterization of the V genes used by HIV-
neutralizing. -nonneutralizing, and -enhancing human MAbs 
will lead to a better understanding of the interaction between 
HIV and the antibody repertoire. Furthennore, molecular data 
are ne<:essary for the ill ~'i/ro construction of broadly reactive, 
high-affinity HIV-neutralizing human antibodies and in dis-
criminating between neutralizing and enhancing antibodies. 
These data will provide a valuable contribution to the develop-
ment of an efficacious anti-HIV vaccine to be used in passive 
immunization protocols. Therefore, in the present study we 
give a detailed molecular characterization of the V regions of 
the five antibodies mentioned above. Remarkably, two of five 
HIV-specific human MAbs presented here express a VII3 gene 
segment, whereas data suggest a superantigen-Iike binding of 
gpl20 to (membrane) immunoglobulin VII3 gene products and 
the SUbsequent deletion of Vu3-ex.pressing n cell clones in 
AIDS patients.21.l2 
MATERIALS AND METHODS 
HIV-l-specific hllmall monoclonal antibodies 
Human MAbs to HIV-I were isolated from Epstein-Barr 
virus (EBV)-transfonned B cell lines, derived from peripheral 
blood mononuclear cells from asymptomatic HIV-l-seroposi-
tive donors, as described previouslyY·2D Briefly. EBV-trans-
fomled B cells producing IgG antibodies specific for HIV-l 
were selected by screening for reactivity in enzyme-linked im-
munosorbent assay (ELISA) with either gpl20, gpl60, or V3 
loop peptides.9.17 Five IgG] MAbs from three donors were stud-
ied: GPI3, GP44, and GP68, recognizing a confonnational epi-
tope partly overlapping with the CD4 b.s. of gp12017; MN215, 
recognizing the principal neutraliZing domain (V3 domain) of 
gpl20 of the MN fsolate9; and K14, re<:ognizing an epitope on 
gp41.20 Monoclonal antibodies GP13 and GP68 have been 
demonstrated to neutralize various HIV-Ilaboratory isolates ill 
vitro, GPM neutralizes the SF2 iSOlate, and MN215 neutralizes 
the MN and SF2 isolates.9•11 
Oligonucleotides 
The oligonucleotides used in the PCR amplifications were 
synthesized on an Applied Biosystems (Foster City, CAl DNA 
synthesizer. Sequences of the oligonucleotides are shown in 
Table I. 
Single·strallded cDNA s)'lIthesis and polymerase 
chain reaction 
Total RNA was ex.tracted from 101 EBV-transfonned B cells 
by the RNAzol method (CINNAlBiotex Laboratories, Inc., 
Houston. TX). Single-stranded eDNA (s5-cDNA) was synthe-
sized by using Moloney leukaemia \'irus (M-MLV) H- reverse 
transcriptase superscript (GmCO-BRULife Technologies, 
Gaithersburg. MD) and an oligo(dn primer. Polymerase chain 
reactions (PCRs)D were done essentially via the method recom-
mended by the manufacturer (Perkin-Elmer Cetus, Norn'aik, 
el'). The PCR eycles were as follows: denaturation at 96"C for 
I min. annealing al6Q°C for 2 min, and extension at noc for I 
min 30 sec. controlled in a DNA thennal cycler (Perkin-Elmer 
Cetus). 
Isolati01l. clolling. and sequencing of 
amplified products 
Amplified DNA was digested with SstI and Hilldlll and size 
selected on a 1% ethidium bromide agarose gel. The purified 
TABLE L SEQUENCES OF OUGO}.'UCLEOTlf)ES USED IN POLYMERASE CUAIN 
REACTIO:-l" AMPUHCATIO:-l"S 
42 
Oligonuc/eolide 
VIII leader 
VII3 leader 
VH 3 BACK 
VIIS leader 
V"I leader 
V "I leader 
V ,,4 leader 
V~2 leader 
V~6 leader 
C, 
C< 
C, 
Sequence 
5' ATAGAGCfCATGGACTGGACCTGGAGG 3'· 
5' ATAGAGCfCfGGAGTTTGGGCTGAGCTGG 3'· 
5' ATAGAGCTCGAGGTGCAGCTGGTGGAGTCT 3'a 
5' ATAGAGCfcrCGCCCTCCTCCTG 3" 
5' ATAGAGCfCCTGCTGCTGCTGTGGCTGCCC 3'-
5' ATAGAGCTCATGGACATGAGGGTCCCC 3'a 
5' ATAGAGCTCATGGTGTTGCAGACCCAG 3'-
5' ATAGAGCfCTGGACTCCCCTCCTCCTCACT 3" 
5' ATAGAGCTCCTCACTCACTGTACTGGTTCT 3" 
5' CTCAAGCrrCAGGGGAAGACCGATGG 3'b 
5/CTC~AACAGAGGCAGTTCCAGACTT3~ 
5' CTCAAGCTTTGTGGCCTTGTTGGCTTG 3'b 
"The Sstl reslriction site is underlined. 
t-rhe HindlII restriction site is underlined. 
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product was ligated into the SsfUl/indlII restriction site of a 
Bluescript phagemid vector and transformed into CaClr 
competent XLI·blue bacteria. Several recombinant clones were 
selected and sequenced in both orientations using nonradioac· 
tive dye· labeled T3 and Tl oligonucleotide primers (Applied 
Biosystems) on a 370 A automated sequencer (Applied 
Biosystems). 
Owing to limited availability of patient materials we were 
not able to obtain genomic DNA for the isolation of the respec-
tive germline gene counterparts. Therefore the latest update of 
the total EMBUGenBank database was searched to identify ex· 
pressed as well as germline genes displaying the highest nu· 
cleotide sequence similarities with the V genes presented in 
these article. Primary amino acid sequences were deduced and 
alignments were carried out using the DNAstar program 
(DNAstar. Inc., Madison, WD. 
RESULTS 
Analysis of the expressed VH genes encoding HIV·/· 
specific human monoclonal allabodies 
'The complete nucleotide sequences determined for the VII 
region of each antibody are shown in Fig. L As a result of the 
databank searches each of the expressed VII regions could be 
compared with its closest germline counterpart (Fig. 2). An 
overview of the five HIV-i·specific human MAbs and their 
characterization is given in Table 2. 
The GPl3 VII gene contains an open reading frame, has all 
the features characteristic of a functional VII gene, and is most 
homologous to the previously described VIIS gennline gene 
VII32 {94.2%).u There arc two nucleotide differences in frame· 
work (FR) t, one being silent and one causing an amino acid 
substitution, and there is one silent mutation in FR n. The most 
extensh'e variation is found in the twoCDRs (8-22%), which is 
indicative for an antigen--driven immune response. More than 
60% of the total mutations in the complementarity--dctermining 
regions (CDRs) result in amino acid substitutions. An unusual 
number of nucleotide differences (n "'" 6) was observed within 
framework III ofGPI3 VH as compared to the analogous frame-
work of V H32. Three of the six nucleotide differences in frame· 
work III resulted in amino acid substitutions (Fig. 3A). 
Furthermore, the degree of variation (6%) is higher than the 
usual mutation rate described for frameworks (i.e., 2%), indio 
cating a possible role for the framework residues in HlV+! 
binding.v 
The GP44 Vn gene segment is a member of the VH' gene 
family and is most homologous to the HVlnO gemlline gene 
(94.9%).26 Furthermore. there is 88.7% nucleotide sequence 
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FIG. 2. Nucleotide sequence of each HIV·I·specific heavy chain variable region compared to the nucleotide sequence of the 
closest germlinc genes, Identities between sequences are indicated by dashes. (A) Nucleotide sequence of GPI3 compared to the 
VII32 genniine sequence. (B) Nucleotide sequence of GP44 compared to the identical Dp·7 gennline and hvlfiO geonline se· 
quences and to the expressed gene 71·31. (C) Nucleotide sequence of GP68 compared 10 the Dp·iO geonline sequence. (D) 
Nucleotide sequence of MN215 compared to the Dp·77 germ line seqence. (E) Nucleotide sequence of KI4 compared to the Dp·47 
germline sequence. gl. Germline; ego expressed gene. 
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TABLE 2. CHARACfERlSTlCS OF FIVE mV-I-SPECIFIC HUMAN MONOCLONAL ANIlBOD!ES 
Vints 
Antibody Specificity neutralizing 
OPB (IgOI,K) CD4 b.s. y" 
OPM (lgOI)..) CD4 b.s. Yes 
OP68 OgOI,K) CD4 b.s. y" 
MN215 OgOI,A) V3 domain Yes 
KJ4 (lgOI,,,,) gp41 No 
a_, No significant homology. 
similarity with a previously described VIII gene, 71-31, ex-
pressed by an HIV-I-specific human MAb.21 However. this 
MAb is directed against an epitope on HIV-I p24. The GP68 
VII gene is also derived from the VIII gene family and is most 
homologous to the DP-1O VIII gennline gene (87.8%).28 
The MN215 VII gene is derived from the !argest gene family 
(V1I3) and is most homologous to the DP-77 gemliine gene 
(96.3%}.2& The K14 VII gene is also derived from the VII3 gene 
family and is 89.8% identical to the DP-47 gennline gene.28 A 
remarkable difference between KI4 VII and DP-47 is three ad-
ditional nucleotides encoding an isoleucine residue in CDR-ll 
of KI4. Therefore it is unlikely that DP-47 would be the 
gennline counterpart of KI4 VII' 
Owing to the relatively high number of still unidentified 
members of the VIII and Vl/3 gene families it remains difficult 
to determine whether our expressed OPM, GP68, MN2IS, and 
K 14 V l/ genes represent somatically mutated or as yet unidenti-
fied gennline genes. 
Analysis of expressed VL genes 
The complete nucleotide sequences detennined for the VL 
region of GPI3. GPM, GP68. MN2l5, and Kl4 are shown in 
Fig. 4. Each of the expressed VL regions was compared with the 
respective. closest gennline sequence obtained from the 
EMBUOenBank database (Fig. 5). 
The OPJ3 VL gene contains an open reading frame that has 
all the features characteristic of a functional V,,4 gene segment. 
There is 94.1% homology with the previously described V,,4 
gemlline gene,2'~ which is the only V,,4 gene found on the hu-
man Ig K locus. There are six nucleotide differences within the 
frameworks, all causing an amino acid substitution. except for 
the one in FR III (Fig. 3B). The variation in the three CDRs 
ranges from 5 to 16%, with most of the nucleotide differences 
A 
% homology with closest 
gennline gelle 
VH V, VH V, 
VuS V<4 94.2% Vu32 94.1%V,A 
VIII V,2 94.9% HVlfW 88.1% IGLV21 
VHI V<I 87.8% DP-tO 93.6% HKlO2 
VII3 V,6 96.3% DP-77 -' 
Vu3 V<I 89.8% DP-47 89.0% HK137 
accumulated within CDR-I. FurthemlOre, 75% of the nu-
cleotide mutations in the CDRs result in amino acid substitu-
tions. 
The GP44 V L gene segment is a member of the V)..2 gene 
family and is 88.1% identical to the IGLV21 germline gene.JO 
However, it is unlikely that the IGLV21 germline gene would 
be the gennline counterpart of the GPM V l gene, because there 
is 94.6 and 94.2% homology with two other expressed VL 
genes, WLRll and PV6.31 respectively. Furthermore. there is 
92.S% homology with the expressed gene HBW4_I,Jla also en-
coding an HIV-l gpl20-specific human MAb. The GP68 VL 
gene is derived from the V •. J gene family and is 93.6% identical 
to the HKlO2 germline genel ] and 94.7 and 9S.4% identical to 
the expressed genes 3D6}4 and kalc6,35 respectively. Gene 3D6 
also encodes an HIV-I-specific human MAb. but this MAb is 
directed against gp41, a transmembrane glycoprotein of HIV-I_ 
The MN21S VL gene segment is a member of the V)..6 gene 
family. However, significant homology could be found only 
with two expressed genes, H9S.EBV (93.9%)}6 and EB4V).. VI 
(94.5%).37 The KI4 VL gene is also derived from the V ~I gene 
family and is 89.0% homologous to the HKI37 gemlline 
gene. lS Again. better homology was found with two expressed 
genes, HGQ (9S.I%)39 and A20 (95.2%),40 suggesting another 
germlinegene for Kl4 VL• There is only 87.6% homology with 
the expressed gene No. 86,32. also encoding an HlV-1 gp41-
specific human MAb. 
Analysis of D, JIP and JL gelle segments 
Figure 6 shows the sequences of the expressed D segments. 
compared to their closest gemlline couillerpartl l or to other pre-
viously described expressed D segments.~l-1O Part of the GP 13 
o segment may be derived from the DXPl gennline. This part 
could be preceded by another unknown D segment, causing a 
..£Q.!:! (O~. II 
B 
V.IY 91 
GPll V, 
H'OLNSG~EV(PGESLRlS((GSGrsFTsnllSWRCMi'G(GlE~GRIDPSOSnNYSPSrOG~YI[SAO(SISTAnOllSSlUSOTA!lnCAR 
................ - ... -.R- ..... PN .. Y ......... -----.l(-.---·£·-··--····--·---·-L·J·---·II·-···-
OIV!!IOSf'OSLAYSlGEU'IIlC(SSQSV~~~!~(~lLA\{fQQ(PGQppnlIY~~;UG\'PDUSGSGSGI(lF'lIIS5lQAEOVAVllC.!:~S}!~ 
............ ·-·-·-·~~-·---··I(HT··(I~·-······R···S·R--·-·------··-··_ ..... _ ... __ ...• __ • ____ ._ .• __ •• , .. , 
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sequences of the closest germline g.enes. Identities between sequences are indicated by dashes. 
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FIG. 6. Possible origins of the D segments of each HlV-l-specific human monoclonal antibody. Identities between sequences 
are indicated by dashes. 47 
D-D fusion,47 or by an N segment addition. The last three nu-
c1eotides (GAT) could not be derived from a JH segment and are 
likely N segment additions. The 0 segment of KI4 may be de-
rived from the ON! gernlline. For GP44, GP68, and MN215 we 
found little homology between the expressed D segments and 
the known gemlline D segments. Instead, higher homologies 
with other expressed D segments were observed (Fig. 6). 
In Fig. 7 the expressed J" gene segments are compared with 
their gemlline counterparts.48 Four of the five antibodies ex-
press the Jttt gene segment and one expresses J,,6. Nucleotide 
differences were observed within all four expressed Jttt seg-
ments, in some cases resulting in amino acid substitutions. 
Except for MN2t5, they all miss the first five nucleotides. All 
four expressed 1114 segments displayed the same alielic poly-
morphism, A to 0, as described before; only the OP68 J,,4 and 
MN215 Jttt segments may display another polymorphism, C to 
0.49 Remarkable is the absence of the nucleotide stretch at the 
5' end of OPI3 J1I6, nonnally encoding the five tyrosine 
residues, characteristic of a 1H6 segment. Furthennore, two nu-
cleotide differences are observed, neither one causing an amino 
acid substitution. 
KI4 expresses the J,:I gene segment and OPI3 expresses 1.,2 
(Fig. 8). Both J-.: segments are unremarkable except for the last 
three nucleotides (COT), which are absent. OP68 expresses the 
J.,3 gene segment, which also misses these last three nu-
c1eotides. Besides, two nucleotide differences at the 5' end 
cause an amino acid substitution. OP44 and MN215 both ex-
press the 1),2 gene segment. For OP44 three nucleotide differ-
ences are observed, of which the fust one causes an amino acid 
substitution. For MN215 only the first nucleotide is changed, 
causing an amino acid substitution. 
DISCUSSION 
In the present article we have reported the complete nu-
cleotide sequences of the heavy and light chain variable regions 
of five human MAbs, directed against the envelope glycopro-
teins of HN -I. Two heavy chains of these antibodies are de-
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FIG. 7. (A) Nucleotide sequences of the 11( segment of each 
HIV-I-specific human monoclonal antibody compared to the 
nucleotide sequence of the closest JH gemlline gene.H (B) 
Comparison of the deduced amino acid sequences of the 11( seg-
ments as described in (A). Identities between sequences are in· 
dicated by dashes. 
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FIG. 8, (A) Nucleotide sequences of the h segment of each 
HIV-I-specific human monoclonal antibody compared to the 
nucleotide sequence of the closest Jt gemlline gene.48 
(8) Comparison of the deduced amino acid sequences of the Jt 
segments as described in (A). Identities between sequences are 
indicated by dashes. 
rived from the Viii. two from the V1I3, and one from the VIIS 
gene family. For the light chains, two are derived from the V ~I, 
one from the V -.:4, one from the V),2, and one from the V),6 gene 
family. Only for OPI3 were we able to identify the gennline 
counterparts of the V genes. The GPI3 VII gene is derived from 
the VII5 gene family. which consists of three members, one of 
which is a pseudogene.24 It is most likely Ihat VH32 is the VII5 
gennline counterpart of OPI3 VH. Because it has been shown 
thallhe smaller human VH gene families (Vu4. V1I5, and V1l6) 
display remarkably little polymorphism,so the observed nu-
cleotide differences are most likely caused by somatic muta-
tions. The relatively high number of mutations in FR III may in-
dicate a possible role for some of the FR III amino acids in 
antigen binding, as has been suggested before.'5 The OPI3 VL 
gene is derived from the V -.:4 gene family. which consists of 
only one gemlline gene. Most of the somatic mutations arc con-
centrated in the CORso Therefore, the extensh'e somatic varia-
lion in the V regions of OPI3 indicates an antigen-driven (i.e" 
HIV-I) immune response. 
The expressed VII and VL genes of the other four human 
MAbs arc derived from V gene families containing an unknown 
number of still unidentified gennline genes. For example, the 
expressed OP44 V),2 gene segmenl shows more homology with 
two expressed V),2 genes (WLR and PV6) than with any V),2 
gennline gene known at present (Fig. 5). The pattern of nu-
cleotide differences in al\ three sequences is similar in the 
CORs, and even more in the frameworks, suggesting that these 
three V),2 genes may originate from another, as yet unidentified 
V),2 gennlinc gene. A similar observation has been made for the 
expressed KI4 V-.:I gene and two other expressed V"I genes 
(A20 and HOQ) (Fig. 5). 
Extensi\'e computer analysis was performed on the V region 
nucleotides as well as the deduced primal)' amino acid se-
quences of the human MAbs presented in this article. 
Comparisons were also made with the sequences of all mV-I-
specific human antibody V regions known to data2U!a.JU1 and 
with the sequences of the V regions of human Fab fragments 
from combinatorial libraries, recognizing either the CD4 b.s. or 
the V3 domain of HIV-I gp120.33 Also, the corresJXlnding 
o segments were compared. However, information on anti-
gen-antibody binding could not be obtained by these analyses. 
Instead of using linear amino acid sequences, three-dimen-
sional modeling of antibody V regions may provide useful 
structural information. 
To date only little infomlation is available on the im-
munoglobulin variable region gene repertoire used by HIV-I-
neutralizing human MAbs (see Refs. 27, 32a, 52, and this arti-
cle). It was reJXlrted that in AIDS patients there is a clonal 
deficit of V H3-expressing B cells.ll)l Surprisingly, we found 
two V lI3·expressing HIV-I-specifie human MAbs, MN215 and 
K14, obtained from two different HIV- I-seropositi\'e donors. It 
is unlikely, thallhis could however, be due to the reJXlrted ex-
pansion of the VII3 B cell pool in early clinical stages of mv 
infection,22 because MN215 and KI4 were obtained from the 
donors 3-4 years after seroconyersion. So far only one other 
V!l3-expressing HlV -I gp4 I -specific human MAb has been re-
JXlrtoo.J.I A superantigen-like binding of gpl20 to membrane 
immunoglobulin VII3 gene products has been suggestcd.22 Also 
serum VII3 IgM from uninfected individuals was shown to bind 
to gp120. Howeyer, binding of gpl20 to VII3 IgO from unin-
fected indiyiduals was significantir lowerY MN215 and KI4 
are both V 113 JgG antibodies, and therefore we suggest a high 
affinity in binding of MN215 and KI4 to their respective spe-
cific antigenic sites on HIV -I. This in contrast with a lower 
binding affinity of gpl20 as a superantigen for the im-
munoglobulin VII3 gene products MN215 and K14. This may 
provide an explanation for the presence of V 113-expressing D 
cells in later stages of HIV inf«tion. Additional V region nu-
cleotide sequences of HIV-neutralizing human MAbs are nee~ 
essary to obtain significant structural information which will 
eventually lead to a better understanding of mv neutralization 
by antibody-antigen interactions. Furthennore, JXltentiai clini-
cal benefits may be associated with understanding the extent of 
the V gene repertoire directed against specific IIlV antigens 
presenton infection.Jh In the ncar future broadly HIV-neutraliz-
ing engineered antibody preparations may play an important 
role in passive immunization or as therapeutic agents. 
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CHAPTER 5 
Enhancement of infectivity of a non-syncytium 
inducing HIV-1 by sCD4 and by human antibodies 
that neutralize syncytium inducing HIV-1. 
Scand. J. Immunol. 41 :18-22. (1995) 
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Enhancement of virus infectivity after sCD4 treatment has been documented for SIVagm and HIV -2. It 
has been suggested that a similar phenomenon may playa role in HIV-J infection. In the present study 
we have analysed biological activities of vir liS neutralizing polyclonal and monoclonal human antibodies 
and of sCD4. towards HIV -I chimeras with envelope proteins derived from one donor, which display 
different biological phenotypes. The antibodies, which recognize the V3 and/or the CD4 binding 
domains of the glycoproteins of these viruses and also sCD4 showed din"erent levels of virus neutralizing 
activity toward the syncytium inducing HIV-I strains. In contrast, they all dramatically enhanced the 
infectivity of an HIV-l chimera with an envelope glycoprotein displaying the non-syncytium-inducing 
phenotype. Given the relatively conserved nature of non-syncytium-inducing HIV-l surface gJycopro-
tcios early after infection, these data suggest a major role for antibody mediated enhancement of virus 
infectivity in the early pathogenesis of HIV-l infection. 
Professor Dr A. D. M. E. Osterhaus, Erasmlls Vnirersil), Rollerdam, Institule of Virology, Dr 
.Mo/ell"aterp/eill 50, P.O. Box /738, 3000 DR Rotterdam, The Netherlallds 
INTRODUCTION 
The identification and characterization ofyirus neutralization 
inducing (VNI) antigenic sites on the glycoproteins of HIV-I 
have been the focus of many studies (for review see [I)). For 
practical reasons, HIV-I strains and primary HIV-l isolates 
which efficiently replicate in T cells have predominantly been 
used to study virus neutralization [11. In this context it is 
important to note that macrophage-tropic non-syncytium-
inducing (NSI) variants with low efHciency of replication in T 
ceUs predominate in the asymptomatic stage and T cell line-
tropic syncytium inducing (SI) variants arc almost exclusively 
found in late stages of the infection [2, 3]. The macrophage-
tropic NSI strains havc bcen shown to exhibit a relatively 
high level of conservation in their VNI V3 loop [4}. It has been 
suggested that escape from virus neutralizing (VN) antibodies 
is based on the relatively high mutation rate generally 
tCutr~nt Oluure><;: BPRC. lang~ Kki\\eg 15L 2]88 GJ Rij>\\ijk. The 
Ncth~rLlIlu5 
tCurr~nt Oludre»: RegionJI Primate Re,e,lrch Center. l .. l]l HeJllh 
Sci~nce.\ Center SJ·50. Uni>~r;ity of WJ,hington. Se-lttk WA 981'15. USA. 
observed in the virus ell\'e1ope glycoprotein. Given the fact 
that also the CD4 binding domain (bd) is relatively conserved, 
another mechanism of escape from VN antibodies may be 
postulated for the relative sllccess of NSI/macrophage-
tropic viruses to persist in the host. To study the basis of this 
apparent paradox, we have used an em' complementation 
assay in which the biological activities could be compared of 
human HIV-I-specific monoclonal and polyclonal antibody 
preparations towards identical HIV-I strains only differing 
in their glycoproteins which displayed an SI or an NSI 
phenotype. 
MATERIALS AND METHODS 
HI/Il/all (lll(ihodil.'s. sCD.J <III/I IllV-/ t'III·e/OPI.' g(woprotl'ills. The 
human monoclonal antibodies (HuMoAbs) used are dire(:ted Olgainst 
the CD4 binding domain (OP[) and OP68 [5}), a highly consen'ed 
conformationlll epitope on gp41 (K14 [6]lllnd the HIV-J gpl20 V] 
loop (:!57-D Pl). Furthermore sCD..\ (kindly provided by Dr I. Jones 
through the i\tRC AIDS directed programme) and IIIVIO IS}) 
(kindly provided by Dr H. Schuitcmaker) were used as VN agents. 
The <'III' gen('s used {I6.1 (SI). 16.1 (SI). 16.4 (NSI), MN and IIIBJ for 
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the production of envelope glycoproteins in the capture antibody 
ELISA and for the production of chimeric viruses havc previously 
~n characterized and describ<:d [9,10-12]. 
Captllre (llItibody 6LISA/ar measurement a/relatire affinIty. The 
relativc amnity of the HuMoAbs used in the present study was 
detennined in a previously described ELISA. In short, ELISA plates 
(Costar, Cambridge, MA 02140, USA, cal. no. 3590), coated with 
amnity purified sheep immunoglobulins directed against the carboxy 
terminus of gp 120 (Aallo BioReagents, Dublin, Ireland, cat. no. 
D7324), were incubated for 2 h with cell lysate of recombinant 
vaccinia virus (rVV) infected HELA 113] cells (16 (NS!) and 16 
(SI» or HIV-I infected SupTl [14] cells (MN [II] and 1I1B (12]). 
Plates werc subsequently washed and incubated ,\ith serial dilutions 
of previously describ<:d HuMoAbs (OP13, GP68 {5] and 257-D (7l). 
The ELISA was completed and read as previously describ<:d [10]. 
The relative amount of antigen bound to the ELiSA plates was 
calibrated by using the same ELISA protocol with serial dilutions of 
the antigen and a standard excess concentration of polyc!onal serum 
from seropositive individuals. The data presented are the mean 
values of duplicates in one assay which was performed at least 
twice with similar results. 
Em'elope tmlls-complemelltatioll assay. This assay was based on a 
previously described trails-complementation assay in which an 1'1/1'-
defective HIV-I provirus, encoding the bacterial CAT reporter gene 
{I5J, was complemented for a single round of replication by a set of 
recently described HIV-I envelope glycoproteins [9]. TIle elll' genes 
encoding these glycoproteins were derived from biologically cloned 
SI Or NSI viruses, isolated from ODe single donor (number 16) at a 
single point in time in natural target cells (peripheral blood mono-
nuclear cells [PBMC]). In the complementation assay the genes 
encoding these envelope glycoproteins were co-transfected into a 
CD.f- cell line (COS [16]) together with the c/lr-defective molecular 
clone of the HIV-! lIIB strain. This resulted in the production of 
virions carrying heterologous envclope glycoproteins which could 
infect CD4+ ceHs, like the SupTI cells or PHA stimulated PUMC 
used in this study. After 3 days cell free supernatants were collected 
Table I. Relative affinities of HuMoAbs for different HIV-I 
envelope glycoproteins 
HIV~I strain (phenotype) 
16.1 16.2 16.4 MN 
HuMoAb Specificity (SI) (51) (NSI) (51) 
KI4 gp4I 83' 61 61 33 
GPI3 CD4 bd 83 83 33 250 
GP68 CD4 bd 61 61 61 125 
257-0 V3 domain 125 125 125 125 
IITB 
(SI) 
61 
250 
250 
• Reciprocal of dilutions ofMoAbs, starting at I Jlg/ml, still giving 
50% of maximal binding with the respective envelope glycoproteins 
in a capture antibody ELISA as a measure of relative affinity. The 
data presented are the mean values of duplicates in one assay which 
was perfonned at least twice with similar results. 
t No binding: OD450nm values remained at background levels at 
the concentrations tested. 
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by centrifugation and frozen at -135°C. For infection the amount 
of p24 antigen, as determined with a p24 ELISA kit (V5, Organon 
Teknika, Boxtel, The Netherlands) was calibrated and the level of 
envelope e:\prc"5.sioll was checked with the capture antibody ELISA 
(sec above). Infection was perfomled overnight at 37'C in 1011 
medium. After 24h the cells were washed and cultured for 72h. 
CAT acth'ity in these cells was measured ill a previously described 
CAT assay using a two-phase extraction system [I7J. CAT activities 
expressed in the cells were considered a difl'Ct measure of virus 
infectivity in these assays. 
RESULTS 
Retati\'(> 'Ulillity of HuMoAbs Jor II/V-! ellre/ope 
glYCOprolt'ills 
The Hui\loAbs used in these experiments were selected on 
basis of thcir epitope specificities and relative amnities in the 
c,lpture antibody ELISA for different HIV-I envelopc gl),co-
proteins (Table I). The same recombinant em'clope glyco-
proteins were used in the elll' complementation assay (Table 
2). Both CD4 bd specific IIuMoAbs GPI3 and GP68 showed 
an overall higher relative affinity for the glycoproteins of the 
T cell line adapted HIV-I strains IIIB .md ~·lN than for the 
glycoproteins derived from the donor number 16 HIV~I 
strains. The V3 loop specific Hulv[oAb 257-D showed a 
high relative affinity for the giycopro{eins of the ~'lN-Hke 
HIV-I strains and no binding was observed in this ELISA 
with the glycoproteins of HI V-I lIm (Table I). 
Virus 1It'lIlrali::a/ioJl alld elllial/Celllelll (~{ riml i/!{t'ctirlty by 
sCD4 al/d Iilllllall OIlIihotiies 
The VN activities of hUlllan antibodies and sCD4 toward T 
ceillille adapted strains HIV-l MN and HIV-I IIIB (Table 2) 
havc been documented previously [10-13]. The CD4 bd 
specific HuMoAbs GPI3 and GP68. as well as HIVIG and 
sCD4, inhibited infectivity of HIV-I 16.2 (SI) only to a 
limited extent «50%) when tested at a concentration 
(l5J1g/ml) that significantly inhibited infectivity of HIV-I 
IIIB in the 1.'111' complementation assay (reduction to 15%, 
12%, 9% and 8% respectively) (Table 2). The V3 domain 
specific HuMoAb tested at the same concentration, neutral-
ized HIV-I 16.2 (SI), as was shown by a reduction of CAT 
activities to 0.7% (Table 2). No major biological activity of 
any of the antibodies tested or sC04, was observed against 
HIV-l 16.1 (SI) as was shown by a reduction of CAT activity 
with 2-9% only, using 15 pgjml antibody (Table 2). 
In contrast to the VN activities observed with the SI 
viruses, the same concentration of all these VN antibodies 
and sC04 caused a dramatic enhancement of infectivity of 
HIV-I 16.4 which has a NSI envelope (>six-fold increase in 
CAT activity) (Table 2). In order to demonstrate the dose 
dependency of these phenomena, dose response curves werc 
made with the V3 domain specific HuMoAb 257-0, which 
exhibited the highest amnity for all the envelop proteins 
Table 2. Virus neutralizing and enhancement activities of human antibody preparations and sCD~ 
Virus strain (biological phenotype) 
MN" 1118 Illll 16.1 16.2 16.4 
Antibody preparation Epitope (SI) (SI) (SI) (SI) (SI) (NSI) 
none .,.t 1001 100 100 100 
72.461* 55.065 54.428 8.239 
KI4 gp41 103 98 106 96 
GPI3 CD4 bd t + 15 97 65 732 
GP68 CD4 bd + + 12 93 65 741 
sCD4 CD4 bd + + 9 92 84 620 
257-D V3 + 97 91 0.7 655 
HlVIG poly + + 8 95 95 744 
VN assay CIII' complementation assay 
t Due to differences in the VN assays used, biologicill activities are indicated as high (+) or undetectable (-). 
§Pcrccntage of CAT activity relative to the CAT activity observed in the absence of antibody. The mean value 
within one experiment obtained with SnpTI cells is given. The antibody preparations were tested at least twice 
with the same chimeric virus yielding similar results. 
-* CAT activity in counls per minute (cpm), background values range from 300 to 800cpm. 
tested (Table I). Clear dose related VN and enhancement 
activities were found with this antibody in the i'1/\' comple+ 
mentation assay with HIV-I 16.2 (SI) and HIV-I 16,4 (NSI) 
respectively (Fig. I). When these experiments were repeated 
in PHA stimulated PBMC essentially the same phenomena 
were observed. The overall differences were however less 
pronounced in this system (average enhancement about 
50%) probably due to a limited cellular host range of this 
virus (A. C. Andeweg et aI, unpublished observations). 
DISCUSSION 
Using an assay that is highly sensitive for measuring viral 
entry we have shown in the present study that both sCD4 and 
human antibodies which neutralize Sf HIV·I strains may 
enhance infectivity orNSI HIV-I strains. 
HIVIG, sCD4 and the CD4 bd specific Hul\[oAbs GP13 
and GP68 readily neutralized the HIV-I IIIB strain whereas 
limited or no VN activity was observed against the primary 
HIV·I strains from donor number 16. This supports previous 
observations that sCD4, CD4 bd specific Huf>.-foAbs and 
IIIVIG have little or no neutralizing aetivity against primary 
vinls strains (M. Schulten, personal observation and fI8]). Jt 
has been shown by several groups that VN capacity of V3 
loop specific MoAbs toward T cell line adapted HIV-I strains 
is dependent on the am nit)' of the antibody for the V3100p of 
the HIV-I strain llsed [7, 19]. However, in the present 
study we showed thai VN aClivity of V3 loop specific 
Hul\'loAb 257-D toward the SI HIV-l strains from donor 
number 16 is not directly related to its relative affinity for the 
glycoproteins involved: identical relative afiinities for the 16.1 
(SI) and 16.2 (SI) envelope glycoproteins were observed, but 
reductions in the em' complementation assay proved to be 9 
and 99.3% respectively. This was unexpected since both 
envelopes exhibit SI capacity and a 95% overaU predicted 
amino acid sequence homolog), exists between these envel-
opes [9]. Since we have previously shmvll that other domains 
than the V3 domain are involved in membrane fusion (10), it 
may be speculated that mV-l 16.1 is less dependent on the 
V3 domain to establish membrane fusion and infection. 
The efficiency of entry into T cell lines of the NSI lIIV-I 
strain 16.4 was significantly lower than that of the SI HIV-I 
strains 16.1 and 16.2 as shown by a > six-fold 10wer(CAT 
activity. The infectivity of the NSI HIV·1 strain was however 
enhanced to levels comparable to those of the SI HIV·l 
strains by the administration of sCD4 or antibodics that 
neutralized these SI HIV-I strains. Different mechanisms 
for I-IIV·l specific antibody mediated enhancement have 
been described, including Fe receptor- and compIement-
mediated enhancement [20, 21). Two observations argue 
against the same mechanism in our experiments. Firstly, 
SupTI cells do not express Fe receptors [14] and complement 
was not present in the assays. Secondly, enhancement of HI V-
I 16.4 (NSI) was also observed with sCD4 (Table 2). An 
explanation for the observed enhancement can be found in a 
mechanism previously described for the enhancement of non-
cytopathic SIV agm infectivity and induction of HIV-2 
mediated cell fusion ofCD4- cells, by sCD4. In these systems 
sCD4 does not induce dissociation of surface glycoprotein 
(SU) from infected cells [22, 23J. In contrast, sCD4 does 
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Fig. I. Virus neutralizing and inf~thity enhancing activities of 
serial dilutions of HuMoAb 257-0 using SupTi cells in the em' 
complementation assay "ith HlY-1 16.1 (SI), HIV-l 16.2 (SI) and 
HI"-I 16.4 (NSI) chimeric viruses. Counts per min (cpm) obtained 
in the assays ''''lIb antibodies, afe expressed as percentages of cpm 
obtained in the assay carried out in the absence of antibodies. 
Dotted line represents 50% inhibition ohirus infectivity_ 
induce dissociation of SU from cells infected with T ceillioe 
adapted HIV-I strains which are readily neutralized by sCD4 
[24J. We hypothesize that both sCD4 and the antibodies we 
studied, cause conformational changes in the viral envelope 
complex of certain NSI/macrophage-tropic HIV-I strains 
exposing cryptic fusion sites as was also shown in the 
SIVagm and HIV-2 systems [22, 23]. These changes would 
allow a more efficient virus-cell fusion that is less dependent 
on the presence of CD4 on the target cell membrane. 
Taken together our data suggest that naturally occurring 
antibodies to the so-called HIV-I VNI antigenic sites, may 
cause either neutralization or enhancement dependent on the 
biological phenotype of the virus recognized. If indeed our 
findings are a reflection of a more general phenomenon of 
enhancement also found in infections with other lentiviruses 
like HIV-2 [23J and SIVagm I22], they may explain why early 
after HIV-I infection predominantly viruses with an NSI/ 
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macrophage-tropic phenotype are found and why these 
viruses arc able to persist in the infected host despitc the 
conserved nature of their 'VNI' antigenic sites. The observed 
enhancement would actually favour replication of viruses 
displaying the NSf/macrophage-tropic phenotype, whereas 
viruses displaying the SI/T cell line-tropic phenotype are 
nelltralized. 
These observations may not only have implications for our 
understanding of the pathogenesis of HIV-I infection but 
also for thc development of immunization strategies. -If Ihis 
observation is thc rcflection of a more general phenomenon, 
the induction or administration of antibodies that neutralize 
"imses of the SIlT cell-tropic phenotype, which is a com-
monly followed strategy at present, may actually be counter 
productive. 
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Recently we and others have shown that the interaction between envelope specific 
antibodies and primary HIV-1 isolates may result in either inhibition or enhancement of 
viral entry. The outcome proved to be determined by the virus isolate rather than by the 
specificity of the antiserum used. To study the mechanism underlying this phenomenon, 
a series of HIV-1 envelope glycoproteins from closely related primary virus isolates of 
different syncytium inducing phenotypes and chimeras of these proteins, were tested in 
an envelope trans-complementation assay for their sensitivity to either antibody mediated 
inhibition or enhancement of HIV-1 entry. 
Based on the observation that, in contrast to the inhibition of HIV-1 entry, antibody 
mediated enhancement was not temperature dependent and could not be mediated by 
F(ab) fragments, we concluded that the mechanisms underlying both phenomena are 
essentially different and that antibody mediated enhancement of HIV-1 entry is largely if 
not exclusively mediated by HIV-1 glycoprotein cross-linking. The susceptibility of the 
envelope glycoprotein chimeric viruses to neutralization or enhancement of infectivity 
proved to be primarily determined by the configuration of the V3 loop and the affinity of the 
antibodies to monomeric HIV-1 gp160 molecules, proved to be of quantitative importance 
only. 
One human monoclonal antibody directed against gp41 (lAM 2F5), inhibited entry of all the 
viruses studied, irrespective of their phenotype, and directly proportional to its affinity to 
monomeric HIV-1 gp160. 
INTRODUCTION 
The HIV-1 envelope glycoprotein complex of T cell line adapted (TCLA) HIV-1 strains has been 
shown to mediate virus entry by a pH-independent mechanism, which is initiated by a high affinity 
interaction between the surface glycoprotein (SU, gp120) and the cellular receptor CD4 (Stein et 
al., 1987). Apart from this high affinity interaction, a lower affinity interaction with a second 
receptor is required for HIV-1 entry (Maddon et al., 1986). These interactions of the HIV-1 
glycoproteins with cell surface molecules lead to conformational changes within the HIV-1 
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glycoprotein complex and shedding of gp120, which eventually results in the fusion of viral and 
cellular membranes (Allan, 1991; Moore ef al., 1991). Both soluble CD4 (sCD4) and antibodies 
directed against the envelope glycoproteins may interfere wilh this process of virus entry in 
several ways. They may block the interaction between gp120 and the cell surface molecules, 
induce conformational changes which disable the envelope glycoprotein complex to exert further 
functions, or induce premature shedding of gp120 (Clapham ef al., 1989; Moore ef al., 1990; Orloff 
ef al., 1993; Poignard ef al., 1996). 
It has become clear that the glycoprotein complex of HIV-1 isolates that have only been 
propagated in peripheral blood mononuclear cell (PBMC) cultures differs from that of TCLA HIV-1 
strains in several respects. The so-called primary HIV-1 isolates are less susceptible to virus 
neutralization by sCD4 and antibodies directed to the V3 loop or the CD4 binding domain (CD4 
bd) (Moore ef al., 1995; Schulten ef al., 1996). Furthermore, as was also shown for HIV-2 and 
SIVagm, primary HIV-1 isolates do not readily shed gp120 upon binding to sCD4 (Allan, 1991; 
Moore ef al., 1992). We and others have recently shown that sCD4 may enhance primary HIV-1 
envelope glycoprotein mediated entry (Schulten ef al., 1995a; Sullivan ef al., 1995), a 
phenomenon that has also been described for HIV-2 and SIVagm strains (Clapham ef al., 1992; 
Werner ef al., 1990). This enhancement of HIV-1 envelope glycoprotein mediated entry is also 
mediated by polyclonal HIV-1 specific antibody (HIVIG) and by HIV-1 gp120 specific human 
monoclonal antibodies (HuMAb's) directed against either the V3 loop or the CD4 bd. It may be 
speculated, that this antibody mediated enhancement (AME), is a more common strategy of these 
closely related lentiviruses, to escape from - or even take advantage of - virus neutralizing 
antibodies (Moore ef al., 1991, Kostrikis ef al., 1996). Why such a common strategy has not been 
identified previously, may be due to a selection against AME sensitive viruses, in HIV-1 isolation 
procedures. The use of mitogen stimulated PBMC in the absence of virus specific antibodies, may 
be expected to favour the isolation of T cell tropic viruses (Innocenti-Francillard ef al., 1994). 
In the present paper we present results of studies into the mechanism underlying AME, which 
phenomenon is essentially different from previously described Fc receptor and complement 
receptor mediated antibody dependent enhancement mechanisms of HIV-1 infectivity (Eaton ef 
al., 1994; Robinson, Jr. ef al., 1990; Schulten ef al., 1995a). To this end a series of HIV-1 
envelope glycoproteins from closely related primary HIV-1 biological clones of different in vitro 
biological phenotypes and chimeras of these proteins, were tested in an envelope trans-
complementation assay (ETCA) for their sensitivity to either antibody mediated inhibition of HIV-1 
entry (IE) or AME. 
METHODS 
Human antibodies and HIV-1 envelope glycoproteins. The antibodies used in this study are the CD4 bd 
specific HuMAb's GP13 (Schutten e/ al., 1993) and IgG1-b12 (Burton e/ a/., 1994), the combinatorial phage display 
library F(ab) fragment FAB12 (Raben a/ a/., 1994) which was used to generate IgG1-b12, V3100p specific HuMAb's 
257-0 (Gorny e/ al., 1993) and MN215 (Schutten e/ a/., 1995b), HuMAb K14 directed against a highly conserved 
conformational epitope on-gp41 (Teeuwsen-et al., 1990) and lAM 2F5 which is specific for a relatively conserved 
epitope on gp41 (ELDKWAS) (Muster e/ a/., 1993). The use of the TeLA HIV-1 envelope gene derived from the HIV-1 
IIIB isolate (HXB2-D) in the envelope trans-complementation assay has previously been described (Helseth et al., 
1990). The previously described (Andeweg et al., 1992; Groeniok et al.. 1992) HIV-1 envgenes derived from primary 
biological HIV-1 clones from the donors #16 and #320 from the Amsterdam cohort of seropositive individuals 
designated 16.1 (SI), 16.2 (SI), 16.4 (NSI), 320.2A.6 (NSI) and 320.2A. 7 (SI) were used for the production of viruses 
expressing the respective envelope glycoproteins. The envgene from the HIV~1 biological clone 168.10 (SI) had been 
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generated using a similar protocol (de Jong et al., 1992; Schuitemaker et al., 1993). The generation and 
characterization of the SIINSI envelope chimeras have been described in more detail by Andeweg et a/. (Andeweg 
et al., 1993). 
Affinity of the HuMAb's used for fhe monomen'c recombinant glycaproteins. The affinity af the HuMAb's for the 
monomeric form of the envelope glycoproteins expressed by the chimeric HIV-1 virions used in the env-
complementation assay, was determined in a previously described capture antibody ELISA (07324, Aalto Bioreagents 
Ltd., Dublin, Ireland) (Andeweg et al., 1993; Moore, 1990f In short, Ihe primary envelope glycoproleins were 
expressed in COS cells (Gluzman, 1981) using a vaccinia expression system. Vaccinia infected cells were lysed with 
1% Empigen and the amount of HIV-1 glycoprotein in the cell lysate was estimated using the capture antibody ELISA. 
Subsequently equal amounts of HIV-1 glycoprotein were coated and the concentration of HuMAb was determined 
where half maximum binding was reached in the capture antibody ELISA. This concentration Was taken as relative 
affinily of Ihe HuMAb for Ihe HIV-1 envelope glycoprolein lesled. 
Despite the pronounced amino acid variation in the hyper variable regions of the envelope glycoproteins, all HuMAb's 
showed a similar relatively high affinity for Ihe envelope glycoproleins ((Schullen et al., 1995b) + unpublished resulls). 
HuMAb lAM 2F5 (gp41) however, showed low affinity for Ihe 16.4 (NSI) envelope glycoprolein and HuMAb MN215 
013 loop) showed low affinity for all SI envelope glycoproleins (SchuHen et al., 1995b). The low affinity of HuMAb IAM-
2F5 for the #16.4 (NSI) envelope glycoprotein may be explained by the lysine to threonine change in the 16.4 (NSI) 
amino acid sequence (ELDIWAS) (Andeweg et a/., 1992) relalive to the optimal binding sequence for lAM 2F5 
(ELDlSWAS) (Muster et al., 1993). 
Envelope trans-complementation assay (ETCA). The ETCA was based on a previously described assay in 
which an envelope gene defective HIV-1 provirus, encoding the bacterial CAT reporter gene was complemented for 
a single round of replication by the set of HIV-1 envelope genes (Helseth et al., 1990). In the ETCA the plasmids 
encoding the envelope glycoproteins were co-transfected by efectroporation into a C04'ceflline (COS) (Gluzman, 
1981) together with the envelope gene defective molecular clone of the HIV-1I11B strain. This resulted in the production 
of virions carrying heterologous envelope glycoproteins which may infect CD4+ cells. Cell free supernatants were 
collected after three days of culture by centrifugation and frozen at ~135°C. The amount of virus particles used for 
infection was adjusted by calibrating the amount of p24 antigen, as determined with a p24 ELISA kit (V5, Organon 
Teknika, Boxtel, The Netherlands) to a standard amount of p24. The level of envelope expression was checked with 
the capture antibody ELISA described above. For infection the Sup T1 T cell line (Smith et al., 1984) and three days 
PHA (PHA-M, Boerhinger Mannheim, Mannheim, Germany; 15 I1g/ml) prestimutated PBMC were used. Infection of 
SupT1 cells (2x10'lml) and PHA prestimulated PBMC (5x10'lml) was routinely performed overnight at 37"C in 1 ml 
RPMI 1640 (GIBCO BRL, Life Technologies BV, Breda, The Netherlands) wilh 10% fetal calf serum, penicillin and 
streptomycin in the absence or presence of 15 fl9 HuMAb or 30 I1g FAB12. To determine the temperature sensitivity 
of IE and AME, infection was performed at 4°C, 20°C and 37°e for five hours. After infection the cells were washed 
and cultured for another 72 hours. CAT activity, measured in cpm, was determined in a previously described CAT 
assay using a 1\'10 phase extraction system (Seed & Sheen, 1988). CAT activities expressed in the cells were 
considered a direct measure of the capacity of the envelope gene product to mediate virus entry. The mean value of 
duplicates within one experiment is given. Each antibody virus combination was tested at least in two separate 
experiments yielding similar results. 
RESULTS 
Antibody mediated inhibition and enhancement of entry using a set of clJimeric viruses carrying 
primary HIV-1 glycoproteins. 
The efficiency of HIV-1 envelope glycoprotein mediated entry into the SupT1 T cell line and the 
capacity of the respective HuMAb's at a given concentration (15 ~g/ml) to inhibit or enhance the 
process of entry mediated by these envelope glycoproteins, was determined in the ETCA (Figure 
1). The capacity of the HuMAb's to inhibit entry of HXB2-D envelope complemented virus was 
proportional to their previously reported capacity to neutralize the HIV-1 strain IIIB (Burton et al., 
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1994; Gorny et al., 1993; Muster et al., 1993; Schutten et al., 1993; Teeuwsen el al., 1990). 
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Fig. 1. Efficiency of entry into Sup T1 cells of primary and TeLA HN-1 glycoprotein complemented chimeric virllsln the absence and presence 
of HIV-1 envelope glycoprotein specific HuMAb's determined In the ETCA On the X·axis IE or AME mediated by HIV-1 envelope glycoprotein 
specific HuMAb's are given as the percentages of CAT activity obtaIned with 15 ~g/ml of HuMAb relative to CAT activity obtained with the same 
H1V-1 envelope glycoprotefn complemented virus without HuMAb. On the right CAT activities obtained with the chimeric viruses without using 
HuMAb are presented. 
HuMAb K14, which does not neutralize TCLA viruses in in vitro assays, did not influence entry 
mediated by any of the primary envelope glycoprotein complemented viruses. The V3 loop 
specific HuMAb 257-D efficiently inhibited entry (inhibition of entry >90%) of one of the six 
chimeric viruses, which expressed the envelope glycoprotein derived from primary HIV-1 strain 
16.2 (SI), and enhanced envelope 16.4 (NSI) mediated entry (enhancement of entry >200%). The 
CD4 bd specific HuMAb GP13 inhibited envelope 16.2 (SI) mediated entry about 50% and 
enhanced envelope 16.4 (NSI) mediated entry about fivefold. IgG1-b12, which is also directed 
against the CD4 bd, inhibited entry of the envelope 320.2A.6 (NSI), 16.1 (SI) and 16.2 (SI) 
complemented viruses and enhanced envelope 16.4 (NSI) mediated entry about threefold. 
HuMAb lAM 2F5 directed against the proximal putative alpha helix of gp41, inhibited entry into 
Sup T1 cells of all the chimeric viruses more than 90% with the exception of envelope 16.4 (NSI) 
chimeric virus to which it displayed a much lower affinity. Entry of this chimeric virus was reduced 
about 50% by HuMAb lAM 2F5. 
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Inhibition and enhancement of viral entry in relation to HIV-1 envelope glycoprotein cross-linking 
by antibodies. 
IgG1-b12 and the F(ab) fragments (FAB12), which had been used to generate IgG1-b12, 
were used to evaluate whether IE and AME of chimeric 16.2 (SI) and 16.4 (NSI) viruses 
respectively, required cross-linking. IgG1-b12 and its F(ab) fragments were selected since HuMAb 
IgG1-b12 showed broad IE activity against the primary HIV-1 envelope glycoprotein 
complemented viruses (Figure 2). The level of IE of the envelope 16.2 (SI) chimeric virus 
mediated by FAB12 and IgG1-b12 were in the same order of magnitude. However, enhancement 
of envelope 16.4 (NSI) mediated entry was only observed with IgG1-b12, whereas the F(ab) 
fragments of IgG1-b12 failed to enhance entry mediated by this envelope glycoprotein. Since 
IgG1-b12 does not bind to Sup T1 cells in FACS analysis, which is consistent with the lack of Fc 
receptors on SupT1, the lack of AME by FAB12 could not be attributed to the mere absence of 
the Fc portion of the antibody. 
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percentages of CAT activity oblained with 15 pg/ml 
HuMAb and 30 ]Jglml of F(ab) relative to CAT activity with 
the same chimeric virus oblained without using HuMAb or 
F(ab). 
Antibody mediated inhibition and enhancement of entry at different temperatures. 
HuMAb 257-0 was selected to study the effects of different temperatures on IE and AME, 
since this antibody recognizes a linear epitope (IHIGPG) that is most probably less dependent on 
the conformation of the envelope glycoprotein (Gorny et al., 1993). Furthermore, probably due to 
the high affinity of HuMAb 257-0 for the recombinant glycoproteins derived from donor #16, 
HuMAb 257-0 completely blocked entry of envelope 16.2 (SI) chimeric virus. AME of envelope 
16.4 (NSI) chimeric virus mediated by HuMAb 257-0 typically resulted in levels of CAT activity 
which were similar to those found for envelope 16.2 (SI) chimeric virus when tested in the absence 
of HuMAB (Figure 1). At decreasing temperatures CAT activity levels declined for envelope 16.2 
(SI) and envelope 16.4 (NSI) complemented viruses (Figure 3). This was probably due t6 the 
lower efficiencY of entry at lower temperatures although limited cell death upon five hours 
incubation at lower temperature was also observed. The decrease in maximum CAT activities at 
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Fig. 3. Efficiency of entry Into Sup T1 cells of chimeric 
viruses 16.2 (SI) and 16.4 (NS]) at differenllemperalures in 
the presence or absence of HuMAb 257-0. On the X-axis IE 
or AME are given as the CAT activities obtained with 15 
\Jglml HuMAb 257-0. Infection was carried out al 3rC, 
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lower temperatures obscures the efficiency of inhibition and enhancement of entry if these are 
given as ratio's. In figure 3, in contrast to figures 1,2 and 4, actual CAT activity values are 
therefore given. To determine the efficiency of inhibition and enhancement of entry by HuMAb 
257-D, CAT activity values obtained in the presence of HuMAb 257-D at a given temperature are 
compared with the minimum and maximum CAT activity values respectively at that given 
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temperature. IE and AME mediated by HuMAb 257-0 with envelope 16.2 (SI) and envelope 16.4 
(NSI) chimeric viruses, at decreasing temperatures were tested in parallel (Figure 3). The level 
of IE of envelope 16.2 (SI) chimeric virus proved to have decreased significantly at 20°C (CAT 
activity about two times background) and even more at 4°C (CAT activity about five times 
background) when compared to the complete block of entry at 37"C (background CAT activity). 
In contrast, the level of AME of envelope 16.4 (NSI) chimeric virus proved not to be affected by 
the lower temperatures: The CAT activity values obtained with envelope 16.4 (NSI) chimeric virus 
at different temperatures in the presence of HuMAb 257-0 were virtually identical to the values 
obtained with envelope 16.2 (SI) chimeric virus at the same temperature in the absence of 
antibody. Collectively these results show that in contrast to the level of IE, the level of AME is not 
significantly influenced by decreasing temperatures. 
Antibody mediated inhibition and enhancement of entry in a set viruses carrying hybrid SI/NSf 
constructs. 
Using a series of HIV-1 envelope glycoprotein with different biological phenotypes, 
originating from one patient at one time point, and hybrids generated from these proteins, an 
ETCA was carried out with a V3 loop specific (MN215) and a C04 bd specific (GP13) HuMAb in 
Sup T1 cells (Figure 4). The ratio of the CAT activity measured in Sup T1 cells versus the CAT 
activity measured in PHA stimulated PBMC was taken as a measure of the relative efficiency of 
entry of the respective chimeric viruses into Sup T1 cells. 
The sensilivity of envelope 16.2 (SI) to IE was transferred to envelope 16.1 (SI) and 
envelope 16.4 (NSI) proteins by the transfer of the envelope 16.2 (SI) aa 1-610 fragment (12AX 
and 42AX). These two constructs mediated efficient entry into Sup T1 cells, suggesting that both 
the efficiency of entry into Sup T1 cells and the sensitivity of the chimeric viruses to either IE or 
AME mediated by both HuMAb's is a trait of gp120. The transfer of the V3-V5 region of envelope 
16.2 (SI) (Stu I-Avril, aa 211-610) to envelope 16.4 (NSI) (24SA), resulted in a hybrid envelope 
mediating relatively high efficiency of entry into SupT1. This exchange also changed the sensitivity 
of the envelope 16.4 (NSI) from AME sensitive to IE sensitive. We have previously shown that 
within the Stul-Avrll fragment of envelope 16.2 (SI), the V3 domain (aa 272-378, Hindll-Cvnl) 
alone proved to be sufficient to transfer the SI capacity of env 16.2 (SI) to a NSI background 
(Andeweg et al., 1993). In line with this finding the env 16.2 (SI) based construct containing the 
16.4 (NSI) V3 loop (42HC) showed a relatively low efficiency of entry into SupT1 and entry 
mediated by this construct envelope was still significantly enhanced by both HuMAb's. These data 
suggest that within the 16.2 (SI) and 16.4 (NSI) HIV-1 envelope glycoproteins the V3 loop may 
not only determine the efficiency of Sup T1 entry but also the sensitivity to IE or AME. 
However, in contrast with this observation, exchange of the 16.4 (NSI) V3 domain for the 
16.1 V3 domain (14HC) failed to significantly increase the efficiency of entry into SupT1, and also 
failed to change the AME phenotype of the envelope 16.4 (NSI) chimeric virus (Figure 4). 
DISCUSSION 
Naturally occurring changes within the HIV-1 env gene contribute to the in vitro biological 
characteristics used to describe the phenotype of HIV-1 strains. These biological characteristics 
include the syncytium inducing capacity, cellular host range, replicative capacity and the ability 
to induce single cell lysis. In the present paper we have shown that also the sensitivity of HIV-1 
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strains to IE or AME is determined by naturally occurring changes in envelope regions, which 
directly influence the SI capacity and efficiency of viral entry. 
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HuMAb 257-D and HuMAb IgG1-b12 only inhibited entry mediated by a limited number of 
the HIV-1 envelope glycoproteins tested (one and three out of six, respectively) (Figure 1), 
although their affinities for the monomeric HIV-1 envelope glycoproteins used proved to be within 
the same range. The lack of biological activity of these HuMAb's towards the other viruses 
suggests that they either do not bind to the oligomeric HIV-1 glycoprotein complex of these 
viruses or do not exert biological activity after binding. The former explanation seems consistent 
with our previous FACS studies using vaccinia expressed HIV-1 envelope glycoproteins, which 
showed that VN inducing sites are less well presented by oligomeric primary HIV-1 glycoprotein 
complexes used in the present study than by their monomeric counterparts (Sattentau et al., 
1994). However, HuMAb's directed against these sites were shown by others to bind oligomeric 
HIV-1 glycoprotein complexes present on primary HIV-1 infected cells (Zolla-Pazner et al., 1995). 
Indicating that the conformation of the HIV-1 glycoprotein complex present on HIV-1 virions may 
be essentially different from vaccinia expressed cell membrane associated envelope glycoproteins 
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(Q. Sattentau, personal communications). Therefore, lack of biological activity after binding may 
still be a more likely explanation. This may either be due to the absence of involvement of the 
antibody binding site of these viruses in the process of entry, or alternatively, binding of these 
antibodies does not induce the changes needed to inhibit entry of these viruses. The results of 
the ETCA experiments with the SIINSI hybrid constructs, presented in this study, seem to favour 
the explanation that the binding sites are not involved in the process of entry of these viruses. It 
has recently been shown that NSI and SI HIV-1 strains use different second receptor molecules 
during envelope mediated entry (Deng etal., 1996; Feng etal., 1996). The CXCR-4 achemokine 
receptor proved to be the second receptor for SI or T cell line adapted HIV-1 strains, whereas 
NSl/macrophage-tropic HIV-1 strains required expression of the p chemokine receptors CCR-2a, 
CCR-3 or CCR-5 for entry (Doranz et al., 1996; Choe et al., 1996). Despite the fact that T cells 
express different a and p chemokine receptors including CCR-5, NSI HIV-1 strains replicate 
usually less efficient in T cells as compared to SI HIV-1 strains (Schulten et al., 1995a; Sullivan 
et al., 1995). The differential requirements of these HIV-1 strains for second receptor molecules 
proved to be determined at least in part by the configuration of the V3 loop (Choe et al., 1996). 
It may therefore be speculated that the inability of the HIV-1 envelope glycoproteins expressing 
the 16.4 (NSI) V3 loop to mediate entry via the CXCR-4, may be overcome by adding HIV-1 
gp120 specific antibodies. It should be realized that the number of amino acid differences between 
these closely related proteins is limited (Andeweg et al., 1992). Still despite the high degree of 
homology, in particular in those regions that apparently govern syncytium induction and entry, the 
HIV-1 chimeric viruses differ significantly in their sensitivities to IE or AME. 
The temperature dependent nature of IE (Figure 3) suggests that the induction of 
conformational changes in the HIV-1 envelope glycoprotein complex after binding of the HuMAb's 
are essential for IE. This has also been suggested for the neutralization of TCLA HIV-1 strains by 
gp160 specific antibodies (Poignard et al., 1996; Sattentau & Moore, 1991). The observation that 
HuMAb's with relatively low affinity to 16.4 (NSI) envelope glycoprotein induce levels of AME 
similar to those with high affinity (M. Schulten, unpublished observation), together with the 
apparent temperature independent nature of AME (Figure 3), led us to conclude that the changes 
induced by antibodies and sCD4, leading to AME, have a minimal energy requirement. 
Furthermore, IE and AME both proved to be dependent on the concentration of antibody or sCD4 
(Schulten et al., 1995a; Sullivan et al., 1995): IE reached a plateau value at increasing 
concentrations whereas AME increased with concentration to an optimum level. Collectively these 
data indicate that the mechanisms which underly IE and AME are fundamentally different and that 
antibody mediated cross-linking is essential for AME. This was confirmed by the observation that 
FAB12 did not induce AME although its IE inducing capacity toward IE sensitive viruses was equal 
to that of IgG1-b12 (Figure 2). In this light it is interesting to note that sCD4 exhibits the same 
paltern of IE and AME with the respective chimeric viruses as the V3 domain specific antibodies 
and sCD4 induces conformational changes within the HIV-1 glycoprotein complex similar to V3 
loop specific antibodies (Poignard et al., 1996). Moreover, the concentration profiles of sCD4 and 
antibody induced AME were essentially the same, suggesting that cross-linking is required for 
sCD4 induced AME (Sullivan et al., 1995). It is not clear however how sCD4, which is a monomer 
(Malvoisin & Wild, 1994), may cause cross-linking. We postulate that either sCD4 dimerizes with 
membrane associated proteins that also bind to HIV-1 gp120, or that more than one recognition 
site exist between gp120 and sCD4. The former explanation seems most likely since only recently 
it was shown that a D1-D2 fragment of CD4 bound to CCR-5 which also binds HIV-1 gp120 (WU 
et al., 1996). Since sCD4 activated HIV-1 and HIV-2 glycoproteins mediated membrane fusion has 
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been suggested to parallel gp120-CD4 activated membrane fusion (Allan, 1991), the high affinity 
interaction of HIV-1 gp120 with CD4 is probably required to establish a stable complex between 
the oligomeric HIV-1 glycoprotein complex and cellular CD4. This interaction then induces 
conformational changes allowing the gp120/CD4 complex to bind to members of the a and 13 
chemokine receptor family (Choe et al., 1996; Wu et al., 1996). This complex interaction may 
subsequently induce conformational changes within the gp120-CD4 complex, resulting in a 
fusogenic state of the whole envelope-CD4 complex. 
The capacity of HuMAb lAM 2F5 to inhibit entry of all the chimeric viruses tested (Figure 
1), indicates that this antibody, in contrast to the gp120 specific HuMAb's used in these studies, 
blocks an essential step in the process of entry of both TCLA and primary viruses. This antibody 
binds to the relatively conserved proximal part of a putative alpha helix, which is essential for 
HIV-111IB envelope glycoprotein mediated entry. Therefore we conclude that the site recognized 
by HuMAb lAM 2F5, rather than those involved in AME, may be the most suitable target for 
antibody mediate immune intervention. 
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CHAPTER 7 
Human antibodies that neutralize primary HIV-1 in 
vitro do not provide protection in an in vivo model. 
J. Gen. Viral. 77:1667-1675. (1996) 
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Recently, conflicting data have been published 
about the ability of antibodies which efficiently 
neutralize T cell-adapted human immunodeficiency 
virus type 1 (HIV-1) strains to neutralize primary 
HIV-1 strains In vitro and in vivo. Here we present 
data indicating that such antibodies fall to neutralize 
primary HIV-1 strains in vivo. To this end, a newly 
developed chimeric human~to"mouse model was 
used, in which several aspects of primary HIV-1 
infection are mimicked. Poly~ and monoclonal anti~ 
Introduction 
Studies aimed at the development of a vaccine against 
hlUnan immunodeficiency vinlS type 1 (HIV-1) have largely 
focused on the induction of antibodies which neutralize HIV-1 
strains adapted to replication in T cell lines. It was shown that 
the neutralizing capacity of such antibodies was Significantly 
lower or absent against primary HIV-1 strains, directly isolated 
in peripheral blood mononuclear cells (PBMC) from HIV-1-
seropositive individuals (Moore ef a1., 1995). The significance 
of these antibodies for ill vivo protection and consequently the 
need to induce such antibodies by vaccination has been subjed 
of fundamental debate (SchuHen d al., 1995; Moore, 1995). 
Evaluation of the potential of antibodies and antiviral com-
pounds to interfere with the replication of primary HN-1 
strains ill vivo has largely been hampered by the limited 
availability of suitable animal models. Besides the chimpanzee 
(Pml froglodyles) and the pigtail macaque (MaCllCll IIfmt'strilll1), 
human-mouse chimeric models for HIV -1 infedion have been 
described. These are based on the creation of a human type 
haematological environment by grafting human PBMC or 
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bodies protected the grafted,human cel/s, in a dose~ 
dependent way, from infeGtion with T cell~adapted 
HIV-1 in this system. A human monoclonal antibody 
specific for the CD4 binding domain that efficiently 
neutralizes HIV~ 1 IIIB in vitro did not protect the 
human graft from HIV~ 1 IIIB Infection. None of the 
antibodies provided protection in the in vivo model 
against infection with primary HIV-1 strains, 
although they were able to neutralize these same 
strains in vitro. 
haematopoietic tissue into SCID mice (Mosier e1 nl., 1991; 
Namikawa eI nl., 1988); subsequently, the activated human 
graft is infected with HIV-]. In these models it was demon-
strated that polyclonal hyperioumme globulins from sero-
positive donors (HIVIG), a monoclonal antibody (MAb) 
directed against the V3 loop on HN-1 gp120 and 3'-azido-
2',3'.dideoxythymidine {AZn inhibited the replication of T 
cell line-adapted (TCLA) HIV-1 strains (Safrit elal., 1993; Shih 
e1 nl., 1991; McCtme e1 n1., 1990). In infected individuals IiIV-
1 has been shown to replicate predominantly in activated 
macrophages and T lymphocytes resulting in high virus loads 
in lymphoid organs (Embretson eI n/., ]993; Pantaleo eI nl., 
1993). With this in mind an alternative chimeric human-to-
mouse model was developed in, which human PBMC were 
grafted intraperitoneally (Lp.) into gamma-irradiated CBA/N 
mice. This results in an acute xenogenic-graft versus host 
disease (xeno·GvHD) providing a system in which human cells 
of both the monocytic and lymphocytic cell lineages become 
highly activated {Huppes e1 al., 1992, 1993).10 order to infect 
the grafted cells in a quiescent state, infection with HIV-I was 
carried out within 1 h of grafting. Here we describe the 
replication kinetics of primary HIV-I strains in this model. 
Furthermore, we assess the potential of different human HIV-
I neutralizing antibodies to interfere with the replication of 
TClA and primary HIV -1 strains in grafted human cells. 
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Methods __ 
• Viruses and antibodies. The antibody preparations used for 
passive immunization studies with the TeLA and primary HIV-J slrains 
were selecled for a broad and high affinity for the HIV-I strains used. 
They included: CD4 binding domain (bdJ-.-spedRc human monoclonal 
aniibody(HuMAh) CPU (SchuUen dal., 1993); the HIV-J [l[S V3 loop· 
specific mouse l'viAb F58li3 (Broliden cia!., 1992; Hinkula d r1/., 199-1), 
the HIV-l VJ loop-spedficHuMab 257-0 (Gomye/ rl/., 1993); the gp41-
spedfic Hu.\1Ab K14 (Teeuwsen e/ (II., 1990); and HIVIG (Prince d ill., 
1991). 
HIV-J illS was kindly provided by the IvlRC AIDS Directed 
Programme and the virus slock WiIS expanded using Ihe CS15 CD4' T 
(ell line (Gallo el al., 1983; Nick d al., 1993). The primary HIV-J 
molecular dones 320.2A.1.2 lSI (syncytium inducing/non.macrophage 
tropic)] and 320.2A2.1 [NS! (non·syncytiwn indUcing/macrophage 
IropicJL and the primary HIV-1 sirains ACH 171.BA·L (NSI) and ACH 
168.10 (SI), were provided by H. &huilemaker from the Central 
laboralory for Ihe Blood Transfusion Service in Amslerdam. Their ill 
pilro) passage history has been described previously (Schuilemaker e/ III., 
199211", I" 1993). The full.length infedious molecular dones HIV-1 
320.2A 1.2 (SI) and HIV·1320.2A2.1 were transfeded inlo Ihe cor cell 
line cos and cell-free supemalants were obtained after 3 days. A high 
tilred virus stock from HTV -1 320.2A1.2 (SI) was made within 2 weeks 
of primary infedion using the CB15 cell1ine. During this short Single 
pJssJge il is unlikely thai the genotype and phenotype of the HIV·l 
molecular done changed significJnlly (Back (/ al., 1993; Gadner & 
Popovic, 1990). Since HIV-1320.2A.2.1 (NS]) does noi replicJte to high 
titres in phytohaemagglutinin (PllA)-stimulated PBMC and immortalized 
T eel! Jines, xeno·GvHD mice were infeded with HTV-1320.2A2.1 (NSI) 
and after 2 weeks peritoneal tissues from Ihese mice were cultured for 
anolher 6 days to produce high titre virus stocks. Virus slocks from ACH 
168.10 (SI) and ACH 171.BA·L were produced using PHA-stimulated 
human PBMC according 10 established procedures (Schuitemaker el/ll., 
1992a). 
• Xeno-GvHD mice. Xeno·GvHD mice were gener<1ied as previously 
described by Huppes e/lIl. (1992). In brief. 4 to 5·week_old CBA/N/Rij 
mice (Harlan CPB, leist, The Nelherlands), bred and kept under specinc 
pathogen-free conditions, were conditioned by total body imdiation 
(9 Gy) with haemalological support of 5 X 10' syngeneic bone marrow 
cells intravenously. For grafling 2 X 101/g bodyweight human PBMC 
isolated on a Ficoll gradient were used; this has been shoml to induce an 
acute GvHD in 100% of cases (lJuppes tla!., 1992, 1993). Mice within 
an experiment received PBMC from one individual only. The data plotted 
in figs 2 and 3 represent the results of one experiment with data 
measurements at a single time.point. All experiments were performed in 
duplic<1le with similar [esuits. Each virus-antibody combination was 
therefore tesled with PBMe from at leasl six different donors. 
• Virus load. The \'irus load of the human lymphocytes isolated from 
the xeno-GvHD mice infected with the different lITV·l strains was 
determined wnh an infectious centre tesl {ICT). Human lymphocytes 
from peritoneal lavages of each mouse were counted and tilrated 
individually in duplicate starting at 2'5 X 106 per well in 96-w .. 11 round 
bollom plales. Hwnan PBMC that had been prestimulated with PHA for 
3 days were also added at a concentration of 5 X 10 1 per well. Cells were 
cultured for 1 week in RPMI 1640 (GIBCO BRL), 10% heat inactivated 
fetal bovine serum (Hydone laboratories Ine-), penicillin (100 U/ml), 
streptomycin (lool-'g/ml) and 50 unih; of recombinant human IL-2/mL 
(proleukin, EuroCetus). Afler 7 days, 501-'1 of supernatant per wen was 
tested in a p24 antigen ELISA (V5 p24 antigen ELISA kit; a kind gift of 
Organon Temika, Boxtet The Netherlands) according to Ihe manu-
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fachl[er's instrudions. The minimwn number of cells from the peritoneal 
lavage from each individual mouse that was rl'quired 10 detect viral 
antigen in more than 50'l,~ of the wells was taken as a measure of viral 
load. Both peritoneallissue and spleen were also cultured using the same 
culture medium for detection of produdively infected cells. 
• Immunohistochemistry and in situ hybridization. CD45 
(human leukocyte marker) and CD68 (human macrophage marker) 
immunohistochemistry was performed as described previously (Tenner-
Racz e/ al .. 1994). SeGuential series of 4 flm sections were stained for HIV-
1 in combination with CD45 and CD68. For deledion of productively 
infeded cells by ill silll hybridiz<1tlon, a ~;S·labe!Ied antisense RNA probe 
of HTV-l and a J'$-Iabelled sense RNA probe as negative control 
(Lofslrand labs) were used. Sedions (4 )lm) of formalin·fi.xed paraffin-
embedded tissues were digested with Proteinase K (Sigma) al 37 "c for 
15 min. The tissue sedions were subsequently acelylaled in 0'25 <;,~ acetic 
anhydride-O'1 ~.:. trietholamine pH 8'Oat room temperalure for 5 min Jnd 
subsequenHy prehybridized with 50% formamide, 0'5 ",-NaC!. 10 mM· 
T ris-HCI pH 7'4. I mM-EDT A, 0'02 % Fkoll--poly-viny! pyrrolidone-
BSA and 2 mg/ml tRNA for 2 h at 45 0c. Radiolabelled prohl' 
(2 X 10~ d_p.m';!!I) in prehybridization mixlure+ 10% dextroln sulphate 
was added to the slides and incubated overnight at 45 0c. Aflcr extensive 
washing and Rt,\,Ase digestion (Boehringer Mannheim) tissue sections 
were dehydrated .md incubated with Kodak NTB·2 emulsion and 
de\'eloped in Kodak D-19 developer; the sedions were then counter-
slained wilh haemalum and mounted. Also, photographs were taken of 
Ihe ill silll hybridiz.ltion slides using excitation at one specific wavelength 
to identify the silver grains showing HIV-I-specific ill silu hybridization. 
Results 
HIV-1 infection in xeno-GvHD mice 
Xeno-GvHD mice were infected Lp. with 30 xeno-Gvl lD 
mice infedious doses 50'!jo (XelD.w ) of primary and TClA HIV-
1 strains with 51 and N51 phenotypes, These included the 
TelA HIV-l strain IIIB and the primary HIV-l strains 
320.2A.L2 (51), 320.zA.2.1 (N51), ACH.l72,BA-l (NS!) and 
ACH 168.10 (51), Diredly after development of acute xeno-
GvHD, combined if! situ hybridization and immuno-
histochemistry studies were carried out, using an HIV-l probe 
and CD45 and CD68 specific conjugates, on peritoneal tissues 
and lymphoid organs of mice infected with the primary HIV-
1 strains. Acute xeno-GvHD conSistently started between 6 to 
14 days after grafting. depending on the numbers of human 
PBMC grafted. The HIV-l-specific staining showed a signifi-
cant increase between days 6 and 12 after grafting (not shown). 
Fig. I (a-c) shows a sequential series of sections from part of the 
diaphragm stained for the macrophage marker CD68 and HIV-
L large numbers of human macrophages were present in the 
peritoneal tissues of these mice. In mice infeded with the N5L 
HIV-l strains, like HIV-I 320.ZA.2.1 (Schuitemaker ef lit 
1992(1), HIV-1-specific staining was found mainly in these 
areas. HIV-I-spedfic staining of T cell-rich areas was also 
observed, although to a lesser extent since HIV-l 320.2A.2.1 
also infects CD4 + T cells, In mice infeded with 51 HIV-l strains 
like 320.2A.1.2 and 168.10, which do not infect monocyte-
derived macrophages ill vitro (5chuilemaker ef (1/., 1992n). 
HIV-l-specific staining was Significantly lower in the 
macrophage-rich areas (Fig. Id-f). However, in the lymphoid 
organs of these mice, as in the periarteriolar lymphoid sheath 
shown in Fig. l(l?-i) where predominantly human T cells and 
hardly any human macrophages were present. abundant HIV-
1 staining could also be demonstrated. The number of 
produdively infeded cells per field at the same magnification 
was about ten times higher in these T cell-rich areas compared 
to tissues in the peritoneal cavity. The numbers of HIV-1-
infeded human cells in peritoneal lavages of those mice whose 
tissues were used for immunohistochemistry and ill situ 
hybridization were detennined in the ICT. For the primary 
HIV-l strains, ratios between infeded and non-infeded cells 
increased from about 10--t at day 6 to more than 10- 1-5 at day 
12 after grafting. This proved not to be related to the capacity 
of the virus to induce syncytia ill vi/roo HIV-l illS infedion in 
the xeno-GvHD model proved to be self-limiting since the 
ratio of infeded and non-infeded cells in the peritoneal lavage 
cel!s was 1O--t at day 6 and diminished to an undetedable level 
at day 11 (Fig. 2a, b). Infectious HIV~l could not be detected 
at day 11 in spleen or peritoneal tissues of mice infected with 
HIV-l HIS. 
Passive immunization studies with HIV-1 IIIB 
Intraperitoneal administration of 20 mg/kg poly- or mono-
clonal antibody preparations, 1 h prior to grafting of the 
PBMe followed by infedion with 30 XeID.;o HIV-l IlIB, 
resulted in different paUerns of interference with virus 
replication (Fig. 2(1). Administration of the CD4 bd-specific 
HuMAb GPI3, which neutralizes HIV-1 IIIB ill vifro linhibitory 
concentration 90% (lCso) = 2 flg/m!} (Back dll1.. 1994}j had 
no effed on the virus load in hlmlan cells at day 6 in the 
peritoneal lavages. Administration of the V3 loop-specific 
mouse MAb F58H3 either alone or in the presence of HuMAb 
GPI3 (both administered at 20 mg/kg), and adminish.1tion of 
HIVIG, resulled in the absence of detedable HIV-1 IIIB 
infeded cells in peritoneal lavages, peritoneal tissues and 
spleen. The minimum concentration of mouse MAb F58H3 
that interfered with the numbers of detedable HIV-l IIIB 
infeded cells was de!ennined by titrating the antibody ill vhlo. 
Between 10 and 20 mg/kg was needed to abolish the presence 
of HIV-1 IIIB-infeded cells (Fig. 2c). At day 11, HIV-IIlIB was 
deteded by ICT in the peritoneal lavage cells from xeno-
GvHD which had received the CD4 bd-spedfic HuMAb 
GPU. This is surprising since peritoneal lavage cells, spleen 
and peritoneal tissue colleded at day 11 from xeno-GvHD 
mice that had received identical numbers of PBMe from the 
same blood donor and the same dose of HIV -I IIlB were 
negative in the ICT (Fig. 2b). 
Passive immunization studies with primary HIV-1 
In contrast, Lp. administration of 20 mg/kg of the Htu\1Abs 
or HIVIe. prior to infedion of the human PBMC grilft with 30 
XelDSQ of the primary HIV-1 strains, did not result in a 
Significant redudion in the virus load in any of the antibody-
primary HIV-l strain combinations tested (Fig. 3a---{l). The 
antibody preparations used in these assays included the 
following. 
CD4 bd-spedfic HuMAb GPB, which neutralizes TClA 
HIV -1 strains ill vHro (Back el II/., 1994). 
V3 loop-sped fie HuMAb 257-D, which neutralizes the 
primary HIV-l strain 320.2A.1.2 ill vitro with an ICSQ of 
10 ~Ig/ml and an ICrlO of 35 J-Ig/ml. 
A combination of equal amounts of these two antibodies, 
which neutralized HIV-1 320.2A.1.2 (51) ill vUro better than 
HuMAb 257-D alone, with an ICso of 6 J-Ig/ml and an IC90 of 
20 )Ig/m!' 
Polyclonal HIVIG preparation, which had previously been 
shown to neutralize HIV~IIIIB ill vitro and ill vivo (Prince if al., 
1991) (Fig. 1) and primary HIV-1 strains ill vitro (H. 
5chuitemaker, personal communication). 
Discussion 
Recently, confliding data have been published about the 
capacity of antibodies which efficiently neutralize T cell-
adapted HIV-I strains to neutralize primary HIV-1 strains ill 
vitro and ill vivo. Here, we present data indicating that stich 
antibodies fail to neutralize primary HIV -1 strains ill vivo. 
in the HuPBl-5CID and HuCBl-SCID models it has been 
shown that in more than 50% of the grafts HIV-l IIIB fails to 
establish a persistent infedion (Reinhardt if al., 1994; Mosier 
el al., 1991). It has been speculated that the self-limiting nature 
of this infedion is due to the relatively high cytopathogenidty 
of HIV -I IIIB resulting in the elimination of all pennissive cells 
in infeded foci (Mosier & Sieburg, 1995). In our model we also 
observed clearance of HIV-l IIlB infedion as early as 11 days 
post-infedion. However, a persistent infedion was observed in 
mice which also received the CD4 bd-spedfic HuMAb GPI3. 
We speculate that this is due, on the one hand, to the ability of 
the antibody to inhibit syncytium indudion of HIV-1 IIIB 
(Schullen dll/., 1993), and, on the other hand, to the inability 
to inhibit virus entry (Fig. In), colledively resulting in 
diminished ill vivo cytopathogenicity. All other antibody 
preparations tested efficiently neutalized HIV~l IIlB infedion 
in this ill vivo model. 
The concentrations of antibodies used in the ill vivo 
neutralization assays wHh the primary HIV -1 strains were 
higher than the concentrations of mouse MAbs F58H3 and 
HlVIG needed to neutralize HIV-1 IIIB in the same system (Fig. 
1). They were in the same range as the concentrations used to 
neutralize HIV-l IIlB in chimpanzees with other poly- and 
monoclonal antibodies (Emini et III., 1992; Prince eta!., 1991). 
In the xeno-GvHD mouse model for HIV-l infection we have 
recently also tested negatively charged succinyiated hlllnan 
serum albwnins (Suc-HSA), which neutralize TClA and 
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Fig. 1. HIV-l in situ hybridization, (045 and (068 
immtH1ohistochemlsby of spleen and peritoneal tissue from xeno-GvHO 
mice infected with either 320.2A.l.2 (51, non.macrophage tropIc) or 
320.2A.2.1 (NSI, macrophage tropic). (a--c) Sectior,s from the 
diaphragm of xeno-GvHO mice infected with HIV-l 320.2A2.1 and 
stained for C068 (0) or HN-l RNA (b) and epifloorescence of the same 
H1V-l RNA in situ hybridized section (c) (magnification 220 x). (d-I) 
Sections from the spleen (at the right-hand side of the figure) and 
pancreas (at the left-hand side of the figure) infected wjth HIV-l A(H 
168.10 and staIned for C068 (d) or HN-l RNA (e), and 
epiftuorescence of the same HIV-l RNA in situ hybridized section (f) 
(magnification 44 x). (g-I) 5ections from the spleen of HIV-l 
320.2A.l.2-infected xeno-GvHO mice, stained forCD45 (g) or HIV-l 
RNA (h). and epifluorescence of the same HIV-l RNA in situ hybridized 
section (I) (magnification 430x). 
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In vitro day 6 mice mice 
HuMAb VN 
day 11 
"" 
HuMAb 
day 6 
"" 
[FSSH3j 
nona 
GP13 
'WH3 
GP13 + 
F5SH3 
HIVIG 
82 
nona o mg/kg 
• GP13 0.1 mgl',:g 
F5sm 1 mg/kg 
10 mg/};g 
20 mgikg 
log (lCT value) log (lCT value) log (lCT value) 
Fig. 2. Cell-associated virus load determined by ICT in human cells from peritoneal lavages of xeno-GvHD mice at the day 
xeno·GvHD was observed in mice infected with 30 XeID50 HIV-l 11iB. Prior to infection. f4Abs or HIVIG were administered Lp. 
at 20 mg/kg. In the antibody mixtures (V3 specific f.1Ab+CD4 bd specific HuHAb) 20 mg/kg of each antibody was given. In 
(c) different concentrations of the V3 specific 10lAb F58H3 were tested as indicated on the left-hand side of the plot. The 
number of mice used per group is indicated on the right-hand side of each plot (n). On the hOlilonlaJ axis the logarithm of the 
numbers of celis needed to yield positive cultures in the JCT are given. So:id grid lines indicate the actual dilutions made (5-fold 
d,lution steps starting at 5 )( 105 cells). Where> 105 cells is indicated, none of the mouse tissues tested in culture (peritoneal 
tissue, sp~een, ascitic fluid cells) proved to be positive for HIV-l p24 after 7 days of culture. 
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Fig. 3. Cell-associated virus load determined by ICT in human cells from peritoneal lavages of xerlo·GvHD mice at the day 
xeno·GvHD was observed in mice infected with HIV-l 320.2A.l.2 (51). HIV·l 320.2A 2.1 (NSI), HIV-l ACH 168.10 (51) and 
HN·l ACH 172.BA·L (NSI). Prior to infection. MAbs or HIVIG were admirlistered i p. at 20 mg/kg. In the antibody mixtures (V3 
specific MAb+CD4 bd specific Hut,lAb) 20 mg/kg of each antibody was given. Data are presented as indicated in Fig. 2. 
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primary HIV-1 strains by binding to the V3 loop of gp120 
(Jansen e/ III., 1993). The concentration of Suc-HSA needed to 
neutralize HIV-1 HIB in the xeno-GvHD mouse system was 
approximately the same on a molar basis as that of the V3 
loop-specific mouse MAb F58H3 (Fig. 1) (Kuipers el a/., 1996). 
Preliminary data, however, showed that a lOo-fold higher 
concentration failed to proVide neutralizing activity towards 
primary HIV-1 strains. This concentration is more than 50 
times the ill vitro IC51l against HIV~I 320.2A.1.2 used in this 
study (unpublished results). Therefore, we conclude that the 
inability of the V3 loop-specific antibodies to neutralize 
primary HIV-1 strains ill [li[lo cannot be aHributed to the use of 
insufficiently high concentrations of these compounds in our ill 
~'il'O model. 
These data extend ill {litro observations showing that 
primary HIV -1 strains are more resistant to virus neutralization 
in human PBMC than TCLA strains (Moore et AI.. ]995; Bot/-
Habib d AI., 1994; Schulten d AT., 1995). The relevance of the 
ill vivo data generated with primary HIV~ 1 strains in the xeno-
GvHD model in which no protedion was found, as compared 
to the ill vitrtl data showing limited neutralization of these 
strains, is determined by the similarities between HIV~1 
infedion in humans and HIV -1 infedion in this model. Like 
HIV~I-infected human lymphoid tissues, the model provides a 
substrate of highly activated cells of the monocytic and T 
lymphocytic lineages, of which the latter are skewed toward a 
CD4+ subpopulation (Huppes e/ a/., 1992, 1994). This allows 
high levels of HI V-I replication, a feature that is thought to be 
essential for persistence of HIV-I infection in humans (Wei ef 
al., 1995; Ho d al., 1995). Furthermore, the close interaction 
between lymphoid cells and antigen-presenting cdls, which is 
a hallmark of the development of aGite xeno-GvHD, also 
seems to be essential in the pathogenesis of HJV-l infedion 
(Gartner d AI., 1986; Huppes e/ AI., 1992). Therefore, the xeno-
GvHD HIV-I model proVides a htunan lymphoid environment 
which clearly exhibits more similarities with HIV~I-infeded 
human lymphoid tissues (Fig. 2) (Embretson d fll., 1993; 
Pantaleo ef III., 1993) than ill vitro HIV-I-infected PBMC 
cultures. FurthemlOre, macrophages are thought to play an 
important role during primary HIV~l infection in humans. The 
ill sitll hybridization experiments with HIV-I 320.2A.2.1 (NSI) 
showed that at the site of primary infection, macrophages were 
productively infected. In order to mimic primar}' HIV -I 
infection in humans more closely and in contrast 10 the other 
chimeric models (Namikawa d AI., 1988; Mosier e/ AI., 1991), 
human cells were challenged soon after grafting, long before 
the characteristic adivation of the grafted cells could be 
demonstrated. 
The reason why primary HIV-l strains appear to be more 
resistant to the neutralizing activity of antibodies and Suc-HSA 
iI/ vivo than their TCLA HIV-1 counterparts is not clear. A 
major difference bdween both virus types is that the fonner do 
nol shed gp120 as readily (Moore d al., 1992; Groenink ef A/., 
1995). It may be speculated that after binding of Ihe virus to 
the receptor, V3-specific antibodies may at least temporarily 
prevent the process of fusion between the virus~ and cellular-
membranes. This leaves the TCLA viruses in particular 
vulnerable to gpUO shedding without being able to pend rate 
the cell membrane, which eventually results in more effective 
neutralization of TCLA HIV-l strains. Finally, it should be 
realized that other mechanisms of antibody-mediated en-
hancement of infedivity have been described. At least one 
of these may also be dependent on the phenotype of the vims 
and the cell type involved (Schulten ef AI., 1995). The lack of 
neutralizing adivity found in the xeno-GvHD mouse model 
with the antibody preparations tested may therefore also 
partly be due to the interference of enhancing antibody 
activity. 
Taken togdher, our data show that primary HIV-1 strains 
cannot easily be neutralized in an ill vivo system that closely 
mimics HIV -I infection in htunans. Since induction of vin.ls-
neutralizing antibodies is still one of the major targets in the 
development of candidate HIV ~ 1 vaccines, we propose to usc 
for their evaluation assay systems like the xeno-GvHD mouse 
model for HIV ~ 1 infedion. 
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primary HIV~l strains by binding to the V3 loop of gp120 
Gansen e1 al., 1993). The concentration of Suc-HSA needed to 
neutralize HIV-I IIlB in the xeno-GvHD mouse system was 
approximately the same on a molar basis as that of the V3 
loop-specific mouse MAb F58H3 (Fig. 1) (Kuipers ef al., 1996). 
Preliminary data, however, showed that a IOO-fold higher 
concentration failed fo provide neutralizing activity towards 
primary HIV-I strains. This concentration is more than 50 
times the ill [li/ro ICso against HIV-1 320.2A.1.2 used in this 
study {unpublished results}. Therefore, we conclude that the 
inability of the V3 loop-specific antibodies to neutralize 
primary HIV~I strains ill [livo cannot be attributed to the lise of 
insufficiently high concentrations of these compmmds in our ill 
vi[lo model. 
These data extend ill [litro observations showing that 
primary HIV -1 strains are more resistant to vinls neutralization 
in human PBMC than TCLA strains (Moore ef al., 1995; Bou-
Habib el al., 1994; Schutten ef al., 1995). The relevance of the 
hI vitlo data generated with primary HIV~1 strains in the xeno-
GvHD model in which no protection was found, as compared 
to the ill vUra data showing limited neutralization of these 
strains, is determined by the similarities between HIV-1 
infection in hlmlans and HIV-1 infedion in this model. Like 
HIV-1-infected human lymphoid tissues, the model provides a 
substrate of highly adivated cells of the monocytic and T 
lymphocytic lineages, of which the latter are skewed toward a 
CD4+ subpopulation (Buppes d al., 1992, 1994). This allows 
high levels of HN -1 replication, a feature that is thought to be 
essential for persistence of HIV~l infection in humans (Wei el 
al., 1995; Ho d til., 1995). Furthermore, the close interadion 
between lymphoid cells and antigen-presenting cells, which is 
a hallmark of the development of acute xeno-GvHD, also 
seems to be essential in the pathogenesis of HIV -1 infedion 
(Gartner eI al., 1986; Huppes e/ at 1992). Therefore, the xeno-
GvHD HIV-1 model provides a human lymphoid environment 
which clearly exhibits more similarities with HIV-l~infeded 
human lymphoid tissues (Fig. 2) (Embrdson eI a/" 1993; 
Pantaleo el til., 1993) than ill [lilro HIV-1-infeded PBMC 
cultures. Furthermore, macrophages are thought to play an 
important role during primary HN -1 infection in hwnans. The 
ill sHu hybridization experiments with HIV -1 320.2A.2.1 (NSI) 
showed that at the site of primary infection, macrophages were 
productively infected. In order to mimic primary HIV-l 
infection in humans more closely and in contrast to the other 
chimeric models (Namikawa el al., 1988; Mosier el al., 1991), 
human cells were challenged soon after grafting. long before 
the characteristic activation of the grafted cells could be 
demonstrated. 
The reason why primary HIV-l strains appear to be more 
resistant to the neutralizing activity of antibodies and Suc~HSA 
ill vivo than their TCLA HJV-l counterparts is not clear. A 
major difference between both virus types is that the former do 
not shed gp120 as readily (Moore ef al .• 1992; Groenink el al., 
1995). It may be speculated that after binding of the virus to 
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the receptor, V3-specific antibodies may at least temporarily 
prevent the process of fusion between the virus- and cellular-
membranes. This leaves the TCLA viruses in particular 
vulnerable to gp120 shedding without being able to penetrate 
the cell membrane, which evcntually results in more effedive 
neutralization of TCLA HIV ~ 1 strains. Finally, it should be 
realized that other mechanisms of antibody-mediated en-
hancement of infectivity have been described. At least one 
of these may also be dependent on the phenotype of the virus 
and the cell type involved (Schulten e1 al .. 1995). The lack of 
neutralizing activity found in the xeno-GvHD mouse model 
with the antibody prcparations tested may therefore also 
partly be due to the interference of enhancing antibody 
activity. 
Taken together. our data show that primary HIV-l strains 
cannot easily be neutralized in an ill vivo system that closely 
mimics HIV -1 infection in humans. Since induction of virus~ 
neutralizing antibodies is still one of the major targets in the 
development of candidate HIV -1 vaccines, we propose to use 
for their evaluation assay systems like the xeno-GvHD mouse 
model for HIV-J infection. 
This work was suppor!cd by the Uutch Council for Health ReseMch 
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CHAPTER 8 
General Discussion 
in part taken from: 
Antibody mediated enhancement of lentivirus 
infection: Stumbling block for vaccine 
development or in vitro artefact? 
submitted. 

General discussion 
The induction of HIV-1 specific antibodies that prevent HIV-1 infection or limit the spread of 
the virus during the initial stages of the infection, is thought to be an essential feature of future 
HIV-1 vaccines. In vitro and in vivo studies on the virus neutralizing capacity of HIV-1 envelope 
specific monoclonal antibodies and sera obtained from seropositive individuals have shown that 
factors determined by the virus strain and the assay system used, may have a pronounced 
influence on the outcome of the antibody-virus interaction"'. The primary goal of the studies 
presented in this thesis was the evaluation of factors that influence the virus neutralizing capacity 
of HIV-1 specific antibodies. 
In chapter 2, 3 and 4 the generation and characterization of human monoclonal antibodies 
(HuMAS's) directed against the V3 loop and the CD4 binding domain (CD4bd) are described. Sy 
pepscan analysis of the linear epitope of the V3 loop specific HuMAb MN215 it was shown that 
the "best fitting" V3 loop derived sequence for HuMAb MN215 exhibited striking similarities with 
the relatively conserved V3 loop consensus sequence of macrophage-tropic HIV-1 strains5 . 
Furthermore, uncharged residues at position 13, uncharged or negatively charged residues at 
position 30 and negatively charged residues at the C-terminal side of the V3 loop proved to be 
important for a high affinity interaction with HuMAb MN215. Non syncytium inducing (NSI) HIV-1 
strains have also been shown to exhibit such charge characteristics at these positions, whereas 
syncytium inducing (SI) strains tend to have more positively charged residues at these positions 
within the V3 loop·"'. It is therefore conceivable that HIV-1 strains within a host delimited 
quasispecies distribution, that have acquired mutations within the V3 loop, improving the 
fusogenic capacity of the envelope glycoprotein complex, will be recognized with lower affinity. 
Only recently HuMAb MN215 was tested in a peptide inhibition ELISA with peptide derivates of 
the subtype S consensus sequence with an early NSI, late NSI and SI character. HuMAb MN215 
proved to have the highest affinity for late NSI derived peptides, a somewhat lower affinity for 
early NSI derived peptides and low affinity for SI derived peptides (Dr. F. Sarin personal 
communication). Indeed when tested in a peptide inhibition ELISA and catching antibody ELISA 
with solid phase whole gp160, HuMAS MN215 showed significantly higher affinities for the NSI 
as compared to the SI derived V3 domains from donors #16 and #320 from the Amsterdam 
cohort.The NSI and SI HIV-1 derived peptides and envelope glycoproteins were obtained from 
biologically cloned primary NSI and SI strains obtained at the time point where the NSI to SI 
phenotype switch was observed in the donor. We have recently tested the affinity of HuMAb 
MN215 with one early NSI and a SI derived envelope glycoprotein from donor #168 from the 
Amsterdam cohort (ACH 168.1 and ACH 168.10 respectively"'). The 168.1 and 168.10 envelope 
glycoproteins were recognized with similar affinities by HuMAb MN215, despite the fact that it was 
predicted, on basis of the pepscan criteria for the "best fitting" V3 loop sequence for HuMAb 
MN215, that HuMAb MN215 would have it's highest affinity for the early NSI derived glycoprotein 
(M. Schutten et al., unpublished data). It may therefore be postulated that within early NSI HIV-1 
glycoproteins, the V3100p is less accessible for HuMAb MN215 binding as compared to late NSI 
and SI derived glycoproteins. This suggests that during evolution of the virus within the infected 
host from slowly replicating stable NSI strains towards fast replicating SI variants 10, exposure of 
the V3 loop within the envelope glycoprotein complex precedes the acquisition of amino acid 
changes required for the SI phenotype. 
The V3100p of HIV-1 has been shown to playa role in determining the SI capacity of both 
TCLA and primary HIV-1 strains·",". Naturally occurring amino acid changes within the V3100p 
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have been shown to influence the SI capacity of the envelope complex, HIV-1 cell tropism and 
the capacity of V3 loop specific antibodies and polyclonal HIV-1 specific sera to neutralize the 
virus',7,12,", Mutations within several other regions of HIV-1 gp120 (Vi, V2, C4) also exhibit the 
capacity to change these characteristics of the virus 15-19. Furthermore specific insertion of potential 
glycosylation sites by AAT triplet reiteration within the V4 and V5 domains suggests that these 
domains are also under selective antibody pressure, which may point towards a role of these 
domains in viral entry". The envelope trans-complementation assay and the envelope genes 
derived of biological HIV-1 clones from donors #16, #168 and #320 were used to study the 
mechanism of primary HIV-1 entry, and the way in which envelope specific antibodies modulate 
this entry. In chapter 5 it was shown that the soluble form of the primary receptor of HIV-1 (sCD4) 
significantly enhanced entry mediated by the 16.4 (NSI) derived envelope glycoprotein. Similar 
observations had been described for SIVagm infection of the MOLT4 clone 8 CD4+ T cell line and 
HIV-2 infection of CD4' cell lines. This suggests that enhancement of entry by the soluble form of 
the primary receptor is a more common phenomenon in lentivirus infections"'''. It is therefore 
conceivable that more HIV-1 strains will be found that are susceptible to sCD4 mediated 
enhancement". Indeed recently our observations were confirmed by Sullivan et al. using the 
envelope genes derived from the HIV-1 YU2 (NSI) and ADA (NSI) strains". Moreover entry of 
16.4 (NSI) and YU2 (NSI) mediated entry in SupT1/PHA-PBMC and MOL T4 clone 8 cells 
respectively was significantly enhanced by gp120 specific monoclonal antibodies and purified 
hyperimmune immunoglobulines of HIV-1 seropositive individuals (HIVIG). Only recently in an 
extensive study on the biological activity of polyclonal sera of HIV-1 seropositive individuals 
against HIV-1 strains isolated from these individuals, it was shown that 41% of the HIV-1 strains 
were susceptible to enhancement of infection rather than to neutralization'. It was suggested that 
the enhancement observed is similar to that described in our studies and in the study of Sullivan 
et al.. This indicates that indeed enhancement of HIV-1 entry by a mechanism that parallels sCD4 
mediated enhancement, is a common mechanism in HIV-1 infection. 
In vitro studies on the biological activity of HIV-1 glycoprotein specific antibodies may provide 
valuable information on the molecular mechanisms underlying viral entry which may allow the 
identification of steps within the process of HIV-1 entry that are essential for HIV-1 strains with 
different biological phenotypes. Further studies conducted to gain insight into the molecular 
mechanisms of entry in the absence and presence of envelope specific antibodies are described 
in chapter 6. The susceptibility of the glycoprotein complex to neutralization versus enhancement 
of entry by gp120 specific antibodies proved to be determined by properties of gp120. By 
exchanging parts of the genes encoding the glycoproteins susceptible to either neutralization or 
enhancement of entry, it was shown that the V3 loop and an as yet undetermined part of gp120, 
determined the level of entry measured in this assay, and the susceptibility to neulralization versus 
enhancement. Alternatively an interaction between V3 and another region located within the V3 
to V5 region might have been at the basis of the observed differences in entry and susceptibility 
to neutralization versus enhancement. Preliminary data confirm that this is indeed the case. 
Furthermore, the induction of conformational changes required for enhancement proved to have 
a minimal energy requirement, and cross-linking was shown to be a prerequisite for the 
enhancement observed with the HuMAb's. Based on the observations described in chapter 6, the 
following working hypothesis may be postulated for primary HIV-1 entry: 
Conformational changes in gp120 after CD4 binding, result in the exposure of positively charged 
loops like the V3 loop and possibly other regions like the V1N2 region'5-". Depending on the 
flexibility and the conformation of these variable regions, which seems to be determined at least 
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in part by inter- or intramolecular interactions", these domains may interact with C04, like the 
previously reported V3/COR3 interaction", or with other cellular proteins. This secondary 
interaction induces additional conformational changes by intermolecular cross-linking, required 
for the induction of the fusion attack complex. Within the fusion attack complex, the ability of the 
glycoprotein complex to bind to members of the C-C and C-X-C chemokine receptor subfamilies 
of the G-protein binding receptor superfamily determines the efficiency with which the HIV-1 
particle infects different target cells"'''. 
The role of HIV-1 specific antibodies in protection against HIV-1 challenge in passive and 
active immunization strategies and protection against disease in HIV-1 induced pathogenesis, has 
been difficult to asses due to limitations of in vitro and in vivo models for HIV-1 infection. HIV-1 
infection of cells of the monocytic cell lineage and infection of compact lymphoid tissues are 
thought to be essential factors for a reliable model for HIV-1 infection. Furthermore infection of 
quiescent lymphoid cells and subsequent virus replication, specifically activates the human 
immune system, which then in turn allows efficient HIV-1 replication"'''. With this in mind, a 
human to mouse model was developed in which human PBMC were grafted intraperitoneally into 
immuno-suppressed CBAlN mice: the "Xeno-GvHO model". This results in an acute xeno-graft 
versus host reaction providing a system, in which human cells of the monocytic and lymphocytic 
cell lineages become highly activated",". To infect the grafted human cells in a quiescent state, 
HIV-1 infection was carried out within one hour after grafting. In chapter 7 it was shown that a 
relatively high percentage of the human macrophages and T lymphocytes in compact tissues of 
these chimeric mice then become productively infected. Furthermore, protection against HIV-11I1B 
challenge could be achieved by administering HIVIG and a HIV-1 V3 loop specific monoclonal 
antibody, which is in line with previous studies in chimpanzees and HuPBL-SCIO mice""·". In our 
xeno-GvHO mouse model, none of the antibody preparations tested were able to protect against 
a challenge with primary HIV-1 strains of a different biological phenotype. This despite the fact 
that antibody concentrations were well above the in vitro IC50 and in some cases (HIV-1 
320.2A.1.2 with HuMAb 257-0 in combination with GP13) most probably reached the in vitro IC". 
However, the antibody concentrations used may still have been too low to achieve protection 
since it has been shown in the HuPBL-SCIO model that at least the IC" should be reached to 
achieve protection against TCLA HIV-1 strains'. The relevance of this observation seems 
questionable however, since in vitro determined inhibitory doses may vary up to 100 fold between 
laboratories using the same virus strain in the same VN assay"'''. To further address the 
difference in susceptibility to VN of TCLA and primary HIV-1 strains in this model, we also tested 
negatively charged human serum albumins. We were able to show that despite the rapid 
clearance of these compounds in the xeno-GvHO mice, a single dosage of succinilated human 
serum albumins protected the human graft from a challenge with the TCLA strain HIV-1 II I B"·41. 
The efficiency with which this compound protected the human graft against a HIV-1 IIiB challenge 
on a molar basis proved to be similar to the capacity of a monoclonal antibody directed against 
the V3 loop. A 1 DO-fold higher concentration as compared to the minimally required dose that 
neutralized HIV-1 IIIB still proved to be ineffective against a challenge with primary HIV-1. This 
despite the fact that more than 50 times the in vilro IC50 against HIV-1 320.2A.1.2 used in this 
study, was reached during the primary infection (Chapter 7, M. Schutten et al., unpublished data). 
On basis of these experiments we speculate that the susceptibility to shedding of gp120 after C04 
binding is at the basis of the difference in susceptibility to VN of TCLA and primary HIV-1 strains 
in this model. Binding of TCLA HIV-1 strains to membrane associated C04 in the presence of 
fusion inhibiting compounds, may result in the irreversible inactivation of the virus due to shedding 
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of gp120 from the glycoprotein complex". Primary HIV-1 strains on the other hand may remain 
associated with the cell membrane since they do not shed gp120"·". Decrease of the 
concentration of the inhibitory compound below the minimally required concentration at which 
neutralization is achieved, may in turn result in infection and overt replication of these HIV-1 
strains. This phenomenon may have been at the basis of recent failure of passively administered 
HuMAb IAM-2F5 to protect against a challenge with a primary HIV-1 strain in the HIV-
1/Chimpanzee model (H. Katinger personal communication). In this study temporary protection 
was observed with HuMAb IAM-2F5 against a challenge with primary HIV-1. HIV-1 infection could 
be demonstrated, approximately 80 days later as compared to the negative controls, when levels 
of HuMAb IAM-2F5 started to decline. From that point onward the kinetics of primary infection 
proved to be similar to that observed in the included control animals. The observations in the 
xeno-GvHD model and in the HIV-1/chimpanzee model have major implications for vaccine 
development strategies and indicate that much may still be learned about mechanisms of HIV-1 
entry in the absence and presence of HIV-1 specific antibodies. Further insight in this subject may 
facilitate the development of a vaccine against AIDS. 
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ANTIBODY MEDIATED ENHANCEMENT OF LENTIVIRUS INFECTION: 
STUMBLING BLOCK FOR VACCINE DEVELOPMENT 
OR IN VITRO ARTEFACT? 
Martin Schutten', Thomas Schulz', Kees Siebelink' and Albert Osterhaus' 
'Erasmus University Hospital Rotterdam, Department of Virology, Dr. Molewaterplein 50, 3015 GE 
Rotterdam, The Netherlands, 
'The University of Liverpool, Department of Medical Microbiology and Genito-urinary Medicine, 
Duncan Building, Daulby Street, Liverpool L69 3GA, United Kingdom, 
Antibody dependent enhancement (ADE) of infection with enveloped viruses via Fc or 
complement (C') receptors is a feature commonly observed in in vitro systems (for review see 
Morens '), However, in only few virus infections, ADE has been shown to playa role in vivo, Active 
and passive immunization strategies which induce or transfer antibodies exhibiting Fc- or C' 
mediated ADE in vitro, still proved to be effective in providing protection in several in vivo viral 
systems, casting doubt on the relevance of ADE measured in vitro', Recently we and others have 
shown that antibodies against the primate lentiviruses HIV-1, HIV-2 and SIVagm, may mediate 
enhancement of viral infectivity via another mechanism, that closely resembles normal activation 
of the virus-cell fusion (receptor activated membrane fusion (RAMF)),,', Although data on the in 
vivo relevance of this type of antibody mediated enhancement are still lacking, there are 
indications that enhancement of infection by envelope glycoprotein specific antibodies may indeed 
play a role in the pathogenesis of lentivirus infections which may thus frustrate vaccine 
development efforts',', Accelerated virus replication and exacerbation of disease progression has 
been observed upon vaccination with experimental vaccines against the lentivirus equine 
infectious anaemia virus (EIAV)8 and recently we observed a similar phenomenon upon 
experimental vaccination against feline immunodeficiency virus (FIV)', This paper reviews the 
presently known mechanisms of antibody mediated enhancement of lentivirus infectivity and their 
possible relevance for the pathogenesis of lentivirus infections and vaccine development. 
ANTIBODY MEDIATED ENHANCEMENT OF VIRUS-CELL ADHESION: Fc-ADE AND C'-ADE 
Until recently two mechanisms of ADE have been described in vitro which are mediated by 
antibodies that recognize the envelope glycoprotein complex of lentiviruses: Fc receptor and C' 
receptor mediated antibody dependent enhancement (Fc-ADE and C'-ADE), In lentivirus systems 
these mechanisms have been studied most extensively for HIV-1 infection, It has been shown that 
HIV-1 infection enhanced by antibodies and C' may be either dependent or independent on the 
interaction of the glycoprotein complex and CD4, the primary receptor for primate lentiviruses'Q.13, 
This suggests that, two distinct mechanisms of this type of ADE exist. In CD4-dependent Fc-ADE 
and C'-ADE the physical interaction between the virus and the cell may be facilitated by the 
binding of the cellular Fc- and C' receptor to the opsonized virus particle, This in turn results in a 
more efficient receptor mediated membrane fusion", These findings have been confirmed in 
binding studies using HIV-1 and CD4' cells in the absence and presence of antibody and C'''''', 
Antibody and C' have also been reported to enhance infectivity of HIV-1 in a CD4-independent 
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manner. Fc- and C' receptors may therefore act as "pseudo" primary receptors 13, The actual 
mechanism involved in the subsequent fusion of the virus with the cellular membrane is not known 
at present. 
ANTIBODY MEDIATED MODULATION OF RECEPTOR ACTIVATED VIRUS-CELL FUSION: 
VN VERSUS AAMF 
The soluble form of the primary receptor of HIV-1 (sCD4) and a large number of HIV-1 
envelope glycoprotein specific antibodies inhibit entry of T cell line adapted (TCLA) HIV-1 
strains"''', It has been shown that the VN capacity of V3 loop specific antibodies positively 
correlated with the affinity of the antibody for the V3 loop", VN mediated by sCD4 and these 
antibodies involves dissociation of the non-covalently linked surface glycoprotein from the 
transmembrane glycoprotein part of the complex ("shedding")", Antibodies directed against other 
VN inducing sites on gp120, the surface part of the envelope glycoprotein (SU) do not induce 
shedding in most cases, The induction of conformational changes and/or interference with binding 
of the glycoprotein complex to a cellular counterpart also contributes to the neutralizing potential 
of these antibodies and V3100p specific antibodies", The interaction between sCD4 or antibodies 
with monomeric and multimeric SU glycoprotein, induces a variety of conformational changes, 
including changes that influence the exposure of gp120 and gp41 regions and the dissociation 
of gp120"''', To what extent and how these conformational changes contribute to sCD4- and 
antibody-mediated neutralization is not known at present. Primary HIV-1 strains do not readily 
shed their SU after sCD4 and V3 loop specific antibody binding"''', The (premature) induction of 
conformational changes alone appears to be sufficient to neutralize these viruses, 
In contrast, entry of certain strains of HIV-2 and SIVagm, which also utilize the CD4 molecule 
as their primary receptor, is enhanced by sCD43,', We and others have recently shown that entry 
of certain primary HIV-1 strains of the non syncytium inducing (NSI) phenotype, is also enhanced 
by sCD4',", Furthermore, HIV-1 SU specific antibodies that neutralize TCLA HIV-1 strains proved 
to induce enhanced infectivity of HIV-1 strains susceptible to enhancement by sCD4, by a 
mechanism different from Fc-ADE and C'-ADE, We propose to call this mechanism that closely 
resembles sCD4 induced enhancement, antibody activated membrane fusion (AAMF), 
Enhancement through AAMF may be a commonly observed phenomenon for primary HIV-1 
strains", It was furthermore shown that the outcome (VN versus AAMF) in a neutralization assay 
with polyclonal sera from HIV-1 seropositive individuals was determined by the susceptibility of 
the virus to either mechanism, The relatively strong association of SU and the transmembrane 
part of the envelope glycoprotein (TM) of primary HIV-1 strains and HIV-2 and SIVagm strains 
susceptible to sCD4 and SU specific antibody induced enhancement of infectivity, has been 
postulated to be at the basis of this phenomenon30·", This would allow the induction of a stable 
sCD4-glycoprotein complex or in the case of AAMF a stable antibody-glycoprotein complex, with 
increased capacities to fuse with the cell membrane, It seems unlikely however, that this is the 
only factor responsible for the observed enhancement, since the association between SU and TM 
is also high for primary HIV-1 isolates which are neutralized by sCD4 and glycoprotein specific 
antibodies, albeit to a lesser extent than TCLA HIV-1 strains", Besides the strong association 
between SU and TM, the exact nature of the conformational changes induced by sCD4- and 
antibody binding, are likely to determine the final outcome of the interaction: VN versus AAMF, 
This hypothesis is supported by the observation that conformational changes after sCD4 binding, 
like the exposure of the V3 loop, are significantly different between HIV-1 strains susceptible to 
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neutralization and enhancement". Unlike sCD4 mediated enhancement of HIV-2 entry, recent 
data on AAMF of primary HIV-1 strains indicate that the interaction of the envelope glycoprotein 
complex with membrane associated CD4 is still required for entry, since CD4 specific antibodies 
directed against the SU binding site, blocked the entry that was enhanced by SU specific 
antibodies (M. Schulten et al., unpublished data). Studies on the conformational changes within 
the glycoprotein complex induced by CD4 binding, are seriously hampered by the fact that crystal 
structures of the envelope glycoprotein in it's native conformation and in the fusion attack 
complex, have sofar proved elusive. The present knowledge about the conformation of the 
glycoprotein complex is largely limited to the TM part of the glycoprotein complex. Based on 
peptide inhibition experiments, and in line with the model proposed for the HA2 part of the 
influenza virus heamagglutinin in it's native form and as a fusion attack complex, Matthews et al. 
proposed a model for the formation of a HIV-1 TM fusion attack complex"·37. In this model the 
formation of a central coiled coil core structure by the leucine zipper regions of the TM 
glycoprotein, is an essential step in the fusion process. Formation of this central core in the native 
state is inhibited by the putative distal alpha helix". In parallel with the HA2 model, this alpha helix 
may be part of the central core in the fusion attack complex by placing itself on top of the central 
core, thereby bridging the space between viral and cellular membranes". Insertion of the fusion 
related sequence into the adjacent membrane is thought to destabilize the cell membrane, which 
eventually allows fusion of both membranes to take place. It may be anticipated that the 
conformational changes induced by the binding of sCD4, in the glycoprotein complex of HIV-1, 
HIV-2 and SIVagm strains susceptible to sCD mediated enhancement, parallel those induced by 
membrane associated CD4 which lead to the induction of the fusion attack complex"'''. Further 
studies the conformational changes and aspects that determine the difference in susceptibility to 
either VN or AAMF, may provide valuable information to resolve the molecular mechanism of 
entry. 
MOLECULAR MECHANISMS UNDERLYING LENTIVIRUS ENTRY AND SUSCEPTIBILITY TO 
VNORAAMF 
The molecular mechanism of envelope glycoprotein mediated entry has been studied most 
extensively for the human lentiviruses HIV-1 and HIV-2. which both use the CD4 molecule as 
primary receptor. Primary NSI HIV-1 and HIV-2 strains require expression of one of the 13 
chemokine receptors CCR-2A, CCR-3 or CCR-5 to infect CD4' cells39~l. TCLA and primary SI 
strains may also infect CD4' cells that express the a chemokine receptor CXCR-442. HIV-1 and 
HIV-2 strains may utilize more than one of these molecules as second receptors. Binding of the 
envelope glycoprotein complex to CD4 induces conformational changes within the SU and the 
CD4 molecules allowing regions of both molecules to bind to one of these second receptor 
molecules"'''. Several HIV-2 strains may also infect CD4 'celilines by a direct interaction with 
CXCR-4, whereas other HIV-2 strains may infect these cell lines after preincubation with sCD445 • 
We have recently shown that CD4 independent infection via CXCR-4 of a HIV-2 isolate was 
dependent on one amino acid change, A526T, close to the predicted coiled coil domain of TM". 
This amino acid change was essential but not sufficient for CD4 independent entry. Changes 
flanking the V4 domain of this HIV-2 SU glycoprotein, in combination with the A526T TM change, 
on the other hand, also increase the susceptibility to sCD4-mediated enhancement of infectivity, 
presumably by lowering the "activation threshold" for conformational changes leading to the fusion 
process". A fourth mutation in V3, when combined with the TM and V4 changes, further increases 
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the susceptibility to sCD4 mediated enhancement and allows efficient infection of some CD4 
negative cells". These four amino acid changes therefore produce an envelope protein complex 
which is easily triggered into the "fusogenic" confirmation, perhaps akin to those influenza virus 
mutants which are capable of fusing at a higher than normal pH". The CD4-independent tropism 
of some HIV-2 strains may therefore be linked to the increased propensity of their envelope 
glycoproteins to "flip" into a conformation, which allows them to bind to CXCR-4 independent of 
the conformational changes induced by CD4. In HIV-2, the same mutations which increase RAMF 
also allow CD4-independent entry, and the two phenomena therefore seem to be related, or in 
fact, identical. 
Several differences have been observed between sCD4 mediated enhancement of HIV-1 
and of HIV-2. First sCD4 enhanced entry of HIV-1 infection still requires the interaction of the 
envelope glycoprotein complex with membrane associated CD4" (see above). Second, sCD4 and 
antibody mediated enhancement of HIV-1 does not allow these strains to bind to CXCR-4 (C. 
Guillon, manuscript in preparation). sCD4 and antibody mediated enhancement however seems 
to increase the affinity of the envelope glycoprotein complex for different members (CCR-2 and 
CCR-5) of the Il chemokine receptor family". For primary HIV-1, domains of the glycoprotein 
complex determining the susceptibility to VN or AAMF, have only been defined to a limited extent. 
However, we have recently shown that analogous to HIV-2, one or more domains of SU are 
involved in determining this susceptibility". An interaction of the V3 domain with an as yet 
unidentified domain within the C3-V5 region were shown to be involved in determining the 
susceptibility to VN or AAMF. Mutations in the V3100p of HIV-1, as well as a region encompassing 
V4-V5 have been shown to contribute to the CD4-independent tropism for some neural cell lines 
of certain HIV-1 strains". It is not known whether, as for HIV-2, the same mutations are 
responsible for AAMF IRAMF and CD4-independent tropism. 
Although in other than primate lentiviruses, little is known about the mechanism governing 
viral entry, VN and AAMF, and the regions involved in these phenomena, some interesting 
similarities between the FIV and the primate lentiviruses have recently been identified. Similar to 
HIV-1 and HIV-2 also FIV utilizes members of the Il chemokine receptor family50. We and others 
have shown, that like in HIV-1, the ability of FIV to replicate in established cell lines, is determined 
by the V3 region of SU"·". Furthermore, preliminary in vitro data show the existence of a 
mechanism of enhancement different from Fc-ADE and C'-ADE in the FIV system. Using a series 
of two highly homologous molecular FIV clones and chimeras constructed on the basis of these 
clones, we demonstrated that the V4 and V5 regions, are also involved in determining the 
susceptibility to VN"·53 versus antibody mediated enhancement of infectivity (Siebelink et ai., 
unpublished data). 
Collectively the in vitro data concerning the mechanism underlying VN and AAMF, indicate 
major similarities between the respective lentivirus systems. The molecular mechanisms 
underlying CD4 activated virus-cell fusion seem to govern the apparently closely related 
phenomena of cell tropism, syncytium induction and susceptibility to antibody mediated 
neutralization and enhancement of virus infectivity in these systems (Figure 1). The conformation 
of the lentivirus glycoprotein complex determines the ability to infect different cell types, most 
probably by allowing the glycoprotein complex to bind to different members of the recently 
identified C-C and a and Il chemokine receptor families. Furthermore, changes in the SU 
glycoprotein seem to determine the nature of the conformational changes induced by sCD4 and 
antibodies and thereby the susceptibility of these lentiviruses to either VN or AAMF. 
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ANTIBODY MEDIATED ENHANCEMENT OF LENTIVIRUS INFECTIONS IN VIVO 
Although studies in in vitro systems may provide valuable information about the interaction 
between antibodies and replicating viruses, it should be realized that the in vivo situation is 
generally more complicated. For example, we and others have shown that the use of established 
T cell lines or mitogen stimulated peripheral blood mononuclear cells, to isolate and propagate 
HIV-1 and FIV, may lead to the selection of viruses that are genotypically different from cell free 
virus found in vivo"·55. Our current knowledge on the role of antibody mediated VN and 
enhancement of lentivirus infectivity in the pathogenesis of lentivirus infections and in vaccination 
studies is limited. This is largely due to the lack of relevant experimental in vivo models. Vaccine 
studies in the EIAV and FIV animal models, have shown that the induction of enhancement of 
lentivirus infectivity by experimental vaccination may be a problem. The first study, clearly showing 
antibody mediated enhancement of lentivirus infectivity in vivo, used monomeric EIAV SU based 
vaccine preparations to vaccinate ponies'. After EIAV challenge the ponies which had developed 
SU specific antibodies, developed viraemia and disease most rapidly. Similarly we have shown 
that domestic cats vaccinated with certain candidate FIV vaccines developed an accelerated 
viraemia after FIV challenge as compared to the controls vaccinated with non-FIV related SIV 
glycoproteins'. This enhancement effect could be transferred to naive kittens with plasma 
collected at the day of challenge, suggesting that it is indeed antibody mediated. Although the 
mechanisms of enhancement in both systems has not been conclusively identified yet, it is 
interesting to note that with infectious molecular clones of FIV, we identified a mechanism of 
enhancement that closely resembles AAMF (see above). Therefore we speculate that this 
mechanism of enhancement has played a role in our FIV vaccination experiments. However, we 
cannot fully rule out that also Fc-ADE or C'-ADE have played a role in the observed enhancement, 
since intramuscular FIV challenge infection was used in these experiments. For HIV-1 it has been 
shown that in contrast to a intravenous infection, this route favours the replication of macrophage-
tropic NSI viruses56• If indeed this would also be true for FIV infection, the replication of FIV strains 
susceptible to FC'-ADE or C'-ADE would increase in the presence of FIV specific Fc-ADE or C'-
ADE mediating antibodies induced by vaccination. 
It is likely that enhancement of virus infectivity by envelope glycoprotein specific antibodies, 
plays a role in the natural pathogenesis of lentivirus infections. There are indications that the 
currently used HIV-1 isolation procedures favour replication of viruses susceptible to VN rather 
than those susceptible to enhancement in vivo55.". Although only few studies have analysed 
amino acid sequence differences of in vivo cell free viruses with viruses that can be isolated in 
vitro from the same individual, it has been shown that SI HIV-1 strains are only rarely found in vivo 
as cell free viruses, even in the later stages of the disease when the immune system is seriously 
compromised 55.". Viruses isolated from these individuals however consist of only SI strains in 
approximately 50% of the cases. It was furthermore shown that virus strains isolated in vitro from 
serum or plasma were recognized with low affinity by antibodies present in the body at the same 
time, whereas the in vivo cell-free viruses were recognized with high affinity". This makes it 
unlikely that the circulating viruses are neutralized by those antibodies in vivo. Moreover the HIV-1 
strains isolated in vitro seem highly susceptible to VN in vivo. The observation that in a HIV-1 
infected individual, SI strains constitute approximatelly 50% of the strains found in monocytes and 
only 0.5% of the strains found in T lymphocytes, indicates that the NSI strains that are isolated 
less frequently in vitro in the absence of antibodies, require HIV-1 specific antibodies for optimal 
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Legend to Figure 1 
A simplified model afleLA and primary HIV-1 entry, VN and MMF. For simplicity reasons the requirement of multiple 
envelope glycoprotein/CD4 interactions and the involvement of the second receptor are not depicted in this model. 
TeLA HIV-1: HIV-1 envelope glycoprotein-membrane associated CD4 interactions have been shown to result in the 
induction of conformational changes in the envelope glycoprotein complex eventually leading to the formation of the 
fusion attack complex and shedding of gp120 from the complex. Insertion of the fusion related sequence of HIV-1 gp41 
into the cell membrane is thought to destabilize the cell membrane allowing fusion to take place. HIV-1 gp120 V3100p 
specific antibodies induce conformational changes within the envelope glycoprotein complex leading to shedding of 
gp120. This in turn leads to the irreversible inactivation of the virus particle. 
Primary HIV-1 susceptible to VN: The conformational changes of primary HIV-1 strains susceptible to VN largely seem 
to parallel those of TCLA HIV-1 strains although some differences may be observed depending on the configuration 
of the different domains involved in the fusion process (V1N2, V3 and amino acids 610-701). Primary HIV-1 strains 
do not readily shed gp120 after sCD4 and antibody binding. Neutralization of primary HIV-1 is therefore thought to be 
the result of the premature induction of conformational changes leaving the envelope glycoprotein complex unable to 
exert further functions. 
Primary HIV-1 strains susceptible to MMF: A relativelly low efficiency of entry into the target cell of these HIV-1 strains 
as compared to TCLA and primary HtV-1 strains susceptible to VN is thought to result from the inefficient induction 
of conformational changes within the envelope glycoprotein complex by membrane associated CD4. Binding of gp120 
specific antibodies and subsequent cross-linking (not represented in the figure) leads to the induction of a stable 
complex with increased capacity to mediate fusion after binding to membrane associated CD4. 
infection of T lymphocytes57 • Collectively, these findings suggest that antibody mediated 
enhancement, indeed favours the selection in vivo of a population of viruses susceptible to 
enhancement, with phenotypic characteristics different from those isolated in vitro. Therefore it 
is reasonable to postulate that their in vivo role has been underestimated sofar. 
Most antigen preparations currently evaluated in vaccination strategies against HIV-1, are 
based on the complete gp120/gp160 proteins or alternatively on fragments containing antigenic 
sites, which elicit antibodies that neutralize certain HIV-1 strains. However, as discussed above, 
these antibodies may also be involved in the enhancement of the infectivity of certain virus strains. 
Therefore it seems more appropriate, in the framework of vaccine development activities, to pay 
more attention to the elucidation of the molecular mechanism which determine whether entry is 
blocked or enhanced by glycoprotein complex specific antibodies. Especially understanding the 
changes within the glycoprotein complex and CD4, which allow the process of virus-cell fusion to 
take place, may lead to the identification of antibodies which interfere with crucial events in this 
process. This would probably lead to a more rational approach for the induction of truly VN 
antibodies in the framework of lentivirus vaccine development. 
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Samenvatting 
De inductie van HIV-1-specifieke antilichamen die infectie met HIV-1 kunnen voorkomen of 
verspreiding van het virus gedurende de primaire fase van de infectie limiteren, is waarschijnlijk 
een belangrijke eigenschap van een te ontwikkelen succesvol vaccin tegen HIV-1. De 
virusneutraliserende activiteit van HIV-1-specifieke antilichamen wordt onder andere bepaald door 
aspecten van het virus. Daarnaast is deze activiteit afhankelijk van de celcultuur waarmee de 
virusneutralisatietest uitgevoerd word. Het primaire doe I van het in dit proefschrift beschreven 
onderzoek is om meer inzicht te verkrijgen in de factoren die de uitkomst van de interactie tussen 
antilichaam en virus bepalen. Hiertoe werd onderzoek uitgevoerd naar de moleculaire 
mechanismen waarmee HIV-1 zowel in de af- als aanwezigheid van HIV-1-specifieke antilichamen 
CD4' cellen infecteert. Daarnaast werd een model voor in vivo HIV-1-infectie opgezet dat diverse 
aspecten gemeen heeft met primaire HIV-1-infectie in de mens. In dit model werd de antivirale 
activiteit van HIV-1-specifieke antilichamen bestudeerd. 
In de introductie wordt aan de hand van een overzicht van de internationale literatuur over 
HIV-1 achtergrondinformatie gegeven over aspecten van het virus die betrekking hebben op de 
in dit proefschrift beschreven onderzoeken. 
In hoofdstuk 2 worden humane monoclonale-antilichamen (HuMAb's) beschreven die een 
antigeen gebied op HIV-1 gp120 herkennen, dat overlapt met de CD4-bindingsplaats. Deze 
HuMAb's herkennen HIV-1-stammen die tot verschillende subtypen behoren. Tevens wordt 
aangetoond dat aminozuren, gelokaliseerd in verschillende constante regio's van gp120, een 
bijdrage leveren aan het tot stand komen van de epitopen die herkend worden door deze 
HuMAb's. De HuMAb's bleken tevens in staat om HIV-1-stammen die meerdere malen in vitro 
gepasseerd zijn in ge"immortaliseerde T-cellijnen, te neutraliseren. 
In hoofdstuk 3 wordt de karakterisering van een HuMAb beschreven dat is gericht tegen het 
derde hypervariabele (V3)-domein van HIV-1 gp120 (HuMAb MN215). Er is uitvoerig onderzocht 
welke aminozuren in het V3-domein van HIV-1 bijdragen aan de binding van HuMAb MN215. 
Tevens is de bindingssterkte bepaald van HuMAb MN215 met monomeer glycoproteinen die 
afkomstig zijn van HIV-1-stammen met verschillende biologische fenotypen. Tenslotte is de 
virusneutraliserende activiteit tegen primaire HIV-1-stammen vastgesteld. HuMAb MN215 bleek 
in staat te zijn om te discrimineren tussen niet-syncytiuminducerende (NSI) en syncytium-
inducerende (SI) HIV-1-stammen. 
De DNA-sequentieanalyse van de variabele gedeeltes van de zware en lichte ketens van 
de HuMAb's worden beschreven in hoofdstuk 4. Ook worden de mogelijke consequenties hiervan 
besproken voor enerzijds de inductie van een immuunrespons gericht tegen HIV-1 in 
ge"infecteerde individuen en anderzijds de pathogenese ge"induceerd door HIV-1-infectie. 
In de hoofdstukken 5 en 6 worden experimenten beschreven die tot doe I hebben meer 
inzicht te verkrijgen in de manier waarop HIV-1 envelop-specifieke antilichamen het proces van 
envelop gemedieerde entry moduleren. Zowel de oplosbare vorm van de primaire receptor voor 
HIV-1 (sCD4) als HIV-1 envelopspecieke antilichamen die in meer of mindere mate in staat bleken 
SI-virusstammen te neutraliseren, bleken een verhoogde capaciteit van NSI-envelop gemedieerde 
entry teweeg te brengen. De gevolgen van antilichaam/antigeen-interactie in biologische zin 
(neutralisatie versus verhoging van infectiviteit) bleek bepaald te worden door de configuratie van 
specifieke regio's op gp120 enerzijds en inter/intramoleculaire-interacties anderzijds. De door 
cross-linking ge"induceerde veranderingen in het envelopeiwit, die leidden tot verhoging van 
infectiviteit, bleken een minimale energiebehoefte te hebben. 
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Om meer inzicht te verkrijgen in de virusneutraliserende capaciteit van HIV-1-specifieke 
antilichamen in de mens, werd een chimeer mens/muis-model (xeno-GvHD muismodel) voor in 
vivo HIV-1 infectie opgezet (Hoofdstuk 7). Bij het ontwikkelen van dit model werd nadrukkelijk 
rekening gehouden met aspecten die van be lang worden geacht voor HIV-1-infectie in de mens. 
Antilichaampreparaten die in vitro zowel T-cellijn-geadapteerde, als primaire HIV-1-stammen 
neutraliseerden, bleken in het xeno-GvHD muismodel aileen in staat de T-cellijn-geadapteerd 
HIV-1-stammen te neutraliseren. De primaire HIV-1-stammen bleken in hoge mate resistent te zijn 
tegen neutralisatie. 
In de algemene discussie in hoofdstuk 8 wordt verder ingegaan op de implicaties van de 
studies die zijn beschreven in dit proefschrift, voor in vivo HIV-1-infectie in de mens en voor HIV-1 
vaccinontwikkeling. De belangrijkste conclusie die getrokken kan worden, is dat verhoging van 
infectie in vivo, gernduceerd door HIV-1-specifieke antilichamen opgewekt met kandidaatvaccins, 
als een reeel probleem gezien dient te worden. Het is daarom belangrijk om in het kader van 
onderzoek aan HIV-1 vaccinontwikkeling speciale aandacht te besteden aan de moleculaire 
mechanismen van entry van primaire HIV-1-stammen. Een beter inzicht in deze moleculaire 
mechanismen kan leiden tot een rationelere ontwikkeling van antigeenpreparaten die in staat zijn 
om antilichamen te induceren die HIV-1-stammen met verschillende fenotypen zowel in vitro als 
in vivo kunnen neutraliseren. 
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